Clinical trial NCT00096460
Conditions: Recurrent Grade 1 Follicular Lymphoma Recurrent Grade 2 Follicular Lymphoma Recurrent Grade 3 Follicular Lymphoma Follicular Lymphoma
Sponsor: Medical College of Wisconsin
Start date: 2004-08-01; Completion date: 2009-03-01
Enrollment: 30 participants; Allocation: NON_RANDOMIZED; Intervention model: PARALLEL

Brief summary:
This study is designed as a Phase II/III, multi-center trial, comparing two transplant strategies to determine whether non-myeloablative allogeneic Hematopoietic Stem Cell Transplantation (HSCT) will improve long-term progression-free survival compared to autologous HSCT. Recipients will be biologically assigned to the appropriate treatment arm depending on the availability of a Human Leukocyte Antigen (HLA) matched sibling.

Detailed description:
BACKGROUND:

Although patients with follicular non-Hodgkin's lymphoma (NHL) typically experience a relatively indolent course, the disease is rarely curable with conventional chemotherapy. Patients with follicular NHL are usually treated only when symptoms require palliation or if bulky disease exists since no survival advantage has been shown as compared to administering conventional treatment at initial diagnosis. While most patients achieve a remission with initial chemotherapy, a continuous pattern of relapse occurs, resulting in progressively shorter remission durations. Additionally, the increased response rates conferred by anthracycline-containing regimens have not translated into improved survival and thus the median survival time of 6 to 10 years has not been significantly impacted over the last decade.

DESIGN NARRATIVE:

The overall study design is a comparison of two treatment arms determined by biologic assignment, based on the availability of an HLA-matched sibling, in patients diagnosed with relapsed follicular non-Hodgkin's lymphoma. Patients without an HLA-matched sibling will receive an autologous HSCT. Patients with an HLA-matched sibling will receive a non-myeloablative allogeneic HSCT.

The overall study design is that of biologic assignment, based on the availability of an HLA-matched sibling, to one of two strategies to improve the outcome for follicular lymphoma patients with chemosensitive disease. All patients will undergo cytoreduction with cyclophosphamide 4 gm/m\^2 and rituximab 375 mg/m\^2 x 2 doses. Rituximab will be given in two doses, approximately 1 week apart, with the cyclophosphamide administered the day after the first dose of rituximab. Patients assigned to the autologous arm will have their hematopoietic stem cells mobilized from this cytoreductive regimen. Patients with an HLA-matched sibling will undergo a non-myeloablative allogeneic HSCT. Pre-transplant conditioning will consist of fludarabine 30 mg/m\^2/day and cyclophosphamide 750 mg/m\^2/day x 3 days with rituximab 375 mg/m\^2/day on Days -13 and -6 pre-HSCT and on Days +1 and +8 post-HSCT. The immunosuppressive regimen will consist of tacrolimus and methotrexate (MTX) to control graft-versus-host and host-versus-graft reactions. Patients without an HLA-matched sibling who have collected an adequate autologous hematopoietic cell graft, defined as at least 2.0 \* 10\^6 CD34+ cells/kg, will receive a preparative regimen of total body irradiation (TBI) 1200 cGy or Carmustine (BCNU) 15 mg/kg. In addition, VP-16 60 mg/kg and cyclophosphamide 100 mg/kg will be given for both autologous preparative regimens. Post-autologous HSCT therapy with rituximab 375 mg/m\^2 weekly x 4 doses will commence between Days 42-75 post-HSCT.

Arms: arm 1: Cyclophosphamide and Rituximab with Filgrastim conditioning and chemotherapy or radiation therapy prior to autologous Hematopoietic Stem Cell Transplant (HSCT). Rituximab maintenance therapy following HSCT. arm 2: Non-myeloablative conditioning regimen followed by allogeneic Hematopoietic Stem Cell Transplant (HSCT). Graft-versus-Host Disease (GVHD) Prophylaxis therapy following HSCT.
Interventions: intervention 1: Cyclophosphamide and Rituximab intervention 2: Filgrastim intervention 3: Chemotherapy or Radiation therapy intervention 4: Non-myeloablative Conditioning regimen intervention 5: Allogeneic transplant intervention 6: Autologous transplant intervention 7: Rituximab maintenance therapy intervention 8: GVHD Prophylaxis
Intervention descriptions: intervention 1: Prior to undergoing HSCT, all patients will receive Cyclophosphamide 4 gm/m2 with Rituximab 375 mg/m2 x 2 doses and G-CSF support. intervention 2: Autologous HSCT patients will receive 10 mcg/kg/day and allogeneic HSCT patients will receive 5 mcg/kg/day subcutaneous (SQ) or intravenous (IV) starting 2 days after the initiation of Cyclophosphamide. intervention 3: Chemotherapy - BCNU 15 mg/kg IV x 1 dose to be administered over 2 hours on Day -6 pre-HSCT. VP-16 60 mg/kg IV x 1 dose to be administered over 4 hours on Day -4.

Radiation - administered at a rate of \< 20 cGy/min in one of the following doses; 120 cGy/fraction are administered at no less than 4-hour intervals three times/day or 2 times/day for a total of 10 doses (1200 cGy) over 4 days (Day -8, -7, -6 and -5), or doses of 150 cGy/fraction twice daily for a total of 8 doses (1200 cGy) over 4 days (Day -8, -7, -6 and -5). VP-16 60 mg/kg IV x 1 dose to be administered over 4 hours on Day -4 pre-HSCT.

Cyclophosphamide 100 mg/kg IV x 1 dose to be administered over 2 hours on Day -2 pre-HSCT. G-CSF 5 mcg/kg SQ or IV to start on Day +5 post-HSCT and continue until ANC \> 500/mm3 x 3 days. intervention 4: Fludarabine 30 mg/m2 IV x 3 doses total to be administered daily over 30 minutes on Days -6, -5 and -4 pre-HSCT. Cyclophosphamide 750 mg/m IV x 3 doses total to be administered daily over 1 hour on Days -6, -5 and -4 pre-HSCT. Administer cyclophosphamide approximately 4 hours after start of fludarabine infusion. Rituximab 375 mg/m2 IV x 4 doses total to be administered on Days -13 and -6 pre HSCT and Days +1 and +8 post HSCT. intervention 5: Infusion of G-CSF mobilized allogeneic hematopoietic stem cells intervention 6: Infusion of G-CSF mobilized autologous hematopoietic stem cells intervention 7: Patients must have sufficiently recovered from autologous HSCT in order to receive rituximab maintenance therapy as specified below:

Dose #1: Day +42 post-autologous HSCT Dose #2: Day +49 post-autologous HSCT Dose #3: Day +56 post-autologous HSCT Dose #4: Day +63 post-autologous HSCT intervention 8: Tacrolimus 0.09 mg/kg/day PO, based on body weight formulas will start on Day -2 and continue until Day +90 post-HSCT. Tacrolimus (or cyclosporine, if applicable) will be given orally in a twice-daily divided dose. Methotrexate 5 mg/m2 Intravenous Pyelogram (IVP) will be administered on Days +1, +3 and +6 post-HSCT.

Protocol documents:
Prot_SAP_ICF_000.pdf: 
BMT CTN 0202 
Autologous vs. Non-Myeloablative Allogeneic 
Hematopoietic Stem Cell Transplantation (HSCT) 
for Patients with Chemosensitive Follicular Non-
Hodgkin’s Lymphoma Beyond First Complete 
Response or First Partial Response 
NCT00096460 


 
 
Autologous vs. Non-Myeloablative Allogeneic Hematopoietic Stem 
Cell Transplantation (HSCT) for Patients with Chemosensitive  
Follicular Non-Hodgkin’s Lymphoma Beyond First Complete 
Response or First Partial Response 
 
 
BMT CTN PROTOCOL 0202 
VERSION 4.0 
 
 
Study Co-Chairpersons 
Ginna Laport, M.D. 1 
Robert Negrin, M.D. 1 
 
 
Protocol Team
Marian Ewell, Sc.D 2 
John Klein, Ph.D. 3 
David Maloney, M.D., Ph.D 4 
Julie Marchick, M.P.H. 2 
Auayporn Nadamanee, M.D. 5 
Patrick Stiff, M.D. 6 
Marcie Tomblyn, M.D.7 
Julie Vose, M.D. 8 
 
 
 
Sponsored by the National Institutes of Health 
National Heart, Lung and Blood Institute 
National Cancer Institute 
 
 
 
1  Stanford Hospital and Clinics  
2 The EMMES Corporation  
3 Center for International Blood and Marrow 
Transplant Research (CIBMTR), Medical 
College of Wisconsin 
4 Fred Hutchinson Cancer Research Center  
5 City of Hope National Medical Center 
6 Loyola University Health System 
7 University of Minnesota 
8 University of Nebraska Medical Center  
 


BMT CLINICAL TRIALS NETWORK 
 
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
 
Core Study Participants: 
 Non-Core Study Participants: 
Case Western Reserve Consortia 
Oregon Health & Science University 
University Hospitals of Cleveland 
Washington University 
City of Hope National Medical Center 
Dana Farber/Partners Cancer Center 
Duke University Medical Center-Adult  
Stanford Hospital and Clinics 
UCSD/SCRIPPS School of Medicine 
University of Florida College of Medicine (Shands) 
University of Michigan Medical Center 
University of Minnesota 
University of Nebraska Medical Center 
University of Pennsylvania Cancer Center 
University of Texas, MD Anderson Cancer Center 
 
 Baylor University Medical Center 
Blood and Marrow Transplant Group of Georgia 
Emory University 
Hackensack University Medical Center 
H. Lee Moffitt Cancer Center 
Indiana BMT at Beech Grove 
Kansas City Blood & Marrow Transplant Center 
Karmanos Cancer Institute, BMT 
Loyola University Medical Center 
Medical College of Wisconsin 
Providence Portland Medical Center 
Temple University 
University of Maryland 
University of Pittsburgh 
University of Wisconsin 
Vanderbilt University Medical Center 
Virginia Commonwealth University Medical Center 
 
 


BMT CLINICAL TRIALS NETWORK 
 
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
i 
PROTOCOL SYNOPSIS - BMT CTN PROTOCOL #0202 
 
Autologous vs. Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation 
(HSCT) for Patients with Chemosensitive Follicular Non-Hodgkin’s Lymphoma Beyond 
First Complete Response or First Partial Response 
 
Study Co-Chairpersons: 
Ginna Laport, M.D. and Robert Negrin, M.D. 
Accrual Objective:  
A minimum of 80 patients with recurrent follicular non-Hodgkin’s 
lymphoma (REAL classification follicle center lymphoma, follicular 
grades I and II or patients with histologically confirmed WHO 
classification follicular lymphoma grades 1, 2, 3a or 3b) and an HLA-
matched sibling will be entered on the protocol.  It is expected during 
the same period that an additional 187-320 patients without an HLA-
matched sibling will be entered on the protocol. 
Study Design: 
This study is designed as a Phase II/III, multi-center trial, comparing 
two transplant strategies to determine whether non-myeloablative 
allogeneic HSCT will improve long-term progression-free survival 
compared to autologous HSCT.  Recipients will be biologically 
assigned to the appropriate treatment arm depending on the availability 
of an HLA-matched sibling. 
Accrual Period: 
The estimated accrual period is three years. 
Primary Objective: 
The primary objective is to compare progression-free survival (PFS) at 
three years between the two treatment arms.  
Secondary Objectives: 
Secondary objectives for the comparison of non-myeloablative 
allogeneic HSCT vs. autologous HSCT are three-year overall survival, 
time to progression, time to complete response (CR) and partial 
response (PR), time to off-study therapy, incidence of infections, and 
incidence of NCI Common Terminology Criteria Adverse Events 
(CTCAE) Version 3.0 Grade ≥ 3 toxicities. 
 
Secondary objectives for the non-myeloablative allogeneic HSCT 
recipients include incidence and severity of acute and chronic GVHD, 
and incidence of primary and secondary graft failure. 
The efficacy of cyclophosphamide plus rituximab in vivo purging will 
also be evaluated as well as the prediction of disease relapse by 
measurement of t(14;18) by quantitative polymerase chain reaction 
(PCR). 
Quality of life as measured by the SF-36 and the FACT-BMT will be 
described in both patient populations. 
Eligibility Criteria: 
Eligible patients are ≤ 75 years of age with Karnofsky performance 
score ≥ 70% who have histologically confirmed recurrent follicular 
lymphoma (REAL classification follicle center follicular grades I and 
II or patients with histologically confirmed WHO classification 
follicular lymphoma grades 1, 2, 3a or 3b).  Patients must have 
received ≤ 3 prior treatment regimens. Monoclonal antibody therapy 


BMT CLINICAL TRIALS NETWORK 
 
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
ii 
and local radiation will not be counted as prior therapies.  Patients 
must demonstrate chemosensitive disease by achieving reduction in 
lymph node axial diameter to < 3 cm or > 50% reduction in estimated 
lymph node volume AND ≤ 20% BM involvement after their most 
recent salvage therapy.  Patients do not have to express t(14;18).   
Treatment Description: 
Within 4 weeks of enrollment and after HLA typing and evaluation of 
potential sibling donors is complete, all patients will receive 
cyclophosphamide 4 gm/m2 on Day 2 concomitantly with rituximab 
375 mg/m2 on Days 1 and 8.  G-CSF 10 mcg/kg/day (autologous 
patients) or 5 mcg/kg/day (allogeneic patients) SQ or IV will be given 
starting 2 days after the initiation of cyclophosphamide.  Patients 
assigned to the autologous HSCT arm will undergo leukapheresis upon 
blood count recovery.  After the mobilization process is complete, 
autologous patients will then receive either fractionated total body 
irradiation (FTBI) 1200 cGy or BCNU 15 mg/kg.  VP-16 60 mg/kg 
and cyclophosphamide 100 mg/kg will also be given followed by 
autologous HSCT.  Patients must have an adequate autograft defined 
as ≥ 2.0 x 106 CD34+ cells/kg.  Rituximab 375 mg/m2 x 4 weekly 
doses, to begin on approximately Day +42, will be given as 
maintenance therapy.  Patients with an HLA-matched sibling will 
receive a non-myeloablative conditioning regimen of fludarabine  
30 mg/m2/day and cyclophosphamide 750 mg/m2/day from Day -6 to -
4 followed by infusion of G-CSF mobilized donor hematopoietic stem 
cells.  Rituximab 375 mg/m2 will be administered on Day -13, -6, +1 
and +8.  GVHD prophylaxis will consist of tacrolimus (IV or PO) until 
Day +90 followed by a taper and methotrexate 5 mg/m2 IV on Day +1, 
+3, and +6 post-HSCT.  All patients will undergo PCR analysis for 
t(14:18) from the peripheral blood after blood count recovery from the 
cyclophosphamide/rituximab cytoreductive/mobilization regimen and 
on Day +28, +84, +180 and yearly post-HSCT if positive at any time 
from diagnosis to initial study evaluation. 
Quality of Life: 
The FACT-BMT and MOS SF-36 instruments will be used to describe 
the health-related quality of life (HQL) of patients.  A secondary 
analysis will compare the HQL between the two treatment arms.  The 
self-report questionnaire will be performed prior to cytoreductive/ 
mobilization therapy and at two years post-HSCT for English and 
Spanish speaking patients only. 
Study Duration: 
Patients will be followed for at least three years post-HSCT. 
 


BMT CLINICAL TRIALS NETWORK 
 
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
iii 
 
TREATMENT SCHEMA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Only required for patients who had a positive PCR at any point prior to study entry or at the 
baseline screen on study. 
 
 
Eligible patients following salvage chemotherapy: 
               Yes 
 No 
Quantitative PCR t(14;18) 
Cyclophosphamide 4 gm/m2 
Rituximab 375 mg/m2 x 2 doses 
G-CSF 5 mcg/kg 
Quantitative PCR 
t(14;18)* at blood count 
Non-myeloablative conditioning 
Fludarabine 30 mg/m2 (Days -6 to -4) 
Cyclophosphamide 750 mg/m2 (Days -6 to -4)  
Rituximab 375 mg/m2 (Days -13, -6, +1, +8) 
Infusion of G-CSF mobilized allogeneic 
hematopoietic stem cells 
Quantitative t(14;18) PCR after 
blood count recovery, 
Days +28, +84, +180 and yearly 
until 3 years post-transplant if 
positive at any time from diagnosis 
to initial study evaluation* 
Quantitative PCR t(14;18) 
Cyclophosphamide 4 gm/m2 
Rituximab 375 mg/m2 x 2 doses 
G-CSF 10 mcg/kg 
Collection of HSCs ≥ 2x106 CD34+ cells/kg  
Autologous Conditioning 
FTBI 1200 cGy (Days –8 to –5) or  
BCNU 15 mg/kg (Day –6), then 
followed by VP-16 60 mg/kg (Day –4) 
Cyclophosphamide 100 mg/kg (Day –2) 
Infusion of G-CSF mobilized autologous 
hematopoietic stem cells 
Quantitative t(14;18) PCR after blood count recovery, 
Days +28, +84, +180 and yearly until 3 years post-
transplant if positive at any time from diagnosis to 
initial study evaluation*
Quantitative PCR t(14;18) at blood count recovery and 
PCR on each leukaphereis product* 
Rituximab maintenance 375 mg/m2 
Days +42, +49, +56 and +63 post-HSCT 
Availability of an HLA-matched sibling donor? 


BMT CLINICAL TRIALS NETWORK 
 
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
iv 
 
TABLE OF CONTENTS 
 
 
1. 
BACKGROUND AND RATIONALE ............................................................................ 1-1 
1.1. 
Background ......................................................................................................................... 1-1 
1.2. 
Autologous Hematopoietic Stem Cell Transplantation ................................................ 1-1 
1.3. 
Minimal Residual Disease ................................................................................................. 1-2 
1.4. 
In Vivo Purging with Rituximab ...................................................................................... 1-3 
1.5. 
Relapse Prevention with Rituximab ................................................................................ 1-4 
1.6. 
Allogeneic Hematopoietic Stem Cell Transplantation for Follicular Lymphoma ... 1-4 
1.6.1. 
Non-myeloablative Allogeneic Hematopoietic Stem Cell Transplantation ................ 1-5 
1.7. 
Study Approach and Treatment ...................................................................................... 1-6 
2. 
STUDY DESIGN ................................................................................................................ 2-1 
2.1. 
Study Overview .................................................................................................................. 2-1 
2.2. 
Hypothesis and Specific Objectives ................................................................................. 2-1 
2.2.1. 
Hypothesis ....................................................................................................................... 2-1 
2.2.2. 
Study Objectives ............................................................................................................. 2-2 
2.3. 
Patient Eligibility ................................................................................................................ 2-2 
2.3.1. 
Initial Patient Inclusion Criteria ..................................................................................... 2-2 
2.3.2. 
Initial Patient Exclusion Criteria .................................................................................... 2-3 
2.4. 
Patient Eligibility Criteria for Proceeding to HSCT .................................................... 2-3 
2.5. 
Patient Eligibility Criteria for Maintenance Therapy for Recipients of Autologous 
HSCT ............................................................................................................................... 2-4 
2.6. 
Allogeneic Hematopoietic Stem Cell Donor Criteria.................................................... 2-4 
2.6.1. 
Donor Inclusion Criteria ................................................................................................. 2-4 
2.6.2. 
Donor Exclusion Criteria ................................................................................................ 2-4 
2.7. 
Study Treatments ............................................................................................................... 2-5 
2.7.1. 
HLA-Typing of Potential Sibling Donors ..................................................................... 2-5 
2.7.2. 
Body Weight Formulas ................................................................................................... 2-5 
2.7.3. 
Cytoreductive Therapy/Mobilization Chemotherapy ................................................... 2-6 
2.7.3.1. 
Allopurinol....................................................................................................................... 2-6 
2.7.3.2. 
Cyclophosphamide and rituximab administration/mobilization .................................. 2-6 
2.7.4. 
High Dose Chemotherapy with Autologous HSCT ...................................................... 2-7 
2.7.4.1. 
Conditioning regimen - chemotherapy-based regimen ................................................. 2-8 
2.7.4.2. 
Conditioning regimen - total body irradiation-based regimen ..................................... 2-8 
2.7.4.3. 
Rituximab maintenance therapy ................................................................................... 2-10 
2.7.5. 
Non-myeloablative Allogeneic Stem Cell Transplantation for Patients with an HLA- 
matched Sibling ............................................................................................................. 2-10 
2.7.5.1. 
Conditioning regimen ................................................................................................... 2-11 
2.7.5.2. 
Graft-versus-host disease (GVHD) prophylaxis ......................................................... 2-11 
2.7.6. 
Collection and Infusion of Allogeneic HSC ................................................................ 2-12 
2.7.6.1. 
G-CSF administration to donors .................................................................................. 2-12 
2.7.6.2. 
HSC collection and evaluation ..................................................................................... 2-12 


BMT CLINICAL TRIALS NETWORK 
 
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
v 
2.7.6.3. 
Allogeneic hematopoietic stem cell infusion .............................................................. 2-13 
2.8. 
Supportive Care................................................................................................................ 2-13 
2.8.1. 
Post-autologous HSCT.................................................................................................. 2-13 
2.8.1.1. 
Prophylaxis against infections ...................................................................................... 2-13 
2.8.1.2. 
Blood products .............................................................................................................. 2-14 
2.8.1.3. 
Post-HSCT immunization schedule ............................................................................. 2-14 
2.8.2. 
Post Non-myeloablative Allogeneic HSCT ................................................................. 2-14 
2.8.2.1. 
Prophylaxis against infections ...................................................................................... 2-14 
2.8.2.2. 
Blood products .............................................................................................................. 2-15 
2.8.2.3. 
Post-HSCT growth factors ............................................................................................ 2-15 
2.8.2.4. 
Post-HSCT immunization schedule ............................................................................. 2-15 
2.8.2.5. 
Post-HSCT donor cellular infusions (DCI) ................................................................. 2-15 
2.9. 
PCR Monitoring for t(14;18) .......................................................................................... 2-15 
2.10. Participant Risks .............................................................................................................. 2-15 
2.11. Therapy Toxicities............................................................................................................ 2-16 
2.11.1. 
Total Body Irradiation (TBI) ........................................................................................ 2-16 
2.11.2. 
Cyclophosphamide ........................................................................................................ 2-16 
2.11.3. 
Carmustine (BCNU) ..................................................................................................... 2-16 
2.11.4. 
VP-16 (Etoposide) ......................................................................................................... 2-16 
2.11.5. 
Rituximab ...................................................................................................................... 2-16 
2.11.6. 
Fludarabine .................................................................................................................... 2-17 
2.11.7. 
Methotrexate .................................................................................................................. 2-17 
2.11.8. 
Tacrolimus ..................................................................................................................... 2-17 
2.11.9. 
G-CSF (filgrastim) ........................................................................................................ 2-17 
3. 
STUDY ENDPOINTS........................................................................................................ 3-1 
3.1. 
Definition of Disease Status .............................................................................................. 3-1 
3.2. 
Primary Endpoint to be Compared Between Autologous HSCT Recipients and Non-
myeloablative Allogeneic HSCT Recipients .............................................................. 3-2 
3.2.1. 
Three Year Progression-Free Survival........................................................................... 3-2 
3.3. 
Secondary Endpoint to be Compared Between Autologous HSCT Recipients and 
Non-myeloablative Allogeneic HSCT Recipients ..................................................... 3-2 
3.3.1. 
Three Year Overall Survival........................................................................................... 3-2 
3.3.2. 
Time to Progression ........................................................................................................ 3-2 
3.3.3. 
Time to CR and PR ......................................................................................................... 3-3 
3.3.4. 
Time to Off-study Therapy ............................................................................................. 3-3 
3.3.5. 
Incidence of Infections .................................................................................................... 3-3 
3.3.6. 
Incidence of CTCAE Version 3.0 Grade ≥ 3 toxicities ................................................ 3-3 
3.3.7. 
Treatment Related Mortality .......................................................................................... 3-3 
3.4. 
Endpoints That Only Apply to Non-myeloablative Allogeneic Recipients ............... 3-3 
3.4.1. 
Incidence of Primary and Secondary Graft Failure....................................................... 3-3 
3.4.2. 
Incidence and Severity of Graft-versus-Host Disease (GVHD) .................................. 3-4 
3.5. 
Other Endpoints ................................................................................................................. 3-4 
3.5.1. 
Efficacy of Rituximab and Cyclophosphamide in Vivo Purging ................................. 3-4 
3.5.2. 
Prognostic Value of t(14;18) by PCR in Predicting Relapse ....................................... 3-4 
3.5.3. 
Quality of Life ................................................................................................................. 3-4 


BMT CLINICAL TRIALS NETWORK 
 
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
vi 
3.6. 
Regimen-related Toxicities Safety Monitoring Endpoints .......................................... 3-4 
3.6.1. 
Allogeneic HSCT ............................................................................................................ 3-4 
3.6.2. 
Autologous HSCT ........................................................................................................... 3-5 
4. 
PATIENT ENROLLMENT AND EVALUATION ...................................................... 4-1 
4.1. 
Enrollment Procedures...................................................................................................... 4-1 
4.1.1. 
Screening and Eligibility Procedures ............................................................................. 4-1 
4.1.2. 
SWOG Patient Registration Procedures ........................................................................ 4-2 
4.2. 
Study Monitoring ............................................................................................................... 4-2 
4.2.1. 
Follow-up Schedule ........................................................................................................ 4-2 
4.2.2. 
Weekly GVHD Monitoring Post Non-myeloablative Allogeneic Transplant ............ 4-4 
4.2.3. 
Adverse Event Reporting ................................................................................................ 4-4 
4.2.4. 
Patient Assessments ........................................................................................................ 4-4 
4.2.4.1. 
Evaluations prior to rituximab and cyclophosphamide ................................................ 4-4 
4.2.4.2. 
Post initiation of rituximab and cyclophosphamide ...................................................... 4-5 
4.2.4.3. 
Evaluations prior to the autologous or non-myeloablative allogeneic HSCT ............. 4-5 
4.2.4.4. 
Post-HSCT evaluations ................................................................................................... 4-6 
4.2.4.5. 
Prior to initiation of rituximab maintenance therapy in autologous HSCT recipients 4-7 
4.2.4.6. 
Sampling schedule for quantitative PCR of t(14;18) from peripheral blood sample.. 4-8 
4.2.4.7. 
Sampling schedule for chimerism analysis of peripheral blood in non-myeloablative 
allogeneic transplant recipients ...................................................................................... 4-8 
4.2.4.8. 
Required observations for HLA-matched sibling donor............................................... 4-8 
5. 
STATISTICAL CONSIDERATIONS ............................................................................ 5-1 
5.1. 
Study Overview .................................................................................................................. 5-1 
5.1.1. 
Primary Endpoint ............................................................................................................ 5-1 
5.1.2. 
Accrual ............................................................................................................................. 5-1 
5.1.3. 
Biologic Assignment ....................................................................................................... 5-2 
5.1.4. 
Intention-to-Treat Principle ............................................................................................ 5-2 
5.2. 
Statistical Issues Related to Non-randomized Assignment.......................................... 5-2 
5.2.1. 
Selection of Patients to Screen for the Study ................................................................ 5-2 
5.2.2. 
Compliance with Biologic Assignment ......................................................................... 5-3 
5.2.3. 
Effects of Transplant Center ........................................................................................... 5-3 
5.2.4. 
Effects of Disease Risk Status ........................................................................................ 5-4 
5.2.5. 
Effects of Baseline Factors ............................................................................................. 5-4 
5.3. 
Sample Size and Power Calculations .............................................................................. 5-4 
5.4. 
Interim Analysis and Stopping Guidelines..................................................................... 5-5 
5.4.1. 
Guidelines for Accrual Monitoring ................................................................................ 5-5 
5.4.2. 
Guidelines for Efficacy Monitoring ............................................................................... 5-5 
5.4.3. 
Guidelines for Safety Monitoring .................................................................................. 5-6 
5.5. 
Analysis Plan ..................................................................................................................... 5-10 
5.5.1. 
Analysis of the Primary Endpoint ................................................................................ 5-10 
5.5.2. 
Analysis of Secondary Endpoints ................................................................................ 5-10 
5.5.3. 
Analyses of Patients on the Non-myeloablative Allogeneic HSCT Treatment Arm 5-14 
 
 


BMT CLINICAL TRIALS NETWORK 
 
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
vii 
LIST OF APPENDICES 
 
APPENDIX A 
 
REFERENCES 
APPENDIX B 
 
CONSENT FORMS 
APPENDIX C 
 
LABORATORY PROCEDURES 
APPENDIX D 
 
HUMAN SUBJECTS 
APPENDIX E 
STATISTIC FOR TESTING THREE-YEAR 
PROGRESSION-FREE SURVIVAL 
 


BMT CLINICAL TRIALS NETWORK 
 
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
1-1 
CHAPTER 1 
 
 
1. 
BACKGROUND AND RATIONALE 
 
1.1. Background 
 
Although patients with follicular non-Hodgkin’s lymphoma (NHL) typically experience a 
relatively indolent course, the disease is rarely curable with conventional chemotherapy.  Patients 
with follicular NHL are usually treated only when symptoms require palliation or if bulky 
disease exists since no survival advantage has been shown as compared to administering 
conventional treatment at initial diagnosis.  While most patients achieve a remission with initial 
chemotherapy, a continuous pattern of relapse occurs resulting in progressively shorter remission 
durations.  Additionally, the increased response rates conferred by anthracycline-containing 
regimens have not translated into improved survival and thus the median survival time of 6 to 10 
years has not been significantly impacted over the last decade [1-3]. 
 
1.2. Autologous Hematopoietic Stem Cell Transplantation 
 
In light of the discouraging results with conventional chemotherapy, high dose chemotherapy 
with autologous HSCT has been explored as an alternative approach in patients with follicular 
NHL.  Several studies have shown improved disease-free survival (DFS) but one recently 
published study has also shown an advantage for overall survival [3-8].  The European Group for 
Blood and Marrow Transplantation (EBMT) conducted a randomized trial known as the CUP 
Trial in which 140 patients with relapsed follicular NHL were randomized to either 
chemotherapy alone, autologous HSCT with a purged autograft using monoclonal antibodies or 
autologous HSCT with an unpurged autograft.  With a median follow-up of 69 months, the 
patients who received an autologous HSCT, purged or unpurged, show a significantly higher 
two-year progression-free and overall survival (OS).  There was no difference between the two 
autologous HSCT arms in these endpoints. Overall survival at four years for the chemotherapy 
arm, unpurged autologous HSCT arm and purged autologous HSCT arm was 46%, 71% and 
77%.  The two-year progression-free survival (PFS) was 26%, 58% and 55% respectively.  There 
was a significant reduction in hazard rates for both progression-free and overall survival when a 
comparison was made between the chemotherapy patients and the combined groups of 
autologous HSCT patients.  
 
As with conventional chemotherapy, the outcome for patients who receive autologous HSCT is 
related to the number of prior chemotherapy regimens received.  Patients transplanted in first 
remission benefit more than those receiving a transplant after numerous prior therapies.  Two 
retrospective studies and one prospective study have shown that patients with follicular 
lymphoma undergoing autologous HSCT who had received > 3 prior chemotherapy regimens 
showed inferior survival compared to patients treated with < 3 prior regimens [3-6].  Bierman et 
al in one of the largest single institution retrospective analyses, reported on 100 patients with 
follicular NHL.  That study demonstrated a 4-year estimated failure-free survival and overall 
survival of 44% and 65%, respectively [4].  Response rates (RR) were high with an 82% overall 
RR with 68% achieving a complete remission (CR).  Treatment-related mortality was 8%.  


BMT CLINICAL TRIALS NETWORK 
 
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
1-2 
However, despite these encouraging numbers, there was no definite evidence of a plateau in 
failure-free survival (See Figure 1).  The retrospective study by Cao et al of 49 patients with 
follicular NHL showed similar results with a 4-year disease-free survival (DFS) and OS of 44% 
and 60%, respectively [5].  The prospective study of 64 follicular NHL patients reported by 
Rohatiner et al also concurred with these findings reporting a significant correlation between 
survival and the total number of previous regimens with patients who received < 3 regimens 
surviving longer compared to patients who received > 3 treatment cycles [6]. 
 
Another important factor influencing outcome is the previous sensitivity of the patients to 
chemotherapy.  A recent EBMT analysis of 467 patients indicated that patients who had 
previously responded to chemotherapy have similar OS and PFS whether transplanted in 1st 
remission or after chemosensitive recurrence.  The OS and PFS were considerably lower in 
patients with chemoresistant disease [7] (see Figure 2). 
 
 
Fig. 1: Failure-free survival after  
autologous HSCT according to number of  
prior courses of chemotherapy 
 
Fig. 2: EBMT registry data showing OS after  
autologous HSCT according to previous  
response to chemotherapy 
 
1.3. 
Minimal Residual Disease 
 
The characteristic t(14;18) gene translocation characteristic of 70-80% of patients with follicular 
NHL leads to overexpression of the bcl-2 gene in the bone marrow even when there is no 
histologic evidence of bone marrow involvement [10].  The presence of the bcl-2 rearrangement 
in the bone marrow of follicular NHL patients is another important prognostic indicator and there 
has been increasing evidence that the presence of the bcl-2 rearrangement may be a useful 
surrogate endpoint to monitor treatment efficacy in indolent NHL [10,11].  In the t(14;18) 
translocation, the bcl-2 gene is moved from chromosome 18 to the immunoglobulin heavy chain 
(IgH) locus on chromosome 14 [12].  The resultant bcl-2 gene product is an inhibitor of 
apoptosis and it is believed that bcl-2 overexpression may be an important factor in 
lymphomagenesis [13].  Cells bearing this translocation can be detected in the peripheral blood 
or bone marrow by the highly sensitive polymerase chain reaction (PCR) technique [14].  Thus 
PCR for t(14;18) provides a sensitive, quantitative and convenient measure of minimal residual 
disease and there is a clear association between the induction of molecular remission and PFS 
[11]. 
 
 


BMT CLINICAL TRIALS NETWORK 
 
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
1-3 
Freedman et al reported that the presence of minimal residual disease in the reinfused marrow 
was the most significant prognostic factor for relapse in the autologous HSCT setting [11].  In 
this particular study of 153 patients with follicular NHL, patients with bcl-2 negative bone 
marrow after ex vivo purging with monoclonal antibodies had significantly longer relapse-free 
survival (RFS) compared to those who still had the detectable bcl-2 rearrangement.  The eight-
year freedom from recurrence was 83% compared to 19% for patients who were 
PCR+(p=.0001).  Continued PCR negativity in follow-up bone marrow samples was also 
strongly predictive of continued CR and the 12-year OS from diagnosis was 69%.  This data 
provided compelling evidence that autologous HSCT may prolong OS in patients with follicular 
NHL considering that historically the median OS from diagnosis has been 8 years. 
 
1.4. 
In Vivo Purging with Rituximab 
 
Contamination of the hematopoietic stem cell graft by tumor cells is thought to be a major factor 
contributing to the high relapse rates seen with autologous HSCT.  Reducing the rate of relapse 
may be achieved by pre-HSCT purging of the hematopoietic stem cell product followed by post-
HSCT maintenance.  Various in vitro methods have been utilized to decrease or eliminate 
residual tumor cells from the harvest product.  Such techniques have included purging with B-
cell monoclonal antibodies, chemotherapeutic agents such as mafosfamide and CD34+ positive 
selection [15-18].  While all of these methods have reduced the level of tumor cell 
contamination, most grafts have remained PCR positive and there have been no randomized 
trials to date strongly supporting the use of in vitro purging in this setting [8,19].  Additionally, 
in vitro purging methods are typically expensive, labor intensive, require reagents that are not 
generally available and can be associated with substantial cell losses [20].  For example, the 
above mentioned study by Freedman et al required the use of 3 monoclonal antibodies and rabbit 
complement to achieve successful marrow purging [11]. 
 
One of the most promising strategies to reduce relapse involves in vivo purging with rituximab.  
In contrast to in vitro purging methods aimed at removing contaminating tumor cells from the 
hematopoietic stem cell harvest, the administration of rituximab in vivo depletes the peripheral 
blood of all CD20+ cells preventing contamination of the graft by lymphoma cells [21].  
Rituximab is a human/mouse monoclonal antibody recognizing CD20+, an antigen expressed on 
all cells of B cell lineage including B cell NHL [22].  Rituximab eradicates B cells by 
complement-mediated cytotoxicity and antibody-dependent cell-mediated cytotoxicity.  It can 
induce apoptosis in CD20+ cells and may be synergistic with chemotherapy.  The B cells in the 
peripheral blood of patients treated with rituximab are rapidly and effectively cleared for more 
than three months [21].  This strategy has been effectively used in patients with both aggressive 
and indolent lymphomas including untreated patients with follicular NHL and a low tumor 
burden [24-26]. 
 
Rituximab has been successfully incorporated into the hematopoietic stem cell mobilization 
regimen by several groups for the purpose of in vivo purging [27-32].  Rituximab purging has not 
demonstrated any negative effects with regards to hematopoietic stem cell yield or function with 
hematopoietic recovery being comparable following transplantation in purged versus unpurged 
patients [27].  Most importantly, the clearance of bcl-2 positive cells in the graft has been 
unequivocally documented in B cell NHL patients including grafts from follicular lymphoma 


BMT CLINICAL TRIALS NETWORK 
 
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
1-4 
patients.  In a prospective study with 15 patients with mantle cell lymphoma or follicular 
lymphoma, Magni et al administered 2 cycles of intensive chemotherapy with 2 doses of 
rituximab [31].  Ninety-three percent of the patents who received rituximab had PCR-negative 
harvests compared to only 40% of 10 control patients who had received the identical 
chemotherapeutic regimen without rituximab.  Four other studies that incorporated rituximab 
into the mobilization regimen yielded PCR negative harvests ranging from 60%-100% of the 
products that were known to be PCR+ prior to collection [28-30, 33].  However, it should be 
noted that the largest sample size of these 5 studies consisted of only 13 patients.  The optimal 
timing and dosing of rituximab administration during mobilization still remains to be clearly 
established but current reports have ranged from 1 to 4 doses.  The effect of in vivo purging on 
clinical outcome is still not clear but should become more evident as the data mature. 
 
1.5. Relapse Prevention with Rituximab 
 
While in vivo purging addresses the problem of tumor contamination in the hematopoietic stem 
cell graft, the regrowth of persistent malignant cells in the recipient represents another obstacle 
to prolonged survival.  Post-transplant or maintenance chemotherapy with rituximab in the 
follicular NHL setting is currently the subject of active investigation.  Buckstein et al 
administered rituximab maintenance therapy to 17 patients with follicular NHL who had also 
received rituximab prior to the mobilization regimen.  At a median of one year follow-up, all 
assessable patients remained in CR and all 7 patients evaluable for molecular monitoring 
remained bcl-2 negative at 6 months.  In this same study, four of 12 patients who received alpha-
interferon instead of rituximab for maintenance relapsed at a median follow-up of 28 months 
[34].  Horwitz et al administered four weekly infusions of rituximab to 28 patients with NHL 
beginning 42 days after transplant with further infusions given at 6 months.  All patients had 
rapid depletion of B cells with no increase in infection or significant adverse events except for an 
isolated neutropenia that occurred in 54% of patients.  The neutropenic episodes did not result in 
significant adverse events and all episodes resolved spontaneously within seven days or 
responded to G-CSF administration.  At a median follow-up of 30 months, the event-free 
survival and OS was 83% and 88% respectively [35].  In other published reports, Magni et al and 
Ladetto et al demonstrated the safety and feasibility of incorporating rituximab for the purposes 
of in vivo purging and post-HSCT maintenance in patients with B-cell NHL including follicular 
NHL [31, 33].  There are other ongoing studies evaluating rituximab maintenance therapy post-
HSCT including a large comprehensive EBMT study that is evaluating both in vivo purging and 
maintenance with rituximab in a multi-center study with an accrual goal of 460 patients with 
follicular NHL in 2nd or 3rd remission. 
 
1.6. Allogeneic Hematopoietic Stem Cell Transplantation for Follicular Lymphoma 
 
High dose chemoradiotherapy with allogeneic hematopoietic stem cell/bone marrow 
transplantation has also been considered for patients with recurrent follicular NHL with the goal 
of harnessing a graft-versus-lymphoma effect and to circumvent the tumor cell contamination 
associated with autologous hematopoietic stem cell harvests [36-38].  Considerable evidence has 
shown that an immune-mediated graft-versus-malignancy effect occurs after allogeneic HSCT 
and that it contributes to the achievement of durable remissions in patients with hematologic 
malignancies [39-41].  The most direct evidence of the graft-versus-malignancy effect is the re-


BMT CLINICAL TRIALS NETWORK 
 
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
1-5 
induction of CR by withdrawal of immunosuppression and/or the infusion of donor lymphocytes 
in patients who had relapsed after allogeneic HSCT [42, 43].  This treatment strategy has been 
widely described among patients with acute and chronic myelogenous leukemia with several 
responses seen in lymphoma and myeloma patients [44-46].  Von Besien et al described 4 
patients with NHL who relapsed after allogeneic HSCT and then subsequently responded to 
withdrawal of immunosuppression [47]. 
 
Although no randomized trials have been performed, several studies have reported a lower risk 
of relapse compared to autologous HSCT.  However, this benefit has been invariably offset by 
the treatment-related mortality associated with allogeneic HSCT.  In 1997, the Center for 
International Blood and Marrow Transplant Research (CIBMTR) reported the results of 113 
patients with follicular NHL who underwent allogeneic HSCT with HLA-matched siblings [37].  
The three-year probability of DFS and OS was 49% with only a 16% incidence of relapse.  
However, treatment-related mortality was 40% with pulmonary complications leading the causes 
of non-relapse deaths.  A recently updated analysis from the CIBMTR compared the outcomes of 
904 patients with follicular NHL who underwent either myeloablative allogeneic HSCT (n=176), 
purged autologous HSCT (n=131) or unpurged autologous HSCT (n=597).  The risk for relapse 
was 54% lower in the allogeneic recipients (p<.001) and 26% lower in recipients of purged 
autotransplants (p=.04) than in recipients of unpurged autotransplants.  However, in a 
multivariate analysis, the risk of treatment-related mortality was 4.4 times higher after allogeneic 
than after autologous transplantation (p<.001), which resulted in comparable 5-year probabilities 
of overall survival(52% after allogeneic, 62% after purged autologous, 55% after unpurged 
autologous)[48].  In a smaller retrospective study from the Netherlands, the results of 18 patients 
who underwent autologous HSCT was compared to 10 patients who received an allogeneic 
HSCT.  The PFS rates after two years were 68% and 22% for the allogeneic and autologous 
patients, respectively.  Three of the allogeneic patients died from treatment-related mortality as 
opposed to none of the autologous patients [36]. 
 
1.6.1. Non-myeloablative Allogeneic Hematopoietic Stem Cell Transplantation 
 
Non-myeloablative allogeneic HSCT incorporates a less intensive preparative regimen and relies 
solely on the immunotherapeutic effects of the allograft to confer antileukemic activity rather 
than the cytoreductive effects of high dose chemotherapy.  The therapeutic benefit of allogeneic 
HSCT is derived from donor immunocompetent T cells that mediate an important graft-versus-
malignancy effect.  Initial attempts to administer an allogeneic hematopoietic stem cell graft 
without a conditioning regimen resulted in high rates of graft failure [49].  Therefore, it became 
apparent that some degree of immunosuppression is required to achieve engraftment and 
sustained mixed chimerism.  A mixed chimera patient has hematopoietic cells of donor and 
recipient origins for varying lengths of time following allogeneic hematopoietic stem cell 
transplantation as opposed to a complete chimeric patient where only cells of donor origin are 
detectable.  A mixed chimeric state may be adequate to be clinically efficacious in patients with 
autoimmune diseases or inborn errors of metabolism.  However, full donor chimerism or at least 
a high level of donor hematopoiesis may be a prerequisite to eliminate malignant cells and effect 
a cure [50, 51]. 
 


BMT CLINICAL TRIALS NETWORK 
 
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
1-6 
Non-myeloablative allogeneic HSCT also induces less immune compromise in the patient as the 
duration and depth of neutropenia is reduced and host-derived immunocompetent cells are not 
immediately eliminated.  Furthermore, the less intense regimen has been shown to allow for 
faster recovery of a T cell repertoire that is more complex and robust compared to the T cell 
repertoire of patients who received a myeloablative regimen [52, 53].  The transfusion 
requirements of recipients of non-myeloablative allogeneic HSCT are also significantly reduced 
compared to recipients of myeloablative allogeneic HSCT [54]. 
 
Some of the most promising data employing non-myeloablative allogeneic HSCT in follicular 
NHL patients was recently reported by the M.D. Anderson Cancer Center [55].  Twenty patients 
with indolent NHL received a conditioning regimen of fludarabine and cyclophosphamide + 
rituximab.  Tacrolimus and methotrexate were given for graft-versus-host disease (GVHD) 
prophylaxis.  The median age was 51 years old (range 31-68 years old) and all patients had 
advanced recurrent disease or were previously treated.  The median number of prior 
chemotherapy regimens ranged from 1-5 (median, 2).  All had received salvage chemotherapy 
and had stable or responding disease.  Twelve patients were in second or greater complete 
remission at the time of transplantation.  All patients achieved a CR after transplantation with no 
recurrences at a median follow-up of 21 months.  All patients achieved engraftment of donor 
cells with the median percentage of donor cells at 1 month being 80% (range, 10%-100%).  The 
actuarial probability of being alive and in remission at 2 years was 84%.  The incidence of grade 
II-IV acute GVHD was 20% and the cumulative incidence of chronic GVHD was 64%.  Only 
one patient died from a treatment-related complication.   
 
The EBMT recently described the use of reduced-intensity conditioning for 188 patients with 
low-grade lymphoma including 52 patients with follicular and small lymphocytic NHL.  The 
median age of the low grade NHL patients was 46(range, 27-65). The median number of prior 
chemotherapy regimens was 3 (range, 1-5) and 29% had previously received an autologous 
HSCT.  Forty-four (85%) demonstrated chemosensitive disease at the time of transplant.  Most 
patients received a fludarabine-based preparative regimen with 10% of patients receiving BEAM 
(BCNU, etoposide, cytarabine, melphalan), a more intensive and ablative regimen.  Of the low-
grade NHL patients, the 2 year PFS and OS was 54% and 65% respectively with a 21% 
progression rate.  Treatment-related mortality was 31%, which was considerably higher than the 
previously mentioned M.D. Anderson study.  The use of a more intensive conditioning regimen 
most likely contributed to toxicity [56].  
 
1.7. Study Approach and Treatment 
 
Numerous studies have demonstrated that autologous HSCT has clearly improved the PFS for 
patients with follicular lymphoma yet disease relapse remains a major obstacle to eventual cure 
of the disease.  This issue will be addressed by the addition of maintenance therapy with 
rituximab after autologous HSCT while the patient is in a state of minimal residual disease.  For 
those patients with an HLA-matched sibling, initial results of non-myeloablative allogeneic 
HSCT hold promise and will rely primarily on the graft-versus-malignancy effect to generate an 
anti-tumor response with the incorporation of rituximab in the conditioning regimen to enhance 
tumor control early and allow time for the graft-versus-malignancy effect to establish.  Adequate 
immunosuppression will be required to prevent both graft rejection and GVHD.  In this study 


BMT CLINICAL TRIALS NETWORK 
 
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
1-7 
these two treatment strategies will be compared in an effort to identify an optimal approach to 
the treatment of follicular NHL. 
 
Patients with either follicular small cleaved or follicular mixed NHL who have received ≤ 3 prior 
regimens and who have demonstrated chemosensitive disease will receive initial cytoreductive 
therapy with cyclophosphamide and rituximab with G-CSF support.  Patients will be biologically 
assigned to a treatment arm.  Patients with an HLA-matched sibling will receive a non-
myeloablative allogeneic HSCT using a conditioning regimen of fludarabine, rituximab and 
cyclophosphamide and an immunosuppressive regimen combined with tacrolimus and 
methotrexate for achieving donor engraftment and prevention of GVHD.  Patients without an 
available HLA-matched sibling will undergo an autologous HSCT.  The preparative regimen will 
consist of either total body irradiation or BCNU.  VP-16 and cyclophosphamide will be given for 
both autologous preparative regimens.  Rituximab will be administered to autologous patients 
post-HSCT to eradicate minimal residual disease.  Quantitative PCR monitoring for the bcl-2 
fusion transcript will be performed at baseline, after blood count recovery from mobilization 
therapy, and on Days +28, +84, +180 and yearly until three years post-HSCT if positive at any 
time since diagnosis until the initial study evaluation.  The primary objective will be to compare 
3-year progression-free survival between the two groups. 


BMT CLINICAL TRIALS NETWORK 
 
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
2-1 
CHAPTER 2 
 
 
2. 
STUDY DESIGN 
 
2.1. Study Overview 
 
The overall study design is that of biologic assignment based on the availability of an HLA-
matched sibling, to one of two strategies to improve the outcome for follicular lymphoma 
patients with chemosensitive disease.  All patients will undergo cytoreduction with 
cyclophosphamide 4 gm/m2 and rituximab 375 mg/m2 x 2 doses.  Rituximab will be given in two 
doses, approximately 1 week apart, with the cyclophosphamide administered the day after the 
first dose of rituximab.  Patients assigned to the autologous arm will have their hematopoietic 
stem cells mobilized from this cytoreductive regimen.  Patients with an HLA-matched sibling 
will undergo a non-myeloablative allogeneic HSCT.  Pre-transplant conditioning will consist of 
fludarabine 30 mg/m2/day and cyclophosphamide 750 mg/m2/day x 3 days with rituximab 375 
mg/m2/day on Days -13 and -6 pre-HSCT and on Days +1 and +8 post-HSCT.  The 
immunosuppressive regimen will consist of tacrolimus and methotrexate (MTX) to control graft-
versus-host and host-versus-graft reactions.  Patients without an HLA-matched sibling who have 
collected an adequate autologous hematopoietic cell graft, defined as ≥ 2.0 x 106 CD34+ cells/kg, 
will receive a preparative regimen of total body irradiation (TBI) 1200 cGy or BCNU 15 mg/kg.  
In addition, VP-16 60 mg/kg and cyclophosphamide 100 mg/kg will be given for both 
autologous preparative regimens.  Post-autologous HSCT therapy with rituximab 375 mg/m2 
weekly x 4 doses will commence between Days 42-75 post-HSCT. 
 
A secondary analysis comparing the outcome of autologous HSCT patients will be made against 
contemporary/historical controls who underwent autologous HSCT but did not receive rituximab 
maintenance chemotherapy.  These patients will be identified from the CIBMTR database. 
 
2.2. Hypothesis and Specific Objectives 
 
2.2.1. Hypothesis 
 
Non-myeloablative allogeneic hematopoietic stem cell transplantation will reduce the rate of 
disease progression compared to autologous hematopoietic stem cell transplantation.  For 
patients with a matched sibling donor, an allogeneic strategy may prove superior to an 
autografting strategy since the immunotherapeutic effects of an allograft is a potentially powerful 
therapy in eradicating minimal residual disease and conferring a lasting anti-tumor effect. 
 
The addition of maintenance rituximab post-autologous HSCT will improve the PFS of patients 
compared to contemporary/historical controls undergoing autologous HSCT without 
maintenance rituximab. 
 


BMT CLINICAL TRIALS NETWORK 
 
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
2-2 
2.2.2. Study Objectives 
 
The primary objective is to compare 3-year progression-free survival between the two transplant 
arms.  Secondary objectives will compare 3-year survival, time to progression, time to CR and 
PR, time to off-study therapy, incidence of infection and incidence of Common Terminology 
Criteria for Adverse Events (CTCAE) Version 3.0 Grade ≥ 3 toxicities.  The efficacy of 
cyclophosphamide plus rituximab in vivo purging will also be evaluated as well as the prediction 
of relapse by measurement of t(14;18) by quantitative PCR.  Other secondary outcomes in the 
allogeneic transplant arm include the incidence and severity of acute and chronic GVHD and 
primary and secondary graft failure.  Health-related quality of life for English and Spanish 
speaking patients of both groups will be described and exploratory comparisons will be made 
between the two groups.  The relative safety of the two arms will be assessed through the 
collection of toxicity data, routine laboratory monitoring and adverse event monitoring. 
 
2.3. Patient Eligibility 
 
Patients must meet specified eligibility criteria to enroll on the study.  Additional criteria must 
also be met to continue to successive stages of the protocol.  All questions regarding eligibility 
criteria should be directed to the Protocol Coordinator at 301-251-1161. 
 
2.3.1. Initial Patient Inclusion Criteria 
 
Patients fulfilling the following criteria will be eligible for entry into this study: 
1. Patients with histologically confirmed recurrent REAL classification follicle center 
lymphoma, follicular grades I and II, OR patients with histologically confirmed WHO 
classification follicular lymphoma grades 1, 2, 3a or 3b.  For either classification, the 
diffuse component or presence of large cleaved cells (if present) cannot be > 50% of high 
power field.  Patients do not have to express t(14;18) to be eligible. 
2. Patients who are ≤ 75 years old at time of first registration. 
3. Patients who have received ≤ 3 prior regimens of chemotherapy.  Monoclonal antibody 
therapy and involved field radiation therapy will not be counted as a prior therapy. 
4. Patients who are beyond 1st CR or 1st PR AND who demonstrate chemosensitive disease 
are eligible for the study.  Chemosensitive disease will be defined as < 20% bone marrow 
involvement in the aspirate or core biopsy with follicular lymphoma AND lymph node 
size in axial diameter of < 3 cm or a > 50% reduction in estimated lymph node volume to 
be measured as product of bi-dimensional measurements.  PET scanning will not be used 
for staging or response purposes. 
5. Patients with adequate organ function as measured by: 
a) Cardiac:  left ventricular ejection fraction at rest ≥ 45% 
b) Hepatic:  bilirubin < 2x the upper limit of normal and ALT and AST < 3x the 
upper limit of normal 
c) Renal:  creatinine clearance > 40 mL/min 


BMT CLINICAL TRIALS NETWORK 
 
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
2-3 
d) Pulmonary:  DLCO, FEV1, FVC ≥ 50% of predicted (corrected for hemoglobin) 
6. If the patient is < 18 years of age and they have reached the age of assent, then they must 
have completed the local IRB assent process. 
7. Patients who have signed the informed consent. 
8. Patients must be able to receive cyclophosphamide and rituximab mobilization 
chemotherapy no earlier than 3 weeks from the beginning of the most recent cycle of 
salvage chemotherapy and no later than 6 weeks from enrollment. 
 
2.3.2. Initial Patient Exclusion Criteria 
 
Patients with the following will be ineligible for registration onto this study: 
 
1. Karnofsky performance score < 70%. 
2. Patients with follicular lymphoma that show histologic evidence of transformation. 
3. Patients with uncontrolled hypertension. 
4. Patients with uncontrolled bacterial, viral or fungal infection (currently taking medication 
and progression without clinical improvement). 
5. Patients with prior malignancies except resected basal cell carcinoma or treated cervical 
carcinoma in situ.  Cancer treated with curative intent > 5 years previous will be reviewed 
on a case-by-case basis by a Protocol Chair or Medical Monitor. 
6. Female patients who are pregnant (positive β-HCG) or breastfeeding. 
7. Patients seropositive for HIV. 
8. Fertile men or women unwilling to use contraceptive techniques during treatment. 
9. Prior autologous or allogeneic HSCT. 
10. Known anaphylactic reaction to rituximab. 
 
2.4. Patient Eligibility Criteria for Proceeding to HSCT 
 
In order to continue on protocol and receive either an autologous or non-myeloablative HSCT, 
the following conditions must be achieved:  
 
1. Collection of an autologous or allogeneic graft of ≥ 2.0 x 106 CD34+ cells/kg 
2. Blood count recovery defined as ANC > 1000/mm3 and platelets > 100 x 109/L 
 
Patients must be able to proceed to either non-myeloablative allogeneic or autologous HSCT 
within six weeks of peripheral blood count recovery following the cytoreductive/mobilization 
regimen outlined in Section 2.7.3.  Autologous patients will undergo leukapheresis upon blood 
count recovery. 
 


BMT CLINICAL TRIALS NETWORK 
 
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
2-4 
If peripheral blood counts have not recovered within a standard time frame, the patient’s 
treatment plan should be discussed with a Protocol Chair or Medical Monitor.  A decision 
regarding the patient’s future treatment will be made on a case-by-case basis. 
 
2.5. Patient Eligibility Criteria for Maintenance Therapy for Recipients of Autologous 
HSCT 
 
In order to be eligible to continue on protocol and receive maintenance therapy with rituximab, 
patients must have recovered sufficiently from their autologous transplant.  Rituximab will be 
given to patients between Day 42 and Day 75 post-HSCT. 
 
Recovery from autografting will be defined as achievement of the following clinical criteria: 
 
1. Liver and renal function tests within the inclusion criteria for initial autograft. 
2. Off intravenous antibiotics and off amphotericin B formulations for proven, probable or 
possible fungal infections. 
3. No active CMV infections or for patients with CMV infection post-autograft, treated with 
ganciclovir, valganciclovir or foscarnet per institutional guidelines and CMV antigenemia 
negative. 
4. Mucositis resolved and off hyperalimentation. 
 
2.6. Allogeneic Hematopoietic Stem Cell Donor Criteria 
 
2.6.1. Donor Inclusion Criteria 
 
1. The donor must be a 6/6 HLA phenotypically matched sibling to the patient.  The 
minimum level of typing is HLA –A, -B by serologic methodology and HLA DRB1 by 
DNA methodology. 
2. If the donor is < 18 years of age and they have reached the age of assent, then they must 
have completed the local IRB assent process. 
3. Donor must consent to G-CSF administration and to leukapheresis for HSC collection. 
4. Donor must have adequate veins for leukapheresis or agree to placement of central venous 
catheter (femoral, subclavian). 
5. Age ≤ 75 years at the time patient is initially registered on study. 
 
2.6.2. Donor Exclusion Criteria 
 
1. Identical twin of patient. 
2. Female patients who are pregnant (positive β-HCG) or breastfeeding. 
3. Infection with HIV, viral hepatitis (B or C). 
4. Known allergy to G-CSF. 


BMT CLINICAL TRIALS NETWORK 
 
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
2-5 
5. Current serious systemic illness. 
6. Uncontrolled bacterial, viral or fungal infection (currently taking medication and 
progression of clinical symptoms). 
7. Donors receiving experimental therapy or investigational agents. 
8. Donors with cancer other than treated basal cell or carcinoma in situ of cervix.  Cancer 
treated with curative intent > 5 years previous will be reviewed on a case-by-case basis by 
a Protocol Chair or Medical Monitor. 
 
2.7. Study Treatments 
 
The immediate pre-HSCT evaluation will be carried out according to the operating procedures of 
the participating institutions and should be in keeping with the data reporting requirements of 
this study.  Similarly, special orders and procedures will be those defined by the BMT CTN 
Manual of Procedures (MOP).  All patients enrolled on this protocol will be hospitalized in 
accordance with the procedures for recipients of autologous and non-myeloablative allogeneic 
HSCT as defined by the treating institutions.  All questions regarding study treatments should be 
directed to the Protocol Coordinator at 301-251-1161. 
 
2.7.1. HLA-Typing of Potential Sibling Donors 
 
All potential sibling donors must be HLA-typed.  HLA-matched siblings must be evaluated for 
suitability for donation until either an HLA-matched sibling donor is identified or all HLA-
matched siblings are excluded as donors.  This testing and evaluation must be completed by the 
time of study enrollment. 
 
2.7.2. Body Weight Formulas 
 
All chemotherapy, rituximab and tacrolimus (or cyclosporine, if applicable) should be dosed 
based on ideal body weight (IBW) for patients who weigh 100-120% of their IBW.  For patients 
who weigh less than 100% of their IBW, dosing should be based on actual body weight (ABW).  
For patients who weigh more than 120% of their IBW, dosing should be based on the adjusted 
ideal body weight (AIBW).   
 
1.  Ideal Body Weight (IBW) Formulas: 
  
Males IBW = 50 kg + 2.3 kg/inch over 5 feet 
  
Females IBW = 45.5 + 2.3 kg/inch over 5 feet 
  
For patients less than 5 feel, subtract 2.3 kg/inch 
2.  Adjusted Ideal Body Weight (AIBW) Formula: 
  
AIBW = IBW + [(0.25) x (ABW – IBW)] 
 


BMT CLINICAL TRIALS NETWORK 
 
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
2-6 
2.7.3. Cytoreductive Therapy/Mobilization Chemotherapy 
 
2.7.3.1. 
Allopurinol 
 
Patients may receive allopurinol 300 mg/day PO for 10 days starting one day prior to receiving 
the cyclophosphamide according to local institutional practice.  (Dose adjusted according to 
renal function per standard recommendations.) 
 
2.7.3.2. 
Cyclophosphamide and rituximab administration/mobilization 
 
Prior to undergoing autologous or non-myeloablative allogeneic HSCT, all patients will receive 
cyclophosphamide 4 gm/m2 with rituximab 375 mg/m2 x 2 doses with G-CSF support.  See 
Table 2.7.3.2 for the treatment schedule.  This regimen shall begin no earlier than 3 weeks 
from the beginning of the most recent cycle of salvage chemotherapy and no later than 6 
weeks post-enrollment.  Rituximab may be administered in the office/hospital of the referring 
hematologist/oncologist.  Cyclophosphamide must be administered at the transplant center.  
 
 
Table 2.7.3.2:  Cytoreductive/Mobilization Treatment Schedule 
 
Day 
1 
2 
3 
4 
5 
6 
7 
8 
Cyclophosphamide  4 g/m2 
 
X 
 
 
 
 
 
 
Rituximab 375 mg/m2 
X 
 
 
 
 
 
 
X 
G-CSF 10 mcg/kg or 5 mcg/kg * 
 
 
 
X--------------------------- 
 
1. Cyclophosphamide:  4 g/m2 IV x 1 dose to be administered over 2 hours on Day 2 of the 
schedule.  Hydration, if used per institutional guidelines, is to be started pre-
cyclophosphamide and continued until 24 hours after the completion of the 
cyclophosphamide infusion.  Alternatively, mesna may be used in doses per institutional 
guidelines (recommended usage is at least 20% of the cyclophosphamide dose prior to each 
dose of cyclophosphamide and repeated 4 hours and 8 hours after each cyclophosphamide 
dose).  
 
Cyclophosphamide should be dosed based on ideal body weight (IBW) for patients who 
weigh 100-120% of their IBW.  For patients who weigh less than 100% of their IBW, 
dosing should be based on actual body weight (ABW).  For patients who weigh more than 
120% of their IBW, dosing should be based on the adjusted ideal body weight (AIBW).  
See Section 2.7.2 for body weight formulas. 
 
2. Rituximab:  375 mg/m2 IV x 2 doses total, with the first dose to be administered on Day 1 
and the second dose administered on Day 8.  Mix rituximab in either 0.9% NS or D5W 
according to institutional practice.  Rituximab must be infused through an infusion pump 
and should not be mixed or diluted with any other solutions or drugs.  Doses may be 
rounded to nearest vial size (e.g. if dose is ≤ 750 mg, then round to 700 mg; if > 750 mg, 
then round to 800 mg).  Dosing is based on the body weight formulas in Section 2.7.2. 
 


BMT CLINICAL TRIALS NETWORK 
 
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
2-7 
Premedication should be administered prior to rituximab per institutional guidelines 
(recommended: diphenhydramine 50 mg PO, 30 minutes prior to treatment and 
acetaminophen 650 mg PO, 30 minutes prior to treatment). 
 
3. G-CSF*:  10 mcg/kg for the autologous patients administered at once, or fractionated to 5 
mcg/kg SQ BID, or 5 mcg/kg for the allogeneic patients SQ or IV to start daily on Day 4 (2 
days after cyclophosphamide administration).  G-CSF dosing can be rounded based on 
patient’s actual body weight (see Section 2.7.2 for body weight formulas) and available G-
CSF vial sizes to best approximate of 10 mcg/kg or 5 mcg/kg (e.g. < 70 kg use 300 mcg 
vial, 70 to 90 kg use 480 mcg vial and > 90 kg use 2 x 300 mcg vials). 
 
For the autologous HSCT patients, autologous hematopoietic stem cells will be 
collected after the cyclophosphamide + rituximab + G-CSF regimen.  G-CSF will 
continue until leukapheresis is complete.  Leukapheresis will commence per institutional 
guidelines and will continue until the target of ≥ 2.0 x 106  CD34+ cells/kg are collected.  
Cells will be cryopreserved per institutional guidelines.  Patients who collect ≥ 1.0 x 106 
CD34+ cell/kg but  < 2.0 x 106  CD34+ cells/kg will proceed to high dose chemotherapy. 
 
Patients with < 1.0 x 106 CD34+ cells/kg after three collections will continue to be followed 
for relapse, progression and survival.  Patients may proceed to transplant off-study at the 
discretion of their attending physician and subsequent management of these patients is at 
the discretion of their attending physician. 
 
For autologous HSCT patients, G-CSF will continue until leukapheresis is complete.  For 
the non-myeloablative allogeneic HSCT patients, G-CSF will continue until ANC  
> 500/mm3 x 3 days. 
 
2.7.4. High Dose Chemotherapy with Autologous HSCT 
 
Patients without an available HLA-matched sibling will proceed to autologous HSCT.  Patients 
must proceed to HSCT within six weeks of peripheral blood count recovery following the 
cytoreductive regimen outlined in Section 2.7.3.  Blood count recovery will be defined as ANC > 
1000/mm3 and platelets > 100 x 109/L.  Two conditioning regimens are available: a 
chemotherapy only regimen or a TBI-based regimen.  See Tables 2.7.3.2 and 2.7.4.1, 
respectively. 
 
At the commencement of this trial, institutions must specify if they will be uniformly using 
the TBI-based or chemotherapy-based regimen.  If for some reason in a center that has 
specified that the TBI regimen will be used (i.e. previous involved field radiation therapy 
precludes patient from TBI), a patient cannot receive TBI, the chemotherapy-based regimen 
specified below must be utilized and this must be noted at the time of patient registration. 
 
Patients who are 60 years and older will be assigned to receive the chemotherapy-based 
conditioning regimen. 
 


BMT CLINICAL TRIALS NETWORK 
 
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
2-8 
2.7.4.1. 
Conditioning regimen - chemotherapy-based regimen 
 
Table 2.7.4.1:  Autologous HSCT - Chemotherapy-Based Regimen 
 
Day 
-6 
-5 
-4 
-3 
-2 
-1 
0 
+5 
BCNU 
15 mg/kg 
 
VP-16 
60 mg/kg 
 
Cyclophosphamide 
100 mg/kg 
 
PBSCT 
G-CSF 
5 mcg/kg 
 
1. BCNU:  15 mg/kg based on the body weight formulas in Section 2.7.2 (maximum dose not 
to exceed 550 mg/m2 based on actual body weight) IV x 1 dose to be administered over 2 
hours on Day -6 pre-HSCT. 
2. VP-16:  60 mg/kg IV x 1 dose to be administered over 4 hours on Day -4.  VP-16 dosing 
should be based on ideal body weight (IBW) for patients who weigh 100-120% of their 
IBW.  For patients who weigh less than 100% of their IBW, dosing should be based on 
actual body weight (ABW).  For patients who weigh more than 120% of their IBW, dosing 
should be based on the adjusted ideal body weight (AIBW).  See Section 2.7.2 for body 
weight formulas.  The concentrated etoposide solution (20 mg/mL) is to be drawn up into 
syringes and administered via a syringe pump or transferred to an empty non-DEPH bag 
for infusion.  Administer the etoposide dose via a Y-site connection or an adjacent lumen 
running concomitantly with normal saline at 200 mL/hr. 
3. Cyclophosphamide:  100 mg/kg IV x 1 dose to be administered over 2 hours on Day -2 
pre-HSCT. 
Cyclophosphamide should be dosed based on ideal body weight (IBW) for patients who 
weigh 100-120% of their IBW.  For patients who weigh less than 100% of their IBW, 
dosing should be based on actual body weight (ABW).  For patients who weigh more than 
120% of their IBW, dosing should be based on the adjusted ideal body weight (AIBW).  
See Section 2.7.2 for body weight formulas. 
4. G-CSF:  5 mcg/kg SQ or IV to start on Day +5 post-HSCT and continue until ANC  
> 500/mm3 x 3 days.  G-CSF dosing should be based on actual body weight – see Section 
2.7.2 for body weight formulas.  G-CSF dosing can be rounded based on patient weight and 
available G-CSF vial sizes to best approximate 5 mcg/kg (e.g., < 70 kg use 300 mcg vial, 
70 to 90 kg use 480 mcg vial and > 90 kg use 2 x 300 mcg vials). 
 
2.7.4.2. 
Conditioning regimen - total body irradiation-based regimen 
 
Table 2.7.4.2:  Autologous HSCT - TBI-Based Regimen 
 
Day 
-8 
-7 
-6 
-5 
-4 
-3 
-2 
-1 
0 
+5 
FTBI 
 
FTBI 
 
FTBI 
 
FTBI 
 
VP-16 
60 
mg/kg 
 
Cyclophosphamide 
100 mg/kg 
 
PBSCT 
G-CSF 
5 mcg/kg 
 


BMT CLINICAL TRIALS NETWORK 
 
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
2-9 
1. Fractionated Total Body Irradiation:  TBI may be administered according to either one 
of the following two schedules: 
A) Hyperfractionated TBI: TBI is administered at a dose rate of < 20 cGy/minute.  Doses 
of 120 cGy/fraction are administered at no less than 4-hour intervals three times/day or 
2 times/day for a total of 10 doses (1200 cGy) over 4 days (Day -8, -7, -6 and -5).  The 
exact number of treatments per day (one to three) can vary according to institutional 
practice but should include a total of 10 treatments over 4 days.  Sequential doses are 
administered anteriorposterior with standard (5 half value) lung blocks shielding the 
lung parenchyma for the final 600 cGy.  At the time of the last two TBI fractions, the 
blocked areas of anterior and posterior chest walls will be boosted with electrons to a 
cumulative chest wall dose of approximately 1200 cGy (300 cGy/fraction x 2 anteriorly 
and posteriorly). Alternatively, the TBI treatments may be administered with 50% 
transmission lung blocks anteriorly and posteriorly throughout, with the electron chest 
wall boosts to 1200 cGy (300 cGy x 2, anteriorly and posteriorly) administered during 
the course of the 10 TBI treatments.  The energy of the electron beam will be chosen to 
deliver 90% of the dose to the chest wall.  The dose will be calculated at the central axis 
in the midplane.  Appropriate dosimetry will be confirmed prior to or during the 1st TBI 
treatment and compensators will be allowed to keep the dose inhomogeneity at ≤ 10%.  
Corrections for lung inhomogeneity are not required. 
B) Fractionated TBI: This regimen calls for doses of 150 cGy/fraction administered at the 
same dose rate (< 20 cGy/min) twice daily for a total of 8 doses (1200 cGy) over 4 days 
(Day -8, -7, -6 and -5).  Doses are separated by a minimum of 5 hours.  The dose to the 
lungs will reduced to 50% by partial transmission lung blocks used during all TBI 
treatments or full thickness (5 HVL) lung blocks during 5 TBI treatments.  The chest 
wall should then be boosted to a cumulative total dose of 1200 cGy with electrons (300 
cGy/fraction x 2 anteriorly and posteriorly).  The dose will be calculated at the central 
axis in the midplane.  Appropriate dosimetry will be confirmed prior to or during the 1st 
TBI treatment and compensators will be allowed to keep the dose inhomogeneity at  
≤ 10%.  Corrections for lung inhomogeneity are not required. 
2. VP-16:  60 mg/kg IV x 1 dose to be administered over 4 hours on Day -4 pre-HSCT.  VP-
16 dosing should be based on the body weight formulas in Section 2.7.2.  Infuse through an 
IV of normal saline at 250 cc/hr (see previous regimen comment). 
3. Cyclophosphamide: 100 mg/kg IV x 1 dose to be administered over 2 hours on Day -2 
pre-HSCT.   
Cyclophosphamide should be dosed based on ideal body weight (IBW) for patients who 
weigh 100-120% of their IBW.  For patients who weigh less than 100% of their IBW, 
dosing should be based on actual body weight (ABW).  For patients who weigh more than 
120% of their IBW, dosing should be based on the adjusted ideal body weight (AIBW).  
See Section 2.7.2 for body weight formulas. 
4. G-CSF:  5 mcg/kg SQ or IV to start on Day +5 post-HSCT and continue until  
ANC > 500/mm3 x 3 days.  G-CSF dosing can be rounded based on patient’s actual weight 
and available G-CSF vial sizes to best approximate 5 mcg/kg (e.g., < 70 kg use 300 µg vial, 
70 to 90 kg use 480 µg vial and > 90 kg use 2 x 300 µg vials). 
 


BMT CLINICAL TRIALS NETWORK 
 
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
2-10 
2.7.4.3. 
Rituximab maintenance therapy 
 
Patients must have sufficiently recovered from autologous HSCT as defined in Section 2.5 in 
order to receive rituximab maintenance therapy as specified below: 
 
Dose #1:  Day +42 post-autologous HSCT 
 
Dose #2:  Day +49 post-autologous HSCT 
 
Dose #3:  Day +56 post-autologous HSCT 
 
Dose #4:  Day +63 post-autologous HSCT 
Rituximab should be given on or around Day +42 post-autologous HSCT but can be given up to 
Day +75 post-autologous HSCT if patients are not fully recovered by Day +42 post-autologous 
HSCT.  If the patient has not fully recovered at Day +75 post-HSCT, a Protocol Chair or 
Medical Monitor should be contacted regarding future treatment plans.  Rituximab will be 
administered weekly in doses of 375 mg/m2 IV x 4.  Mix rituximab in either 0.9% NS or D5W 
according to institutional practice.  Rituximab must be infused through an infusion pump and 
should not be mixed or diluted with any other solutions or drugs.  Premedication should be 
administered prior to rituximab per institutional guidelines (recommended: diphenhydramine 50 
mg PO, 30 minutes prior to treatment and acetaminophen 650 mg PO, 30 minutes prior to 
treatment). 
 
2.7.5. Non-myeloablative Allogeneic Stem Cell Transplantation for Patients with an HLA- 
matched Sibling 
 
Within 6 weeks of peripheral blood count recovery following the cytoreductive regimen outlined 
in Section 2.7.3, patients with an available 6/6 HLA-matched sibling will proceed to a non-
myeloablative allogeneic HSCT.  Blood count recovery will be defined as ANC > 1000/mm3 and 
platelets > 100 x 109/L. 
 
Pre-HSCT conditioning and hematopoietic stem cell infusion may be administered on an 
outpatient basis.  Patients must comply with all scheduled study visits whether receiving their 
transplant as in inpatient or an outpatient. 
 
Table 2.7.5:  Non-myeloablative Allogeneic HSCT Schedule* 
 
Day 
-13 
-6 
-5 
-4 
-3 
-2 
-1 
0 
1 
8 
Fludarabine 30 mg/m2 
 
X 
X 
X 
 
 
 
 
 
 
Cyclophosphamide 
750 mg/m2 
 
X 
X 
X 
 
 
 
 
 
 
Rituximab 375 mg/m2 
X 
X 
 
 
 
 
 
 
X 
X 
PBSCT 
 
 
 
 
 
 
 
X 
 
 
* See Section 2.7.2 for body weight formulas. 
 


BMT CLINICAL TRIALS NETWORK 
 
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
2-11 
2.7.5.1. 
Conditioning regimen 
 
1. Fludarabine:  30 mg/m2 IV x 3 doses total to be administered daily over 30 minutes on 
Days -6, -5 and -4 pre-HSCT.  Dosing is based on the body weight formulas in Section 
2.7.2. 
 
2. Cyclophosphamide: 750 mg/m IV x 3 doses total to be administered daily over 1 hour on 
Days -6, -5 and -4 pre-HSCT.  Administer cyclophosphamide approximately 4 hours after 
start of fludarabine infusion.  Dosing is based on the body weight formulas in Section 2.7.2. 
 
3. Rituximab:  375 mg/m2 IV x 4 doses total to be administered on Days -13 and -6 pre-
HSCT and Days +1 and +8 post-HSCT.  Mix rituximab in either 0.9% NS or D5W 
according to institutional practice.  Dosing is based on the body weight formulas in Section 
2.7.2.  Rituximab must be infused through an infusion pump and should not be mixed or 
diluted with any other solutions or drugs. 
 
2.7.5.2. 
Graft-versus-host disease (GVHD) prophylaxis 
 
Table 2.7.5.2:  GVHD Prophylaxis Schedule 
 
DAY 
-2 
-1 
0 
1 
2 
3 
4 
5 
6 
Tacrolimus 0.09 mg/kg PO 
or 0.03 mg/kg IV 
X 
 
 
Daily until Day +90, then start taper 
Methotrexate 5 mg/m2 IV 
 
 
 
X 
 
X 
 
 
X 
 
1. Tacrolimus: 0.09 mg/kg/day PO, based on body weight formulas in Section 2.7.2, will 
start on Day -2 and continue until Day +90 post-HSCT.  Tacrolimus (or cyclosporine, if 
applicable) will be given orally in a twice-daily divided dose.  Tacrolimus dosing should be 
based on actual body weight – see Section 2.7.2 for body weight formulas.  Doses should 
be adjusted to maintain whole blood “trough” levels at 5-15 ng/mL.  Tapering of tacrolimus 
doses should commence starting at Day +90 post-HSCT to be completely discontinued by 
Day +180 post-HSCT unless GVHD Grade  III develops.  An equivalent dose of IV 
tacrolimus may be used as per local institutional preference.  Patients with severe 
intolerance to tacrolimus may be placed on cyclosporine. 
 
Patients with severe intolerance to tacrolimus may be placed on cyclosporine at a starting 
dose of 5 mg/kg bid PO based on actual body weight.  An equivalent dose of IV 
cyclosporine may be used as per institutional practice. Doses should be adjusted to 
maintain whole blood “trough” levels that target 500 ng/mL (upper end of therapeutic 
range) during the first month.  Dose reductions should only be made if CSA toxicity is 
present or whole blood levels exceed 600 ng/mL in the absence of toxicity.  Further CSA 
determinations should be performed weekly until CSA is stopped unless high levels are 
detected (i.e., > 600 ng/mL), or toxicity is suspected, in which case more frequent 
monitoring will be performed as clinically indicated.  Dose reductions for high levels 


BMT CLINICAL TRIALS NETWORK 
 
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
2-12 
without 
toxicity 
should 
be 
conservative 
(e.g., 
25%) 
to 
avoid 
inadequate 
immunosuppression.   
 
After Day 28, the CSA level is to be kept within 200-400 ng/mL, according to local 
institutional practice until the Day +90 taper is initiated. 
 
2. Methotrexate: 5 mg/m2 IVP will be administered on Days +1, +3 and +6 post-HSCT.  In 
the event of renal/hepatic impairment, dose changes should be made according to the 
following guidelines: 
 
Bilirubin mg/dL 
% Dose 
Creatinine mg/dL 
% Dose 
< 2.0 
100 
< 1.5 
100 
2.1 – 3.0 
50 
1.5 – 1.7 
75 
3.1 – 5.0 
25 
1.8 – 2.0 
50 
> 50 
hold dose 
> 2.0 
hold dose 
 
 
2.7.6. Collection and Infusion of Allogeneic HSC 
 
2.7.6.1. 
G-CSF administration to donors 
 
All donors will receive G-CSF 16 mcg/kg/day for 5 consecutive days from Day -4 pre-HSCT to 
Day 0.  G-CSF dosing should be based on actual body weight – see Section 2.7.2 for body 
weight formulas.  G-CSF will be administered by daily subcutaneous injections.  If necessary, 
based on volume, the G-CSF can be given in multiple injection sites.  These doses will be 
administered before 10:00 AM each day.  G-CSF dosing can be rounded based on donor weight 
and available G-CSF vial sizes to best approximate 16 mcg/kg. 
 
2.7.6.2. 
 HSC collection and evaluation 
 
Donors will preferably undergo vein-to-vein collections but may receive an appropriate central 
venous catheter inserted on or before the day of apheresis.  HSCs will be collected on Day -1 
pre-HSCT and stored in the refrigerator at 2-8°C overnight.  If necessary, a second collection 
will be performed the following day and both collections will be infused.  Each collection will be 
separately evaluated in the laboratory for cellular composition in keeping with the BMT CTN 
MOP for graft characterization. 
 
A minimum dose of 2.0 x 106 CD34+ cells/kg will be collected (according to institutional 
practices) and given.  If ≥ 5.0 x 106 CD34+ cells/kg are collected on Day -1, a second collection 
will not be necessary.  If < 2.0 x 106 CD34+ cells/kg are collected after 2 aphereses, a 3rd 
collection must be performed on Day +1.  All cells collected should be infused.  
Cryopreservation of donor hematopoietic stem cells may be acceptable, but this must be 
discussed in advance with a Protocol Chair or Medical Monitor.  
 
If < 1.0 x 106 CD34+ cells/kg are collected from the donor after three collections, patients may 
proceed to transplant off-study at the discretion of their attending physician and subsequent 


BMT CLINICAL TRIALS NETWORK 
 
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
2-13 
management of these patients is at the discretion of their attending physician.  However, such 
patients will continue to be followed for relapse, progression and survival.   
 
Table 2.7.6.2:  Treatment Schedule for Donor 
 
Days 
-4 
-3 
-2 
-1 
0 
1 
G-CSF 16 mcg/kg 
X 
X 
X 
X 
X 
 
HSC Collection 
 
 
 
X 
X* 
X** 
HSC Administration 
 
 
 
 
X 
X** 
*  The 2nd HSC collection can be cancelled only if ≥ 5.0 x 106 CD34+ cells/kg are 
collected with the 1st apheresis.  G-CSF administration is not required on Day 
0 if the second collection is cancelled. 
** A 3rd collection is required if < 2.0 x 106 CD34+ cells/kg are collected with the 
2 previous aphereses. 
 
2.7.6.3. 
Allogeneic hematopoietic stem cell infusion 
 
All patients will receive unmodified (other than volume reduction) G-CSF mobilized 
hematopoietic stem cells from an HLA-matched sibling on Day 0 of the treatment regimen.  The 
hematopoietic stem cells will be infused via a central venous catheter using standard blood 
infusion tubing.   
 
2.8. Supportive Care 
 
2.8.1. Post-autologous HSCT 
 
All supportive care will be given in keeping with BMT CTN MOP or local institutional 
guidelines. 
 
2.8.1.1. 
Prophylaxis against infections 
 
All patients will receive prophylaxis against bacterial, fungal and viral infections during the post-
HSCT period according to the BMT CTN MOP or local institutional guidelines.  Additional 
specifications/requirements for this study are summarized below.  Infectious prophylaxis will 
include prophylaxis for: 
 
1. Anti-bacterial:  In keeping with the BMT CTN MOP or local institutional standards. 
2. Pneumocystis carinii:  Prophylaxis will start at the time of engraftment or on Day +30 
post-autologous transplant according to institutional preference.  Prophylaxis should be 
continued until at least 6 months following the autologous HSCT. 
3. Anti-fungal Therapy:  Anti-fungal prophylaxis will be per local institutional practice and 
must be uniformly applied to all patients within each respective center. 
4. HSV/VZV:  Antiviral prophylaxis will be per local institutional practice and must be 
uniformly applied to all patients within each respective center. 


BMT CLINICAL TRIALS NETWORK 
 
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
2-14 
5. IVIG:  Replacement to be initiated according to institutional practice if IgG levels fall 
below 500 mg/dL. 
 
2.8.1.2. 
Blood products 
 
Transfusion thresholds for blood product support will be in keeping with BMT CTN MOP and 
standard institutional guidelines.  All blood products will be irradiated. 
 
2.8.1.3. 
Post-HSCT immunization schedule 
 
Immunization may be given in keeping with the BMT CTN MOP (or local institutional practice). 
 
2.8.2. Post Non-myeloablative Allogeneic HSCT 
 
All supportive care will be given in keeping with BMT CTN MOP and local institutional 
guidelines. 
 
2.8.2.1. 
Prophylaxis against infections 
 
All patients will receive prophylaxis against bacterial, fungal and viral infections during the post-
HSCT period according to the BMT CTN MOP.  Additional specifications/requirements for this 
study are summarized below.   
 
Infectious prophylaxis will include prophylaxis for: 
 
1. Anti-bacterial:  In keeping with the BMT CTN MOP and local institutional standards. 
2. Pneumocystis carinii:  Prophylaxis will start at the time of engraftment or on Day +30 post 
non-myeloablative allogeneic HSCT transplant according to institutional preference.  
Prophylaxis should be continued for at least 1 month after the patient is off all 
immunosuppressive medications. 
3. Anti-fungal Therapy:  Anti-fungal prophylaxis will be per local institutional practice and 
must be uniformly applied to all patients within each respective center. 
4. HSV/VZV:  Antiviral prophylaxis will be per local institutional practice and must be 
uniformly applied to all patients within each respective center. 
5. CMV:  Monitoring and preemptive treatment strategy will be in accordance with the BMT 
CTN Technical Committee (Infectious Diseases) MOP and local institutional practice.  
The duration of monitoring is recommended for at least 100 days post non-myeloblative 
allogeneic HSCT and longer if the patient is on immunosuppressive medications. 
6. IVIG:  Replacement to be initiated according to institutional practice if IgG levels fall 
below 500 mg/dL.  IgG levels to be drawn at 12 weeks, 6 months and 1 year post-HSCT 
(see Table 4.2.1 or 4.2.4.8b). 
 


BMT CLINICAL TRIALS NETWORK 
 
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
2-15 
2.8.2.2. 
Blood products 
 
Transfusion thresholds for blood product support will be in keeping with BMT CTN MOP and 
standard institutional guidelines.  All blood products will be irradiated.  Allogeneic transplant 
candidates who are CMV negative will receive CMV negative or filtered blood products from 
study entry. 
 
2.8.2.3. 
Post-HSCT growth factors 
 
If neutropenia occurs (ANC < 500/mm3) post-HSCT, the decision to use hematopoietic growth 
factors will be guided by the institutional practice of the transplant center. 
 
2.8.2.4. 
Post-HSCT immunization schedule 
 
Once a patient is off all immunosuppressive therapy or has evidence of T cell function 
(approximately one year post-HSCT), immunizations may be given in keeping with the BMT 
CTN MOP and local institutional practice. 
 
2.8.2.5. 
Post-HSCT donor cellular infusions (DCI) 
 
At the discretion of the investigator, DCI may be given to patients for tumor progression.  
Patients receiving DCI will be considered a failure for the primary study endpoint.  DCI will not 
be given (on protocol) for low donor or dropping donor chimerism. 
 
2.9. PCR Monitoring for t(14;18) 
 
Quantitative PCR analysis for t(14;18) from peripheral blood will be performed on all patients at 
the time of registration. Samples will be collected and quantitative PCR will be performed by a 
centralized lab according to the following schedule.  If patient was known to be t(14;18) negative 
prior to registration this test still must be performed once at the time of registration for 
documentation purposes.  Patient’s may have had a t(14:18) analysis that was positive prior to 
study entry (e.g. at diagnosis).  Referring centers should be queried regarding prior patient 
testing for t(14:18).  Patients with any positive test for t(14:18) since the time of diagnosis must 
have the subsequent t(14:18) PCR assessment samples collected.  See Section 4.2 and Appendix 
C for schedule of samples and details on collection, processing, storage and shipment. 
 
2.10. Participant Risks 
 
Recipients of HSCTs incur risks from pre-HSCT conditioning and post-HSCT therapy, which 
must be weighed against the risk of the disease for which the HSCT is prescribed.  Major risks 
following transplantation include: 1) Infection which can be bacterial, viral, parasitic, or fungal.  
Often, these infections are life-threatening, particularly when caused by viral or fungal agents, 
and are associated with high mortality in the transplant population; 2) GVHD, either acute or 
chronic in nature, may occur following allogeneic transplantation.  The degree of GVHD varies 
from mild cutaneous reactions to extensive widespread and systemic involvement of skin, liver, 
and gastrointestinal tract.  Probably due to a direct association, the incidence of fatal infection is 


BMT CLINICAL TRIALS NETWORK 
 
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
2-16 
greater in patients developing GVHD; 3) Graft Failure can occur and is associated with a high 
risk of mortality; 4) End Organ Damage of all or any of the major organs may occur as a result of 
reactions to drugs (e.g., chemotherapy, antibiotics, anti-fungal medications, tacrolimus, 
cyclosporine, etc.), and as a result of destructive processes (e.g., infection, GVHD, etc.), and may 
have a fatal outcome; 5) Relapse or progression of lymphoma may occur, especially in patients 
with advanced disease status at time of treatment; 6) Unknown Toxicities may occur in any 
individual patient due to multiple events and cumulative effects which may involve any and all 
organs, including the brain.  Brain damage can result in severe loss of cognitive or neurologic 
function; and 7) Death. 
 
2.11. Therapy Toxicities 
 
All toxicities will be graded using the Common Terminology Criteria for Adverse Events 
(CTCAE) Version 3.0.  All of the following listed agents are commercially available. 
 
2.11.1. Total Body Irradiation (TBI) 
 
The radiation therapist performs the dosimetry calculations.  TBI may cause nausea, vomiting, 
diarrhea, mucositis, myelosuppression, alopecia, and painful swelling of the salivary glands for a 
few days.  Long-term effects include sterility, secondary malignancies and cataract formation. 
 
2.11.2. Cyclophosphamide 
 
Cyclophosphamide is an alkylating agent as well as an immunosuppressant.  Toxicities include 
nausea, vomiting, myelosupression, hemorrhagic cystitis, alopecia, sterility, mucositis, 
cardiomyopathy and jaundice.  It is available as an IV and oral formulation. 
 
2.11.3. Carmustine (BCNU) 
 
Carmustine is an alkylating agent.  Toxicities from carmustine include myelosuppression, 
nausea, vomiting, transient hypotension, dizziness, hyperpigmentation of the skin, hepatotoxicity 
and a delayed inflammatory lung response (pneumonitis).  It is available as an IV formulation 
only. 
 
2.11.4. VP-16 (Etoposide) 
 
VP-16 is a semi-synthetic podophyllotoxin derivative.  Toxicities include nausea, vomiting, 
myelosuppression, mucositis, hypotension, hand-foot syndrome (dermatitis), and occasionally 
fevers, peripheral neurotoxicity and hepatotoxicity.  It is available as an IV and oral formulation. 
 
2.11.5. Rituximab 
 
Rituximab is a chimeric human/mouse monoclonal antibody directed against CD20+, an antigen 
expressed on all cells of the B cell lineage.  It consists of a murine antigen binding region and a 
human Fc region.  The majority of toxicities occur during infusion such as rigors, fevers, 
hypotension, dyspnea, and nausea/vomiting.  Non-infusion toxicities include myelosuppression, 


BMT CLINICAL TRIALS NETWORK 
 
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
2-17 
fatigue and tumor pain.  It is available as an IV formulation only.  Hepatitis B reactivation with 
fulminant hepatitis, hepatic failure and death is a risk in patients who have ever been infected 
with the hepatitis B virus and/or are carriers of hepatitis B.  The risk of hepatitis B reactivation 
may continue for several months after rituximab administration. 
 
2.11.6. Fludarabine 
 
Fludarabine is a purine analog.  Toxicities include myelosuppression, immunosuppression, 
edema, fever, chills, fatigue, rash, mild nausea/vomiting, paresthesias and myalgias.  It is 
commercially available as an IV formulation only. 
 
2.11.7. Methotrexate 
 
Methotrexate is an antimetabolite that inhibits DNA synthesis and cell reproduction in malignant 
cells.  Toxicities include mucositis, hyperuricemia, elevated liver functions tests, leukopenia, 
thrombocytopenia, nausea, vomiting, diarrhea, anorexia, malaise, fevers, chills, rash, 
nephrotoxicity and pneumonitis.  It is available as an IV and oral formulation. 
 
2.11.8. Tacrolimus 
 
Tacrolimus is a macrolide antibiotic that is a potent immunosuppressant.  Toxicities include 
hypertension, peripheral edema, headache, hyperkalemia, hypokalemia, hyperglycemia, 
hypomagnesemia, nausea, anorexia, vomiting, cramps, nephrotoxicity, elevated liver function 
tests, tremors, paresthesias, rash, pruritus, and increased susceptibility to infection.  It is available 
as an IV and oral formulation. 
 
2.11.9. G-CSF (filgrastim) 
 
Filgrastim is a myeloid growth factor that stimulates the production, maturation and activation of 
neutrophils and activates neutrophils to increase their migration and cytotoxicity.  Common 
toxicities include myalgias and medullary bone pain.  The bone pain can be generally controlled 
with non-narcotic analgesia.  Less common side effects include fluid retention, pericardial 
effusion, local inflammation at the injection site and rarely, cutaneous vasculitis.  Transient 
laboratory abnormalities include mild elevations in uric acid, LDH, alkaline phosphatase, and 
leukocytosis.  There have been reported cases of spleen swelling resulting in splenic rupture.  It 
may be administered as an IV formulation or subcutaneously. 
 


BMT CLINICAL TRIALS NETWORK 
 
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
3-1 
CHAPTER 3 
 
 
3. 
STUDY ENDPOINTS 
 
3.1. Definition of Disease Status 
 
Patients at each data collection period are classified into one of the following states.  Until 
relapse/progression, all disease classifications are relative to the patient’s pre-HSCT disease 
status.  Once the patient has relapsed/progressed, these states are relative to the patient’s best 
disease state.  PET scanning, flow cytometric, cytogenetic and molecular studies will not be 
included in response definitions [57]. 
 
1. Complete Remission (CR): 
 Complete disappearance of all detectable clinical and radiographic evidence of 
disease and disappearance of all disease-related symptoms if present before therapy. 
 All lymph nodes and nodal masses must have regressed to normal size (≤ 1.5 cm in 
their greatest transverse diameter for nodes > 1.5 cm before therapy).  Previously 
involved nodes that were 1.1 - 1.5 cm before treatment must have decreased to ≤ 1 cm 
after treatment. 
 The spleen, if considered to be enlarged before therapy on the basis of a CT scan, 
must have regressed in size and must not be palpable on physical exam. 
 If bone marrow was involved by lymphoma before treatment, this infiltrate must be 
cleared after treatment. 
 Continued CR (CCR) will be applied to patients who were transplanted in CR. 
 Complete Remission Undetermined (CRU) as above but a residual lymph node mass 
of > 1.5 cm must have regressed by > 75% in their sum of the products of the greatest 
diameters [56] (SPD) and individual nodes that were previously confluent must have 
regressed by > 75% in their SPD.  Additionally, indeterminate bone marrow also 
applies here (increased number or size of aggregates without cytologic or 
architectural atypia). 
 
2. Partial Remission (PR): 
 ≥ 50% reduction in SPD of the 6 largest dominant nodes or nodal masses. 
 No increase in size of other nodes, liver or spleen. 
 Splenic and hepatic nodules must regress by least 50% in the SPD. 
 Bone marrow assessment is irrelevant for determination of a PR because it is 
assessable and not measurable disease. 
 No new sites of disease. 
 


BMT CLINICAL TRIALS NETWORK 
 
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
3-2 
3. Stable Disease (SD): 
Less than a PR (see above) but is not progressive disease (see below). 
 
4. Relapsed Disease (RD): 
 Applies to patients previously classified as CR, CCR or CRU. 
 Appearance of any new lesion or increase by ≥ 50% in the size of previously involved 
sites. 
 ≥ 50% increase in greatest diameter of any previously identified node > 1 cm in its 
short axis or in the SPD of more than 1 node. 
 
5. Progressive Disease (PD): 
 Applies to patients previously classified as PR or SD. 
 > 50% increase from nadir in the SPD of any previously identified abnormal node for 
PRs or SD. 
 Appearance of new sites of disease. 
 
3.2. Primary Endpoint to be Compared Between Autologous HSCT Recipients and Non-
myeloablative Allogeneic HSCT Recipients 
 
3.2.1. Three Year Progression-Free Survival 
 
The primary endpoint is three-year progression-free survival.  Patients are considered a failure 
for this endpoint if they die or if they relapse/progress or receive anti-lymphoma therapy.  The 
time to this event is the time from enrollment on study until death, relapse/progression, receipt of 
anti-lymphoma therapy, or last follow up, whichever comes first. 
 
3.3. Secondary Endpoint to be Compared Between Autologous HSCT Recipients and 
Non-myeloablative Allogeneic HSCT Recipients 
 
3.3.1. Three Year Overall Survival 
 
The event is death from any cause.  The time to this event is the time from study enrollment to 
death or last follow up.  Surviving patients are censored at the time of last observation.  
 
3.3.2. Time to Progression 
 
The event is relapse/progression. The time to this event is measured from study enrollment. 
Deaths without relapse/progression are considered as a competing risk.  Surviving patients with 
no history of relapse/progression are censored at time of last follow-up. 
 


BMT CLINICAL TRIALS NETWORK 
 
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
3-3 
3.3.3. Time to CR and PR 
 
The event is achieving CR (or PR and CR).  The time to event is measured from the time of 
study enrollment to the time to CR (or PR).  Patients who die in a state other than CR (PR) are 
considered as failing from a competing risk.  Patients alive and not in CR (PR) are censored at 
the time of last observation. 
 
3.3.4. Time to Off-study Therapy 
 
The event is the initiation of anti-lymphoma therapy other than those defined by the protocol 
arms.  The time to this event is measured from study enrollment.  Patients who die without 
initiation of an off-study therapy will be considered as experiencing a competing risk.  Patients 
who are alive and have not received an off-study therapy are censored at the time of the last 
observation.  
 
3.3.5. Incidence of Infections 
 
The incidence of definite and probable viral, fungal and bacterial infections will be tabulated for 
each patient.  The proportion of patients in each treatment arm with these infections will be 
compared. 
 
3.3.6. Incidence of CTCAE Version 3.0 Grade ≥ 3 toxicities  
 
See the BMT CTN MOP for the CTCAE grading scales. 
 
3.3.7. Treatment Related Mortality 
 
Treatment related mortality (TRM) is defined as death occurring in a patient from causes other 
than relapse or progression. 
 
3.4. Endpoints That Only Apply to Non-myeloablative Allogeneic Recipients 
 
The following endpoints will be used to describe outcomes associated only for the recipients of 
the HLA-matched sibling allograft.  They will not be compared between the two treatment arms. 
 
3.4.1. Incidence of Primary and Secondary Graft Failure 
 
Donor engraftment is defined as > 5% donor peripheral blood T cell chimerism by Day +56 post-
HSCT.  Primary graft failure is defined as a donor peripheral blood T cell chimerism < 5% at 
Day 56 post-HSCT.  Methodological requirements for chimerism are outlined in the BMT CTN 
MOP. 
 
Secondary Graft Failure is defined by documented engraftment followed by loss of graft as 
defined by donor peripheral blood T cell chimerism < 5% as demonstrated by a chimerism assay. 
 


BMT CLINICAL TRIALS NETWORK 
 
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
3-4 
3.4.2. Incidence and Severity of Graft-versus-Host Disease (GVHD) 
 
See the BMT CTN MOP for definitions of acute and chronic GVHD. 
 
3.5. Other Endpoints 
 
3.5.1. Efficacy of Rituximab and Cyclophosphamide in Vivo Purging 
 
In vivo purging will be measured as the proportion of patients whose peripheral blood converts 
from positive for t(14;18) by PCR prior to rituximab and cyclophosphamide to negative 
following this therapy. 
 
For patients with known t(14;18) undergoing collection of autologous HSC, PCR for t(14;18) 
will be conducted on the collected products in addition to peripheral blood samples.  Correlation 
between peripheral blood and apheresis product results for t(14;18) will also be determined. 
 
3.5.2. Prognostic Value of t(14;18) by PCR in Predicting Relapse 
 
A quantitative PCR for t(14;18) from peripheral blood will be carried out on patients with known 
t(14;18).  Results of serial post-HSCT samples will be analyzed to determine if there is a 
threshold value that can reliably predict relapse. 
 
3.5.3. Quality of Life 
 
Health Related Quality of Life will be described pre-initiation of rituximab and 
cyclophosphamide cytoreductive/mobilization therapy for English and Spanish speaking patients 
of both groups utilizing the FACT-BMT self report, transplant specific questionnaire and the 
generic quality of life tool, the SF-36.  The questionnaires will be scored according to standard 
procedures.  In addition, an exploratory comparison of the quality of life of the two groups will 
be made at two years post-autologous or non-myeloablative allogeneic HSCT. 
 
3.6. Regimen-related Toxicities Safety Monitoring Endpoints 
 
3.6.1. Allogeneic HSCT 
 
There are two regimen-related toxicity monitoring plans for the non-myeloablative allogeneic 
HSCT arm.  The rates of hepatic and renal toxicities will be monitored.  Occurrence of these 
toxicities will be recorded as events.  
 
1. Hepatic toxicity, defined as Grade 3 or higher toxicity from the CTCAE Version 3.0, 
under the adverse event type liver dysfunction/failure. 
2. Renal toxicity is defined as serum creatinine > 3.0 mg/dL. 
 


BMT CLINICAL TRIALS NETWORK 
 
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
3-5 
3.6.2. Autologous HSCT 
 
There are two regimen-related toxicities that will be monitored in the autologous HSCT arm. 
 
1. 
Neutropenia is defined as Grade 3 or higher toxicity from the CTCAE Version 3.0 
under the adverse event type blood/bone marrow.  This toxicity applies to the specific 
time period commencing with the first dose of rituximab post-HSCT and ending at one 
year post-HSCT.   
 
2. 
Pulmonary toxicity/pneumonitis is defined as Grade 3 or higher toxicity from the 
CTCAE Version 3.0 under the adverse event type pulmonary/upper respiratory. 
 


BMT CLINICAL TRIALS NETWORK 
 
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
4-1 
CHAPTER 4 
 
 
4. 
PATIENT ENROLLMENT AND EVALUATION 
 
4.1. Enrollment Procedures 
 
4.1.1. Screening and Eligibility Procedures 
 
Patients will be registered using the Advantage EDCSM (internet data entry systems).  Southwest 
Oncology Group (SWOG) centers should follow the instructions in Section 4.1.2 prior to 
following the instructions below.  The following procedures should be followed: 
1. Prior to initiation of rituximab and cyclophosphamide cytoreductive/mobilization 
therapy, an authorized user at the transplant center completes a screening form with 
demographic and eligibility questions.  The Eligibility Form includes a question 
confirming that the patient signed the informed consent form. 
2. If the patient is eligible, a study number is generated. 
3. Potential sibling donors must be evaluated for suitability for donation until either an 
HLA-matched sibling donor is identified or all HLA-matched siblings are excluded as 
donors.  The cytoreductive/mobilization therapy must begin no later than 6 weeks from 
enrollment.  If an HLA-matched sibling is available, the donor and recipient HLA typing 
information is completed on the eligibility form.  If an HLA-matched sibling is not 
available, the Sibling Information Form is required to obtain information pertaining to 
ineligibility of all siblings.  This includes siblings not typed because of prior knowledge 
that they would not be eligible to donate for medical reasons, typed siblings that are not 
HLA matches and HLA-matched siblings who can not donate for medical reasons.  
Enrollment 
occurs 
at 
the 
time 
of 
biological 
assignment 
prior 
to 
the 
cytoreductive/mobilization therapy.  Consent may be obtained in advance but the 
protocol assessments required prior to the cyotreductive/mobilization therapy should not 
be scheduled immediately after the consent is signed if the therapy is not imminent 
(within 4 weeks).  Patients with a donor are then biologically assigned to the non-
myeloablative allogeneic HSCT arm.  Patients without an HLA-matched sibling donor 
are then biologically assigned to the autologous HSCT + rituximab maintenance therapy 
arm.  If an HLA-matched sibling is identified but then declines to be a donor, the patient 
may proceed to the autologous HSCT.  In accordance with the intention-to-treat principle 
for the primary analysis of three-year progression-free survival, this patient will be 
classified as an allogeneic HSCT patient since this was their original biologic assignment. 
4. After recovery from cytoreductive/mobilization therapy, an authorized user at the clinical 
center completes the Pre-HSCT Checklist confirming that the patient has recovered and is 
eligible to receive either a non-myeloablative allogeneic HSCT or autologous HSCT. 
5. If the patient is eligible, the treatment plan is continued and a visit schedule based on the 
transplant date is displayed for printing and is referred to as ‘Segment A Follow-up.’ 
6. For autologous HSCT patients only: After recovery from autologous HSCT, an 
authorized user at the transplant center completes the Pre-Rituximab Checklist to confirm 


BMT CLINICAL TRIALS NETWORK 
 
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
4-2 
the patient has recovered and is eligible to begin receiving rituximab maintenance 
therapy. 
 
4.1.2. SWOG Patient Registration Procedures 
 
Patients from Southwest Oncology Group (SWOG) Member, CCOP and approved affiliate 
institutions must be registered through the SWOG Data Operations Center in Seattle using the 
SWOG Web Registration System.  Affiliate institutions not approved to register patients directly 
with the Data Operations Center must register through their member institution.  The Data 
Operations Center will request information from the SWOG Registration Form.  The institution 
must have these documents completed entirely prior to registering the patient in the SWOG Web 
Registration System.  In addition, the Data Operations Center will collect stratification 
information, will request the date that the informed consent and HIPAA authorization were 
obtained, and will obtain the date of IRB approval for each entry. 
 
4.2. Study Monitoring 
 
4.2.1. Follow-up Schedule 
 
The Follow-up Schedule for scheduled study visits is outlined in Table 4.2.1.  A detailed 
description of each of the forms and the procedures required for forms completion and 
submission can be found in the Data Management Handbook and User’s Guide.  The follow-up 
period for Segment A is 3 years. 
 
 
 


BMT CLINICAL TRIALS NETWORK 
 
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
4-3 
Table 4.2.1:  Follow-up Schedule - Segment A 
 
Study Visit 
Target Day 
(+ 7 Days Prior to Day 100 Post-HSCT) 
(+ 28 Days After Day 100 Post-HSCT) 
1 week1, 2, 3 
7 days 
2 week1, 2, 3 
14 days 
3 week1, 2, 3 
21 days 
4 week2, 3 
28 days 
5 week1 
35 days 
6 week1 
42 days 
7 week1 
49 days 
8 week4 
56 days 
9 week1 
63 days 
10 week1 
70 days 
11 week1 
77 days 
12 week4, 5 
84 days 
13 week1 
91 days 
14 week1 
98 days 
6 month4, 5 
180 days 
12 month4, 5 
365 days 
18 month 
540 days 
24 month4 
730 days 
30 month 
900 days 
36 month4 
1,095 days 
 
1GVHD assessments for non-myeloablative allogeneic HSCT arm only 
2Chemistry panel required twice per week 
3Refer to Section 4.2.4.4 for frequency of follow-up for CBC 
4Chemistry panel required at this time point 
5IgG level required at this time point 
 
Criteria for Forms Submission: Criteria for timeliness of submission for all study forms are 
detailed in the Data Management Handbook and User’s Guide.  Forms that are not entered into 
the web-based data entry system within the specified time will be considered delinquent.  A 
missing form will continue to be requested either until the form is entered into the web based 
data entry system and integrated into the DCC's master database, or until an exception is granted 


BMT CLINICAL TRIALS NETWORK 
 
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
4-4 
and entered into the Missing Form Exception File, as detailed in the Data Management 
Handbook. 
 
Reporting Patient Deaths: Recipient Death Information must be entered into the web-based 
data entry system within 24 hours of knowledge of the patient’s death.  If the cause of death is 
unknown at that time, it need not be recorded at that time.  However, once the cause of death is 
determined, the form must be updated in the web based data entry system. 
 
CIBMTR Data Reporting: All transplant centers will be required to pre-register patients with 
the CIBMTR for all transplant patients whether or not they enroll in a BMT CTN Protocol.  In 
addition, the transplant center must complete the CIBMTR TED Day 100 Report Form 
(including the Core, Graft and Disease Inserts) and CIBMTR TED Follow-up Form (including 
the Core and Disease Inserts) yearly for all patients enrolled in BMT CTN protocols.  CIBMTR 
forms will be submitted directly to the CIBMTR at the times specified on the Form Submission 
Schedule. 
 
4.2.2. Weekly GVHD Monitoring Post Non-myeloablative Allogeneic Transplant 
 
GVHD should be monitored in accordance with BMT CTN guidelines as specified in the MOP.  
Patients should be assessed weekly until Day 100 post-HSCT for GVHD.  After Day 100, 
patients will be assessed at each study visit for the presence of GVHD. 
 
4.2.3. Adverse Event Reporting 
 
Unexpected, grade 3-5 Adverse Events (AE) will be reported through an expedited AE reporting 
system.  Unexpected, grade 4-5 AEs must be reported within 24 hours of knowledge of the 
event.  Unexpected, grade 3 AEs must be reported within three business days of knowledge of 
the event.  Expected adverse events will be reported using NCI’s Common Terminology Criteria 
For Adverse Events Version 3.0 at regular intervals as defined on the Form Submission 
Schedule. 
 
4.2.4. Patient Assessments 
 
Tables 4.2.4.8a and 4.2.4.8b summarize patient clinical assessments over the course of the study.  
All assessments prior to and after the transplant are considered standard of care. 
 
4.2.4.1. 
Evaluations prior to rituximab and cyclophosphamide 
The following observations should be determined within the 4 weeks prior to initiating rituximab 
and cyclophosphamide mobilization chemotherapy.  Observation 3 must be determined ≤ 2 
weeks before initiation of therapy.  Observation 9c must be done after enrollment. 
1. History, physical examination, height and weight. 
2. Karnofsky performance score. 
3. CBC with differential and platelet count, creatinine clearance, creatinine, bilirubin, 
alkaline phosphatase, ALT, AST, LDH, sodium, magnesium, potassium, chloride, and 
CO2. 


BMT CLINICAL TRIALS NETWORK 
 
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
4-5 
4. CMV titer, hepatitis panel (HepA Ab, HepB SAb, HepB SAg, HepB Core Ab, HepC Ab), 
herpes simplex titre, syphilis, HIV and HTLV1 antibody). 
5. EKG. 
6. Left ventricular ejection fraction. 
7. DLCO, FEV1, and FVC. 
8. HLA typing of heparinized peripheral blood sample to determine availability of HLA-
matched sibling.  HLA –A, -B typing can be done by serologic or DNA methods.  HLA 
DRB1 typing must be done by DNA methodology. 
9. Baseline Disease Evaluation: 
a) CT scans of neck, chest, abdomen and pelvis.  Neck CT only required if previous site 
of disease. 
b) Bone marrow biopsy and aspirates to pathology and aspirate to cytogenetics.  Flow 
cytometry not required.  Bone marrow core should be ≥ 2 cm total for unilateral or 
bilateral samples. 
c) 10 mL peripheral blood for quantitative PCR analysis of t(14;18). 
10) Quality of life assessment. 
11) ABO Rh blood typing. 
 
4.2.4.2. 
Post initiation of rituximab and cyclophosphamide 
 
Toxicity assessment upon blood count recovery post rituximab and cyclophosphamide 
mobilization chemotherapy and ≤ 2 weeks prior to administration of the HSCT conditioning 
therapy. 
 
4.2.4.3. 
Evaluations prior to the autologous or non-myeloablative allogeneic HSCT  
 
The following observations will be done ≤ 2 weeks prior to initiation of the HSCT conditioning 
therapy. 
1. History, physical examination, height and weight. 
2. Karnofsky performance score. 
3. CBC with differential, platelet count, creatinine, bilirubin, LDH, alkaline phosphatase, 
AST, ALT, sodium, magnesium, potassium, chloride, and CO2. 
4. Creatinine clearance if 
clinically 
significant nephrotoxicity 
experienced 
with 
cyclophosphamide and rituximab. 
5. Left ventricular ejection fraction if clinically indicated. 
6. DLCO, FEV1 and FVC if clinically indicated. 


BMT CLINICAL TRIALS NETWORK 
 
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
4-6 
7. Baseline Disease Evaluation: 
a) Bone marrow biopsy and aspirate to pathology and aspirate to cytogenetics only if 
bone marrow was involved with lymphoma at any time prior to the rituximab/ 
cyclophosphamide therapy.  Flow cytometry is not required.  Bone marrow core 
should be ≥ 2 cm total for unilateral or bilateral samples. 
b) CT of neck, chest, abdomen and pelvis.  Neck CT only required if previous site of 
disease. 
c) In patients with known t(14;18), 10 mL peripheral blood samples will be drawn for 
t(14;18) analysis by PCR.  These samples will be processed and stored locally for 
later shipment to the BMT CTN Repository for batch analysis. 
d) For autologous HSCT patients with known t(14;18), all leukapheresis products will 
be tested for t(14;18) analysis by PCR.  These samples will be processed and stored 
locally for later shipment to the BMT CTN Repository for batch analysis. 
8. Heparinized peripheral blood samples from all patients on the non-myeloablative 
allogeneic HSCT arm for chimerism assays. 
9. Flow cytometry analysis of autologous or allogeneic graft per the Graft Characterization 
section of the BMT CTN MOP. 
10. One vial (10 cc) of nucleated cells from patient’s peripheral blood for future testing (see 
the table on pages C-4/5 for processing/shipping instructions). 
11. Review consent document for non-myeloablative allogeneic or autologous HSCT with 
patient. 
 
4.2.4.4. 
Post-HSCT evaluations 
1. CBC at least twice a week from Day 0 until ANC > 500 for 2 days after nadir reached.  
Thereafter CBC twice per week until Day 28 (or 4 weeks), then at 8 weeks, 12 weeks, 6 
months, one year and then yearly until three years post-HSCT. 
2. Comprehensive chemistry panel defined as creatinine, LDH, bilirubin, alkaline 
phosphatase, AST, ALT, magnesium, sodium, potassium, chloride, CO2 twice a week 
until Day 28 (or four weeks) and then at 8 weeks, 12 weeks, 6 months, one year and then 
yearly until three years post-HSCT. 
3. Toxicity assessments at 4, 8, 12 weeks, 6 months, one year and every six months until 
three years post-HSCT. 
4. Disease restaging at 12 weeks, 6 months, and 1 year and annually until three years post-
HSCT. 
a. Bone marrow biopsy and aspirate to pathology and aspirate to cytogenetics.  Flow 
cytometry is not required.  Bone marrow core should be ≥ 2 cm total for unilateral or 
bilateral samples. 
b. CT of neck, chest, abdomen and pelvis.  Neck CT only required if previous site of 
disease. 


BMT CLINICAL TRIALS NETWORK 
 
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
4-7 
c. In patients with known t(14;18), 10 mL peripheral blood samples will be drawn for 
t(14;18) analysis by PCR.  These samples will be processed and stored locally for 
later shipment to the BMT CTN Repository for batch analysis. 
5. Measurement of IgG levels at 12 weeks, 6 months and 1 year post-HSCT. 
6. Quality of life assessment at 2 years post-HSCT. 
 
In addition, patients receiving a non-myeloablative HSCT are required to have a history and 
physical exam to assess GVHD weekly until Day 100 post-HSCT, then at 6 months, one year 
and then yearly until three years post-HSCT.  GVHD evaluation and grading to be in keeping 
with BMT CTN MOP. 
 
4.2.4.5. 
 Prior to initiation of rituximab maintenance therapy in autologous HSCT recipients 
 
The following observations will be done ≤ 2 weeks prior to initiation of rituximab maintenance 
therapy.  This assessment can coincide with the 4 week post-autologous HSCT assessment.  If 
progressive disease is found during this assessment, the patient will be off-study but continued to 
be followed for survival.  Subsequent therapy is at the discretion of their attending physician. 
 
1. History, physical examination, height and weight. 
2. Karnofsky performance score. 
3. CBC with differential, platelet count, creatinine, LDH, bilirubin, alkaline phosphatase, 
AST, ALT, sodium, magnesium, potassium, chloride, and CO2. 
4. Disease Evaluation: 
a. Bone marrow biopsy and aspirate to pathology and aspirate to cytogenetics.  Flow 
cytometry is not required.  Bone marrow core should be ≥ 2 cm total for unilateral or 
bilateral samples. 
b. CT of neck, chest, abdomen and pelvis.  Neck CT only required if previous site of 
disease. 
c. In patients with known t(14;18), a peripheral blood sample will be drawn for t(14;18) 
analysis by PCR.  The Day +28 sample can be utilized for this particular time point.  
These samples will be processed and stored locally for later shipment to BMT CTN 
Repository for batch analysis. 
5. Review consent document for rituximab maintenance therapy with patient. 
6. HepB SAb, HepB SAg, HepB Core Ab. 
 


BMT CLINICAL TRIALS NETWORK 
 
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
4-8 
4.2.4.6. 
Sampling schedule for quantitative PCR of t(14;18) from peripheral blood sample 
1. At study entry. 
2. For patients with positive PCR at any time since diagnosis.  These samples will be 
processed and shipped quarterly to the BMT CTN Repository for batch analysis. 
a. After blood count recovery from cyclophosphamide and rituximab cytoreductive/ 
mobilization therapy. 
b. Analysis of each leukapheresis product from autologous HSCT patients. 
c. Post-HSCT: 
 Day +28 post-HSCT 
 Day +84 post-HSCT 
 6 months post-HSCT 
 12 months post-HSCT 
 Annually until 3 years post-HSCT 
 
4.2.4.7. 
Sampling schedule for chimerism analysis of peripheral blood in non-myeloablative 
allogeneic transplant recipients 
1. 
Pre non-myeloablative allogeneic HSCT 
2. 
Day +28 post non-myeloablative allogeneic HSCT 
3. 
Day +56 post non-myeloablative allogeneic HSCT 
4. 
Day +84 post non-myeloablative allogeneic HSCT 
5. 
6 months post non-myeloablative allogeneic HSCT 
6. 
12 months post non-myeloablative allogeneic HSCT 
 
4.2.4.8. Required observations for HLA-matched sibling donor 
 
Routine allogeneic donor work-up will be in keeping with FACT guidelines, BMT CTN MOP 
and institution standard practice of care.  Work-up to include the following: 
1. History, physical examination, height and weight. 
2. HLA typing of heparinized peripheral blood sample. 
3. Laboratory tests: 
a. CBC with differential and platelet count, creatinine, bilirubin, LDH, alkaline 
phosphatase, AST, ALT, magnesium, sodium, potassium, chloride, CO2, hepatitis 
panel (HepA Ab, HepB SAb, HepB SAg, HepB Core Ab, HepC Ab), CMV, syphilis, 
herpes simplex, HIV and HTLV I serologies and ABO Rh blood typing.   
b. If donor has antibodies against red cell antigens of the recipient, the titers will be 
determined.   
c. CBC will be checked prior to and after each leukapheresis collection, thereafter if 
clinically indicated. 
4. Heparinized peripheral blood samples (10 mL) for chimerism assays. 


BMT CLINICAL TRIALS NETWORK 
 
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
4-9 
5. One vial (10 cc) of nucleated cells from donor’s peripheral blood for future testing, 
collected prior to mobilization (see the table on pages C-4/5 for processing/shipping 
instructions). 
6. Five vials, each containing 2-5 x 106 nucleated cells from the allograft stem cells (to be 
obtained for the central repository per the Graft Characterization section of the BMT 
CTN MOP). 
7. Left ventricular ejection fraction if clinically indicated. 
8. DLCO, FEV1 and FVC if clinically indicated. 
9. Evaluation of toxicities experienced post initation of G-CSF. 
 
Donors must be contacted by phone approximately 30 days post initiation of G-CSF for a 
toxicity evaluation. 


BMT CLINICAL TRIALS NETWORK 
 
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
4-10 
Table 4.2.4.8a:  Baseline, Pre-HSCT, Donor Evaluations 
 
Required Studies/Testing 
Prior to Rituximab 
and Cyclophos-
phamide 
4 Weeks Post 1st 
Rituximab Dose 
(Pre-HSCT) 
Pre-
HSCT1 
Pre-Rituximab 
Maintenance Therapy 
for Autologous HSCT 
Recipients7, 16 
Donor 
History, Physical Examination, Height and 
Weight 
X 
 
X 
X 
X 
Karnofsky Performance Score 
X 
 
X 
X 
 
CBC with differential, Platelet Count, 
Creatinine, Bilirubin, Alkaline Phosphatase, 
AST, ALT, LDH, Sodium, Magnesium, 
Potassium, Chloride and CO2 
X1 
 
X 
X 
X 2, 3 
ABO Rh Typing 
X 
 
 
 
X 
Creatinine Clearance 
X1 
 
X9 
 
 
CMV Titer, Hepatitis Panel (A,B,C) Herpes 
Simplex, Syphilis 
X 
 
 
 
X 
HIV/HTLV1 Antibody 
X 
 
 
 
X 
EKG 
X 
 
 
 
 
LV Ejection Fraction  
X 
 
X10 
 
X10 
DLCO/FEV1/FVC 
X 
 
X10 
 
X10 
Toxicity Assessment 
 
X 
 
 
X17 
CT Neck, Chest, Abdomen and Pelvis 
X11 
 
X11 
X11 
 
Bone Marrow Aspirate and Biopsy8 
X 
 
X18 
X 
 
Peripheral Blood for t(14;18) PCR 
X12 
 
X13, 14 
X15, 16 
 
Peripheral Blood for HLA Typing 
X 
 
 
 
X 
Blood Samples for Chimerism Assays 
 
 
X4 
 
X 
Nucleated Cells 
 
 
X6 
 
X5, 6 
Flow Cytometry Analysis of Graft 
 
 
X 
 
 
Health Quality of Life 
X 
 
 
 
 
Consent Review 
X 
 
X 
X 
 
 
1 To be performed within 2 weeks of starting conditioning therapy. 
2 Including ABO Rh blood typing. 
3 CBC will be checked prior to and after leukapheresis collection.  
If donor has antibodies against red cell antigens of the recipient, 
the titers will be determined. 
4 For the allogeneic HSCT arm only. 
5 Five vials each containing 2-5 x 106 nucleated cells from 
allogeneic donor HSC cryopreserved for central repository. 
6 One vial (10 cc) of nucleated cells from peripheral blood for 
future testing (see the table on pages C-4/5 for 
processing/shipping instructions). 
7 This assessment can be coincident with the 4 week post-HSCT 
assessment (see Table 4.2.4.8b). 
8 Bone marrow aspirate and biopsy samples to pathology, aspirate 
for cytogenetic analysis.  
9 Creatinine clearance must be done only if clinically significant 
nephrotoxicity experienced with cyclophosphamide and rituximab. 
 
10 If clinically indicated. 
11 Neck CT only required if previous site of disease. 
12 Even if the patient was known to be t(14;18) negative prior to 
registration, the test must still be performed at the time of 
registration for documentation purposes.  This assessment is to 
be done after enrollment. 
13 Only in patients with known t(14;18) at any time since diagnosis. 
14 Additional samples for analysis of each leukapheresis product 
from autologous HSCT patients only. 
15 The Day +28 post-HSCT sample can be utilized for this time 
point. 
16 To be performed within 2 weeks of starting rituximab 
maintenance therapy. 
17 On Days 5 and 30 (via telephone) post initiation of G-CSF.. 
18 Only if bone marrow was involved with lymphoma at time prior 
to the rituximab/cyclophosphamide. 
 


BMT CLINICAL TRIALS NETWORK 
  
 
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
4-11 
 
Table 4.2.4.8b:  Post-HSCT Evaluations 
 
 
Study Assessments/ 
Testing 
Weeks Post-HSCT 
Months Post-HSCT 
1 
2 
3 
46 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
6 
12 
18 
24 
30 
36 
GVHD Assessments1 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
X 
 
X 
CBC2 
See Section 4.2.4.4 for 
details. 
 
 
 
X 
 
 
 
X 
 
 
X 
X 
 
X 
 
X 
Chemistry Panel  
2 x per week4 
 
 
 
X 
 
 
 
X 
 
 
X 
X 
 
X 
 
X 
Chimerism5 
 
 
 
X 
 
 
 
X 
 
 
 
X 
 
 
X 
X 
 
 
 
 
Bone Marrow Aspirate and 
Biopsy3, 8 
 
 
 
 
 
 
 
 
 
 
 
X 
 
 
X 
X 
 
X 
 
X 
CT Neck, Chest, Abdomen 
and Pelvis3, 7 
 
 
 
 
 
 
 
 
 
 
 
X 
 
 
X 
X 
 
X 
 
X 
Peripheral Blood for t(14;18) 
PCR9 
 
 
 
X 
 
 
 
 
 
 
 
X 
 
 
X 
X 
 
X 
 
X 
IgG Levels 
 
 
 
 
 
 
 
 
 
 
 
X 
 
 
X 
X 
 
 
 
 
Toxicity 
 
 
 
X 
 
 
 
X 
 
 
 
X 
 
 
X 
X 
X 
X 
X 
X 
Health Quality of Life 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
 
1 For allogeneic HSCT arm only.   
2 Will be reported on case report form only on Day 28 to document engraftment for allogeneic HSCT arm only. 
3 Or at time of progression/relapse. 
4 Will not be reported on the case report form. 
5 Chimerism performed on CD3+ cells from peripheral blood. 
6 For the autologous HSCT arm: may coincide with the assessments required prior to initiation of rituximab maintenance therapy. 
7 Neck CT only required if previous site of disease. 
8 Bone marrow aspirate and biopsy samples to pathology.  Bone marrow aspirate to cytogenetics. 
9 For patients with possible t(14;18) at any time from diagnosis to study entry. 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
5-1 
 
CHAPTER 5 
 
 
5. 
STATISTICAL CONSIDERATIONS 
 
5.1. Study Overview 
 
The overall study design is a comparison of two treatment arms determined by biologic 
assignment, based on the availability of an HLA-matched sibling, in patients diagnosed with 
relapsed follicular non-Hodgkin’s lymphoma.  Patients without an HLA-matched sibling will 
receive an autologous HSCT.  Patients with an HLA-matched sibling will receive a non-
myeloablative allogeneic HSCT. 
 
5.1.1. Primary Endpoint 
 
The primary endpoint for the study is three-year progression-free survival.  If any therapy not 
specified in the protocol, such as DCI, is given to prevent relapse/progression or to induce a 
response, the patient will be considered to have experienced an event for the primary endpoint.   
 
Patients who are lost to follow-up prior to three years will be censored at the time of the last 
observation, and the progression-free survival proportion will be estimated using the Kaplan-
Meier method, where time-to-event is measured from enrollment to the minimum of the date of 
death, relapse/progression, last-follow-up or the three-year time point.   
 
The statistic for testing for differences in three-year progression-free survival between treatment 
arms is described in Appendix E.  Basically, the statistic is a standardized weighted sum over 
strata formed by the clinical centers of differences in the Kaplan-Meier estimate of survival at 
the three-year time-point.  If follow-up were complete (no censoring), the test statistic reduces to 
a Cochran Mantel Haenszel test of binomial proportions of progression-free survivors at the 
three- year time-point. 
 
5.1.2. Accrual 
 
Accrual will remain open until at a minimum, 80 patients are assigned to the allogeneic arm.  It 
is estimated that three years of accrual will be necessary to enroll the targeted sample size.  
Assuming that patients with HLA-matched sibling donors comprise 20-30% of eligible patients, 
approximately 187-320 patients will likely be accrued to the autologous arm during the time it 
takes to accrue the targeted number of patients on the allogeneic arm. 
 
To adjust for differences in clinical care practices at participating institutions, the primary 
analysis of three-year progression-free survival will be stratified by transplant center.  At least 
two individuals are required to estimate variability within a stratum so, at a minimum, each 
center must enroll two patients in each treatment arm.  This requirement imposes some 
constraints on the selection of participating transplant centers. 
 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
5-2 
In selecting transplant centers for participation, preference will be given to centers that perform 
both autologous and allogeneic transplants, and that anticipate enrollment of at least 12 patients.  
However, a pair of centers that collectively meet these criteria may be invited to participate (e.g. 
SWOG autologous program with its partner allogeneic program), one of the centers serving as 
the “center of record” for the purposes of monitoring and analyzing accrual or other study data. 
 
5.1.3. Biologic Assignment 
 
To prevent bias in determining whether donors are eligible or not for donation, and resultant bias 
in the biological assignment, all available siblings will be HLA-typed and all HLA-matched 
siblings will be assessed for donation whenever feasible.  If a sibling is deemed unsuitable to be 
a donor, the reasoning will be reviewed with a Protocol Chair or the Medical Monitor.  Patients 
with an HLA-matched sibling who is a suitable donor are biologically assigned to the allogeneic 
arm of the study.  Patients without a suitable HLA-matched sibling donor are assigned to the 
autologous arm.  The protocol requires that all potential donors be typed and evaluated prior to 
the initiation of cytoreductive/mobilization therapy, and within four weeks of enrollment. 
 
5.1.4. Intention-to-Treat Principle 
 
In accordance with the intention-to-treat principle for the primary analysis of three-year 
progression-free survival, patients will be classified according to their original biological 
assignment, regardless of the therapy actually received.  Some secondary and tertiary analyses 
such as the assessment of Health Quality of Life or GVHD will be conducted on an as-treated 
rather than intention-to-treat basis. 
 
5.2. Statistical Issues Related to Non-randomized Assignment 
 
It is not feasible to randomly assign patients to autologous HSCT versus non-myeloablative 
allogeneic HSCT.  A randomized study would entail enrolling only patients potentially eligible 
for the allogeneic transplant.  Since patients with HLA-matched sibling donors comprise only 
20-30% of the patient population, restricting enrollment to such patients would make it 
impossible to meet the accrual goals for the study in a timely fashion. 
 
There are many possible sources of heterogeneity in a multi-center clinical trial.  In a large 
randomized trial, chance ensures balance of both known and unknown risk factors across 
treatment arms.  A non-randomized study is vulnerable to differential assignment of higher risk 
patients to one or the other treatment arm.  Potential sources of heterogeneity include differences 
in: (1) selection of patients to screen for the study; (2) degree of compliance with biological 
allocation; (3) in clinical care practices at participating institutions; (4) baseline disease risk 
status: and, (5) in baseline factors such as recipient age and performance status.  The data 
analytic plan to address each of these is discussed briefly. 
 
5.2.1. Selection of Patients to Screen for the Study 
 
Each transplant center is required to register consecutive transplant recipients with the Center for 
International Blood and Marrow Transplant Research (CIBMTR).  Data are collected on all 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
5-3 
transplanted patients, regardless of whether they are enrolled in a BMT CTN trial.  These data 
will be used to determine if the proportion of allograft recipients, the demographic composition, 
the performance status and the disease risk of patients entered in the study are representative of 
the population of transplant patients treated at a center who were potentially eligible for entry in 
the study.  Disease risk will be assessed using CIBMTR data on disease, disease stage and 
duration, age and performance status.  Comparison of registered and enrolled patients will be 
performed separately within each treatment arm every four months. 
 
5.2.2. Compliance with Biologic Assignment 
 
The procedure for the biological assignment of patients is described in detail in Section 5.1 
above.  Centers will complete a BMT CTN Sibling Information Form that will capture 
information on whether each of the patient’s siblings were typed and, if not, the reason why.  
This form will also capture information for HLA-matched siblings not identified as a suitable 
donor, and the reason(s) they are not donating.  The DCC will query the transplant center for 
additional information as needed to validate the biological assignment, and to ensure that the 
patient is correctly classified in the final intention-to-treat analysis.   
 
If an HLA-matched sibling is determined unsuitable by the center to be a donor, the reasoning 
will be reviewed with a Protocol Chair or the Medical Monitor.  It is anticipated that the rates of 
donor refusal for the allograft transplant will be roughly comparable across institutions.  Centers 
with rates of refusal significantly higher than the average will be reviewed by the DCC regarding 
their procedures for approaching and enrolling patients.  As participation at the center level is by 
choice, it is expected that problems with violating the biologic assignment process will be 
limited. 
 
Accrual of patients to the allogeneic arm will be monitored.  Any center enrolling eight patients 
on the autologous arm without enrolling a patient on the allogeneic arm will be reviewed by the 
DCC to ensure protocol compliance.  This will include a review of patients transplanted for 
follicular lymphoma off-study using data from the CIBMTR registration process described 
above.  Corrective educational measures will be instituted for centers selectively enrolling 
patients or failing to follow the biologic assignment design of the protocol. 
 
5.2.3. Effects of Transplant Center 
 
To adjust for differences in clinical care practices at participating institutions, the primary 
analysis of three-year progression-free survival will be stratified by transplant center.  At least 
two individuals are required to estimate variability within a stratum so, at a minimum, each 
center must enroll two patients in each treatment arm.  Since a transplant center that fails to meet 
this goal will comprise a stratum that cannot contribute to the final test statistic, centers will 
continue enrollment until this requirement is met. 
 
If patients with HLA-matched sibling donors comprise 25% of the patient population, centers 
that accrue at least 12 patients are likely to enroll at least two allograft patients by chance 
(probability > 80%).  As noted previously, in selecting transplant centers for participation, 
preference will be given to centers that perform both autologous and allogeneic transplants, and 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
5-4 
that anticipate enrollment of at least 12 patients.  If necessary, centers doing only autologous 
transplants will be allowed to partner with a transplant center that performs allogeneic 
transplants to facilitate meeting this requirement and to broaden the range of centers able to 
participate. 
 
5.2.4. Effects of Disease Risk Status 
 
A post-hoc analysis will be performed assessing the comparability of patients allocated to each 
treatment arm with respect to disease risk status, as measured by number of prior regimens (0 or 
1 versus 2 or more), and time from diagnosis to transplant.  Number of prior regimens will be 
compared using a chi-squared test, and time from diagnosis to transplant will be compared using 
a Wilcoxon test.  If statistically significant (p<0.10) differences in the treatment arms are found 
in either of these disease risk prognostic factors, a secondary analysis of the primary endpoint 
will be performed adjusting for these covariates in a Cox proportional hazards model. 
 
5.2.5. Effects of Baseline Factors 
 
A post-hoc analysis will be performed assessing the comparability of patients allocated to each 
treatment arm with respect to baseline Karnofsky performance score and age.  Performance 
status will be compared using a chi-square test; and age will be compared using a Wilcoxon test.  
If statistically significant (p <0.10) differences in the treatment arms are found with respect to 
either of these baseline prognostic factors, a secondary analysis of the primary endpoint will be 
performed adjusting for these covariates in a Cox proportional hazards model. 
 
Other baseline factors such as donor age and gender were considered, and rejected, as candidates 
for post-hoc adjustment.  Donor age is highly correlated with recipient age when HLA-identical 
siblings are serving as donors.  The range of ages in the study population is not anticipated to be 
wide enough to lead to imbalances in the treatment arms.  Recipient-donor gender mismatch is 
not anticipated to be a strong predictor of outcome in the allograft transplant setting, and thus 
does not warrant adjustment. 
 
5.3. Sample Size and Power Calculations 
 
The study sample size is specified in terms of the targeted number of patients with an HLA-
matched sibling donor.  Accrual will remain open until at minimum, 80 patients are assigned to 
the non-myeloablative allogeneic HSCT arm.  During the accrual period, enrollment will be open 
to all eligible patients, including those without HLA-matched sibling donors.  The exact 
composition of the study population will depend on the series of eligible patients presenting at 
each clinic.  During the accrual period we anticipate enrollment of 80 patients on the non-
myeloablative allogeneic HSCT arm and 187-320 patients on the autologous HSCT arm. 
 
Three-year progression-free survival after autologous HSCT is estimated to be 45% using data 
from the CIBMTR.  A sample size of 80 non-myeloablative allogeneic HSCT recipients and 187 
autologous HSCT recipients is sufficient to achieve > 85% power to detect a 20% difference 
between a three-year progression-free survival of 45% after autologous HSCT and three-year 
progression-free survival of 65% after non-myeloablative allogeneic HSCT, with a two-sided 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
5-5 
level .05 test of proportions.  Note that the final analysis will use a modified Mantel Haenszel 
test statistic stratified by clinical center, but the binomial test of proportions serves as a useful 
approximation and provides conservative estimates of power. 
 
Table 5.3 shows the power under a variety of scenarios.  The number of autologous HSCT 
patients is computed assuming that the number of patients with eligible HLA-matched sibling 
donors ranges from 20 to 30% of the total patient population. 
 
 
Table 5.3:  Power Under a Variety of Scenarios 
 
Non-myeloablative Allogeneic 
HSCT Arm 
Autologous HSCT Arm 
Power 
N 
3-Year PFS 
N 
3-Year PFS 
 
70 
.65 
163 
.45 
.81 
70 
.65 
210 
.45 
.83 
70 
.65 
280 
.45 
.86 
80 
.65 
187 
.45 
.86 
80 
.65 
240 
.45 
.88 
80 
.65 
320 
.45 
.90 
90 
.625 
210 
.45 
.80 
90 
.625 
270 
.45 
.83 
90 
.625 
360 
.45 
.85 
 
5.4. Interim Analysis and Stopping Guidelines 
 
5.4.1. Guidelines for Accrual Monitoring 
 
Each transplant center is required to enroll at least two patients in each treatment arm.  If this 
requirement is not met after the first eight patients are enrolled, the DCC will contact the center, 
and will evaluate screening and referral practices.  The investigation will not halt enrollment, 
which will continue until the goal of a minimum of two patients per arm is reached.  During the 
final analysis, centers which do not have at least one death per treatment arm will be paired with 
the nearest geographically located center which fulfills the requirement to form a single strata.   
 
In a simulation study, the proportion of subjects with HLA-matched sibling donors was assumed 
to be one-quarter of presenting eligible individuals.  Once the target of 80 subjects with HLA-
matched donors was reached, enrollment was continued only at those centers that had not yet 
enrolled 2 subjects per treatment group (the minimum required to compute the test statistic).  
This resulted in a slight excess in total enrollment.  On average 81 subjects were allocated to the 
allograft arm, and 243 to the autograft arm.   
 
5.4.2. Guidelines for Efficacy Monitoring 
 
There are no planned interim analyses for efficacy in this study, because the anticipated accrual 
period is three years, and the primary endpoint is three-year progression-free survival.  However, 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
5-6 
if accrual is much slower than anticipated, the Data and Safety Monitoring Board will be 
consulted, and consideration will be given to interim analyses for efficacy in the fourth or fifth 
year, using either group sequential methods or stochastic curtailment to conserve type I error. 
 
5.4.3. Guidelines for Safety Monitoring 
 
There are several statistical guidelines employed in this study.  These guidelines are designed to 
assist an independent Data and Safety Monitoring Board (DSMB) in overseeing the study.  The 
DSMB may also request interim analyses and develop other criteria for determining when to 
intervene in the enrollment or treatment of patients in the study. 
 
The stopping guidelines monitor the incidence of transplant-related mortality and selected 
regimen-related toxicities.  Transplant-related mortality (TRM) is defined as death in the absence 
of disease progression.  TRM will be monitored separately in the autologous HSCT and non-
myeloablative allogeneic HSCT arms.  Tacrolimus or cyclosporine associated renal and hepatic 
toxicity will be monitored in the non-myeloablative allogeneic HSCT arm.  Monitoring for 
TRM, renal and hepatic toxicity will commence with enrollment and will continue for six 
months post-HSCT. 
 
The null hypotheses for sequential monitoring are that the true rate of TRM is less than 15% in 
the allogeneic arm and less than 8% in the autologous arm, and that the true incidence of each of 
the specified toxicities is less than 10%.  If any of the observed incidence rates are substantially 
in excess of these targets, the null hypothesis will be rejected and the NHLBI will be notified.  
These guidelines are provided as an “early warning” system.  Suspension of enrollment is not 
automatic, but at the discretion of the NHLBI upon recommendation of the DSMB, which will 
have the opportunity to request and review additional analyses. 
 
Transplant-related Mortality (TRM) 
 
The rate of TRM up to six months post-HSCT will be monitored separately in each treatment 
arm.  Monitoring will be performed monthly until enrollment to that treatment arm is closed.  
Each month, the null hypothesis that six month TRM is less than or equal to a threshold value 
will be tested against the alternative that it is greater than a threshold value.  In the allogeneic 
arm, the threshold value will be 15%; in the autologous arm, the threshold value will be 8%.  An 
extension of the Sequential Probability Ratio Test (SPRT) will be used.  A description of this 
sequential testing procedure is provided below. 
 
The SPRT can be represented graphically.  At each monthly interim analysis, the total time on 
study is plotted against the total number of observed deaths.  The continuation region of the 
SPRT is defined by two parallel lines.  Only the lower boundary will be used for monitoring each 
treatment arm to protect against poor 180-day TRM.  If the graph falls below the lower 
boundary, the SPRT rejects the null hypothesis, and concludes that there are more deaths than 
predicted by the observed time on study.  Otherwise, the SPRT continues until enrollment to the 
treatment arm reaches the target goal. 
 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
5-7 
This procedure assumes an exponential distribution for the time until failure until six months 
post-HSCT, but censors follow-up time after six months.  Only deaths without relapse or 
progression that occur on or before the patient has been followed for six months post-HSCT are 
counted.  Total time on study is computed as time from enrollment to death, or to six months 
post-HSCT, whichever comes first, summed for all individuals on study. 
 
The usual measures of performance of an SPRT are the error probabilities  and  of rejecting 
H0 when  = 0 and of accepting H1 when  = 1, respectively, and the expected sample size 
E(N|i).  The tests to be used in this protocol were developed from a SPRT contrasting 15% 
versus 30% six-month TRM, in the non-myeloablative allogeneic HSCT arm, and 8% versus 
14% in the autologous HSCT arm.  The slope and intercept of the lower boundary are 2.00 and -
6.48, respectively, for the non-myeloablative allogeneic HSCT arm, and 4.33 and –17.69, 
respectively, for the autologous HSCT arm. 
 
The actual operating characteristics of the truncated tests, shown in Table 5.4.1a, were 
determined in a simulation study that assumed uniform accrual of either 80 non-myeloablative 
allogeneic HSCT recipients or 240 autologous HSCT recipients over a three year time period, 
and exponential time to failure after enrollment. 
 
 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
5-8 
Table 5.4.1a:  Operating Characteristics of Sequential Testing Procedure 
Transplant-related Mortality  
from a Simulation Study with 100,000 Replications 
 
Operating Characteristics for Allogeneic Arm N = 80 
True 6 Month Post-HSCT 
Mortality 
15% 
20% 
25% 
30% 
Probability Reject Null 
0.04 
0.24 
0.60 
0.88 
Mean Month Stopped 
36.1 
32.7 
26.1 
19.1 
Mean # Deaths in 6 Mo. 
11 
13 
13 
11 
Mean # Patients Enrolled 
78 
71 
57 
43 
 
 
Operating Characteristics for Autologous Arm N = 240 
True 6 Month Post-HSCT 
Mortality 
8% 
10% 
12% 
14% 
Probability Reject Null 
0.05 
0.24 
0.57 
0.84 
Mean Month Stopped 
36.0 
32.8 
26.9 
20.5 
Mean # Deaths in 6 Mo. 
18 
20 
19 
17 
Mean # Patients Enrolled 
234 
214 
177 
136 
 
In the non-myeloablative allogeneic HSCT arm, the procedure rejects the null hypothesis in 
favor of the alternative 4% of the time when the true six-month TRM is 15%, and 88% of the 
time when the true rate is 30%.  This corresponds to a type I error rate of  = 0.04 and a type II 
error rate of  = 0.12.  When the true six-month TRM is 30%, on average, the Data and Safety 
Monitoring Board will be consulted 19.1 months after opening, when 11 deaths have been 
observed in 43 patients. 
 
In the autologous HSCT arm, the procedure rejects the null hypothesis in favor of the alternative 
5% of the time when the true six-month TRM is 8%, and 84% of the time when the true rate is 
14%.  This corresponds to a type I error rate of  = 0.05 and a type II error rate of  = 0.16.  
When the true six-month TRM is 14%, on average, the Data and Safety Monitoring Board will 
be consulted 20.5 months after opening, when 17 deaths have been observed in 136 patients. 
 
Regimen-related Toxicities 
 
The protocol specifies that the following toxicities are safety endpoints: 
1) Grade ≥ 3 hepatic toxicity in the non-myeloablative allogeneic HSCT arm 
2) Renal toxicity of serum creatinine > 3.0 mg/dL in the non-myeloablative allogeneic 
HSCT arm 
3) Grade ≥ 3 neutropenia in the autologous HSCT arm after rituximab maintenance therapy 
4) Grade ≥ 3 pulmonary toxicity/pneumonitis in the autologous HSCT arm 
 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
5-9 
Hepatic and renal toxicities are considered sufficiently life-threatening to warrant use of 
statistical stopping guidelines to monitor these toxicities monthly.  If cumulative incidence rates 
exceed the target threshold of 10%, the NHLBI will be notified and may require immediate 
DSMB review that could result in termination of enrollment to the non-myeloablative allogeneic 
HSCT arm. 
 
Neutropenia and pneumonitis can often be successfully managed through early intervention, and 
statistical stopping guidelines will not be used to monitor these toxicities monthly.  Instead, the 
cumulative incidence of these toxicities will be reported, along with other accumulated safety 
and efficacy data, to the DSMB at regularly scheduled meetings.  
 
The stopping guidelines for hepatic and renal toxicity were derived from an SPRT contrasting 
10% versus 15% cumulative incidence rates, cumulated at six months post-HSCT.  The slope 
and intercepts of the lower boundary are 3.74 and –12.97, respectively, for the non-
myeloablative allogeneic HSCT arm.  Refer to the description of the stopping guideline for TRM 
in Section 5.4.2 for a discussion of the statistical methodology used.  The parameters of the 
SPRT were adjusted so that the probability of stopping would be approximately < 1%, 10% and 
> 85% at cumulative incidence of 5%, 10% and 20%, respectively. 
 
The usual measures of performance of an SPRT are the error probabilities  and  of rejecting 
H0 when  = 0 and of accepting H1 when  = 1, respectively, and the expected sample size 
E(N|i).  The actual operating characteristics of the truncated tests, shown in Table 5.4.1b, were 
determined in a simulation study that assumed uniform accrual of either 80 non-myeloablative 
allogeneic HSCT recipients or 240 autograft recipients over a three year time period, and 
exponential time to failure after enrollment. 
 
 
Table 5.4.1b:  Operating Characteristics of Sequential Testing Procedure 
Regimen-related Toxicities > 10% 
from a Simulation Study with 100,000 Replications 
 
Operating Characteristics for Non-myeloablative Allogeneic HSCT Arm N = 80 
True 6 Month Post-HSCT 
Incidence 
5% 
10% 
15% 
20% 
Probability Reject Null 
0.00 
0.08 
0.45 
0.84 
Mean Month Stopped 
 
35.7 
30.0 
22.0 
Mean # Events in 6 Mo. 
3.8 
7.3 
9.1 
8.6 
Mean # Patients Enrolled 
79.9 
77.4 
65.7 
48.8 
 
 
In the non-myeloablative allogeneic HSCT arm, the procedure rejects the null hypothesis in 
favor of the alternative 8% of the time when the true six-month incidence is 10%, and 84% of the 
time when the true rate is 20%.  This corresponds to a type I error rate of  = 0.08 and a type II 
error rate of  = 0.16.  When the true six-month incidence is 20%, on average, the Data and 
Safety Monitoring Board will be consulted 22.0 months after opening, when 8.6 events have 
been observed in 48.8 patients. 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
5-10 
 
5.5. Analysis Plan 
 
All analyses are based on an intent-to-treat.  In such an analysis, patients are in the non-
myeloablative allogeneic HSCT arm if they have a suitable HLA-matched sibling donor whether 
or not the non-myeloablative allogeneic HSCT occurs. 
 
5.5.1. Analysis of the Primary Endpoint 
 
The primary outcome of the trial is lymphoma progression-free survival at three years post-
HSCT.  The primary null hypothesis of the study is that there is no difference in three-year 
progression-free survival between the autologous and non-myeloablative allogeneic HSCT arms.  
The alternative hypothesis is that progression-free survival differs between autologous and non-
myeloablative allogeneic HSCT strategies.  The primary outcome will be assessed in a final 
analysis to be performed after the last enrolled patient has been followed for three years post 
enrollment. 
 
In the final analysis, the endpoint of 3-year progression-free survival will be estimated using the 
Kaplan-Meier product limit estimator, and compared between treatment arms using the modified 
Mantel-Haenszel test statistic stratified by clinical center.  The test statistic is described in 
Appendix E.  Additional secondary analyses utilizing this approach will: a) incorporate 
progression-free survival beyond the three-year time-point, and b) test for the effect of follicular 
lymphoma grade at entry on progression-free survival.  Estimates of the differences between 
progression-free survival functions and confidence bands for these differences will be performed 
using the procedure of Zhang and Klein [58].  In the event that there are no significant 
differences between the arms, a post-hoc power analysis will be performed. 
 
In a secondary analysis, outcomes in the autologous transplant arm at 1, 2, and 3 years post-
HSCT will be compared to an external cohort registered with the CIBMTR.  In a subset of 
autologous transplant patients registered with the CIBMTR who met the basic eligibility criteria 
for the study (age 18-70, chemosensitive disease, no more than 3 prior regimens, adequate graft 
and performance status), overall survival, disease-free survival, and relapse-free survival were 
.87, .64, and .32 at one year post-autologous HSCT, and .70, .45, and .48 at three years post-
autologous HSCT, respectively.  Using patient-level data from this trial and from the CIBMTR 
registry, the survival curves will be compared using the procedures of Zhang and Klein. 
 
5.5.2. Analysis of Secondary Endpoints 
 
A number of secondary outcomes will be examined to compare the patient’s disease status over 
time between treatment arms. 
 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
5-11 
Overall Survival: 
 
The event is death from any cause.  Patients alive at the time of the last observation are censored 
at the time of the last observation.  In the primary analysis in all enrolled patients, time-to-event 
will be measured from enrollment.  In a secondary analysis including only patients who received 
their HSCT, time-to-event will be measured from the date of HSCT.  Overall survival will be 
compared between treatment arms using a log-rank test, and the survival curves will be estimated 
using the Kaplan Meier Estimator. 
 
Time to Progression: 
 
The event is relapse/progression.  Death without relapse/progression is considered a competing 
risk.  Patients alive with no history of relapse/progression are censored at the time of the last 
observation.  In the primary analysis in all enrolled patients, time-to-event will be measured from 
enrollment.  In a secondary analysis including only patients who received their HSCT, time-to-
event will be measured from date of HSCT.  Time to progression will be compared between 
treatment arms using a log-rank test, and the cumulative incidence curves will be estimated. 
 
Time to CR and CR+PR: 
 
The event is CR (CR or PR).  The time to event is the time to CR (CR or PR).  Patients who die 
in a state other than CR (CR or PR) are considered as failing from a competing risk.  Patients 
alive and not in CR (CR or PR) at the time of last observation are censored at the time of last 
observation.  In the primary analysis in all enrolled patients, time-to-event will be measured from 
enrollment.  In a secondary analysis including only patients who received their HSCT, time-to-
event will be measured from the date of HSCT.  Time to CR (CR or PR) will be compared 
between treatment arms using a log-rank test, and the cumulative incidence curves will be 
estimated. 
 
Time to Off-study Therapy: 
 
The event is the initiation of any anti-lymphoma therapy other than that defined by the protocol 
treatment arms.  Patients who die without initiation of an off-study therapy will be considered as 
experiencing a competing risk.  Patients who do not receive an off-study therapy but are alive at 
the end of the study will be censored at the time of last observation.  In the primary analysis in 
all enrolled patients, time-to-event will be measured from enrollment.  In a secondary analysis 
including only patients who received their HSCT, time-to-event will be measured from date of 
HSCT.  Time to off-study therapy will be compared between treatment arms using a log-rank 
test, and the cumulative incidence curves will be estimated. 
 
Health Quality of Life: 
 
Overview 
The goal of the Health Quality of Life (HQL) component of this trial is to describe the HQL of 
study participants.  In addition, as possible, with the available sample size differences in quality 
of life among recipients of the two treatment strategies in this protocol will be examined.  All 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
5-12 
patients registered to the clinical trial are potentially eligible for the study, and consent for 
participation will be obtained as part of consent for the clinical trial.  Patients who cannot 
communicate in English or Spanish, cannot complete HQL questionnaires due to cognitive, 
linguistic or emotional difficulties, will be excluded from the study.  We anticipate that 90% of 
registered patients will be eligible, and that compliance will be roughly 80% among surviving 
patients, based on experiences with The Unrelated Donor Marrow Transplantation Trial 
(formerly the T Cell Depletion Trial) and other studies of HQL conducted for the NHLBI in bone 
marrow transplant recipients.   
 
Instruments, Administration and Scoring Methods 
In order to minimize response burden and increase the chance of complete response, the 
selection of instruments has been limited to the FACT-BMT [58] and the SF-36 [60, 61].  The 
FACT-BMT is comprised of a general core questionnaire, the FACT-G, evaluates the Quality of 
Life (QOL) of patients receiving treatment for cancer, and a specific module, BMT Concerns, 
that addresses disease and treatment-related questions specific to bone marrow transplant.  The 
MOS SF-36 is a general assessment of health quality of life that has been widely applied in a 
variety of outcome studies and is being used in this trial as a generic measure of QOL. 
 
HQL will be assessed through a self-administered questionnaire distributed to patients at clinic 
visits.  The assessments will be conducted at baseline prior to the cytoreductive/mobilization 
therapy and at two years post-HSCT.  The protocol permits administration within a two-week 
window before the target date for the first interview, and within a +/- two-week window centered 
on the target date for the subsequent yearly interviews.  The HQL instruments will be scored 
according to standard methods for these tools.  Specifically, the FACT-BMT will be scored using 
software provided in the FACIT Manual Version 4 [59], and the MOS SF-36 will be scored 
using software provided in the SF-36 Health Survey Manual and Interpretation Guide [60] and 
the SF-36 Physical and Mental Health Summary Scales:  A User’s Manual [61]. 
 
Analysis and Interpretation of Results 
While descriptive analyses will consider all HQL outcomes, following the lead of David Cella in 
the analysis of ECOG Study 5592 [62], the primary HQL endpoint for hypothesis testing will be 
the Trial Outcome Index (TOI).  The FACT-BMT TOI is derived by adding the scores on the 
Physical Well-Being and Functional Well-Being subscales of the FACT-BMT, to the BMT 
symptoms module score.  At two years post-HSCT, it is anticipated that the TOI, which contains 
relevant questions about physical functioning and BMT symptoms, will be most sensitive to long 
term differences in HQL attributable to differences in treatment strategy. 
 
The initial analysis of the questionnaire data will focus on describing and reporting the HQL of 
study participants, through tables, graphs, and summary statistics characterizing the HQL scores 
over time in each treatment arm.  Differences in QOL between the autologous HSCT and non-
myeloablative allogeneic HSCT arms will be assessed in several ways.  First, the marginal QOL 
scores given that the patient is alive will be compared at the specific time points described above 
using simple T-tests.  Second, the Integrated Quality Adjusted Survival [63] will be compared.  
This latter approach aggregates QOL over the entire period of observation, and accounts for 
potential differences in survival rates.  If an examination of patterns of missing data indicates 
that there is substantial informative censoring due to causes other than death, techniques for joint 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
5-13 
modeling of survival and longitudinal data developed by Schluchter [64], and extended by 
Ibrahim et. al [67], will be considered. 
 
Statistical Power and Sample Size Considerations 
The trial is not designed to be powered for a primary endpoint of detecting differences in QOL 
between the two treatment strategies.  The HQL analysis in the study will be primarily 
descriptive.  We can, however, estimate the power of the study to detect differences between the 
groups based on expected survival and prior HQL studies.  The TCD Trial observed a baseline 
mean FACT-BMT TOI score of 67.2, with a standard deviation of 13.8 units, and a mean SF-36 
Physical Component Score of 41.6, with a standard deviation of 10.2 units.  These data are 
consistent with published norms for the FACT-BMT in HSCT recipients, and the SF-36 in 
cancer patients, respectively [59, 60, 61]. 
 
To illustrate the statistical power available, consider a comparison of the FACT-TOI at the two-
year time point between the autologous HSCT and non-myeloablative allogeneic HSCT patients.  
Assuming 80 non-myeloablative allogeneic HSCT patients and 240 autologous HSCT patients, 
90% of whom will be eligible for HQL study, a 80% survival rate at two years, and an 80% 
response rate, approximately 46 allograft patients and 138 autologous HSCT patients will 
complete the second year interview.  The estimated sample size is sufficient to detect, with 
statistical power of 80%, a difference in the FACT-TOI score of 6.6 units, and a difference in the 
SF-36 PCS score of 4.9 units, using a two-sided level .05 T-test. 
 
Incidence of Toxicities Grade ≥ 3 According to the CTCAE Version 3.0 
 
For both arms, toxicities that occur over the course of time will be tabulated. 
 
Grade ≥ 3 toxicities will be tabulated for each patient at set intervals over the course of the study.  
The proportion of patients developing toxicity will be compared between treatment arms. 
 
Infections 
 
The incidence of definite and probable viral, fungal and bacterial infections will be tabulated for 
each patient according to criteria in the BMT CTN Manual of Procedures.  Infections will be 
classified by organism, site and severity.  Infection burden will be compared between treatment 
arms. 
 
Efficacy of Rituximab and Cyclophosphamide for In Vivo Purging 
 
In vivo purging will be estimated by the proportion of patients whose peripheral blood converts 
from positive for the t(14;18) by PCR prior to cytoreductive/mobilization therapy to negative 
following this therapy.  For patients in the autologous HSCT arm, the correlation between 
t(14;18) results for peripheral blood samples and for collected autologous HSC will also be 
estimated. 
 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
5-14 
Prognostic Value of t(14;18) by PCR in Predicting Relapse 
 
A quantitative PCR assay for t(14;18) will be done on peripheral blood in patients with known 
t(14;18).  Results of serial post-HSCT samples will be analyzed to determine if there is a 
threshold value that can reliably predict relapse, using statistical methods for classification and 
regression trees.  This analysis will be performed after the trial and the information will not be 
available to direct clinical care of patients. 
 
5.5.3. Analyses of Patients on the Non-myeloablative Allogeneic HSCT Treatment Arm 
 
Several outcomes in this study are specific to the non-myeloablative allogeneic HSCT arm.  
Between treatment arm comparisons will not be performed, but descriptive statistics will be 
computed. 
 
Primary and Secondary Graft Failure 
 
Engraftment is defined as having ≥ 5% donor T cells in the peripheral blood (donor T cell 
chimerism) chimerism.  Median time to engraftment will be estimated from the cumulative 
incidence of engraftment, treating death as a competing risk.  Time to engraftment will be 
measured from the date of receipt of the non-myeloablative allogeneic HSCT. 
 
The rate of Primary Graft Failure will be estimated as the number of patients to engraft by Day 
56 post-non-myeloablative allogeneic HSCT, divided by the total number of patients receiving a 
non-myeloablative allogeneic HSCT. 
 
The rate of Secondary Graft Failure will be estimated as the number of patients who engraft (at 
any time prior to one year after receipt of the non-myeloablative allogeneic HSCT), and 
subsequently lose chimerism (< 5%) in the first year post-engraftment, divided by the total 
number of patients who engraft in the first year after receipt of the non-myeloablative allogeneic 
HSCT. 
 
Incidence and Severity of Graft-Versus-Host Disease 
 
GVHD will be graded according to criteria in the BMT CTN MOP.  The cumulative incidence 
curves for acute and chronic GVHD will be estimated treating death as a competing risk. 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
 
APPENDIX A 
 
REFERENCES 
 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
A-1 
APPENDIX A 
 
REFERENCES 
 
1. Gallagher CJ, Gregory WM, Jones EA et al.  Follicular lymphoma: prognostic factors for 
response and survival.  J Clin Oncol 1986; 1470-1480. 
 
2. Dana BW, Dahlberg S, Nathwani BN, et al.  Long-term follow-up of patients with low 
grade malignant lymphoma treated with doxorubicin-based chemotherapy or 
chemoimmunotherapy.  J Clin Oncol 1993:11:644 
 
3. Portlock, CS.  Management of the low-grade non-Hodgkin’s lymphomas. Semin Oncol 
1990:17:51 
 
4. Bierman PJ, Vose JM, Anderson JR, et al.  High-dose therapy with autologous 
hematopoietic rescue for follicular low-grade non-Hodgkin’s lymphoma.  J Clin Oncol 
1997;15:445-450. 
 
5. Cao TM, Horning SJ, Negrin RS, et al.  High-dose therapy and autologous hematopoetic 
cell transplantation for follicular lymphoma beyond first remission:  the Stanford 
University experience.  Biol Blood Marrow Transplant 2001;7:294-301. 
 
6. Rohatiner AZS, Johnson PWM, Price CGA, et al.  Myeloablative therapy with 
autologous bone marrow transplantation as consolidation therapy for recurrent follicular 
lymphoma.  J Clin Oncol 1994;12:1177-1184 
 
7. Colombat P, Binet C, Linassier C, et al.  High dose chemotherapy with autologous 
marrow transplantation in follicular lymphomas. Leuk Lymphoma. 1992:7 (suppl):3-6. 
 
8. Schouten HC, Qian W, Kvaloy S, et al.  High-dose therapy improved progression-free 
survival and survival in relapsed follicular non-Hodgkin’s lymphoma: results from the 
randomized European CUP trial.  J Clin Oncol 2003;21: in press 
 
9. EBMT Registry Data, 2000. 
 
10. Gribben JG, Freedman AS, Woo SD et a.  All advanced stage non-Hodgkin’s lymphomas 
with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells 
containing bcl-2 rearrangement at evaluation and after treatment.  Blood 1991;78:3275-
3280. 
 
11. Freedman AS, Neuberg D, Mauch P, et al.  Long term followup of autologous bone 
marrow transplantation in patients with relapsed follicular lymphoma. Blood 
1999;94:3325-3333. 
 
12. Liu Y, Hernandez AM, Shibata D et al.  BCL2 translocation frequency rises with age in 
humans.  Proc Natl Acad Sci USA 1994;91:8910-8914. 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
A-2 
 
13. Chao DT, Korsmeyer SJ.  BCL-2 family:  regulators of cell death.  Annu Rev Immunol 
1998;16:395-419. 
 
14. Berinstein NL, Reis MD, Ngan BY et al.  Detection of occult lymphoma in the peripheral 
blood and bone marrow of patients with untreated early-stage and advanced-stage 
follicular lymphoma. J Clin Oncol 1993;11;1344-1352. 
 
15. Yearly-Motta V, Racadot E, Fest T, et al.  Comparative preclinical study of three bone 
marrow purging methods using PCR evaluation of residual t(14;18) lymphoma cells. 
Leuk Lymphoma 1996;23:313-321. 
 
16. Martin-Henao GA, Picon M, Limon A, et al.  Immunomagnetic bone marrow and 
peripheral blood progenitor cell purging in follicular lymphoma.  Bone Marrow 
Transplant 1999;23:579-587. 
 
17. Fouillard L, Laporte JP, Labopin M, et al.  Autologous stem cell transplantation for non-
Hodgkin’s lymphomas: the role of graft purging and radiotherapy posttransplantation - 
results of a retrospective analysis on 120 patients autografted in a single institution.  J 
Clin Oncol 1998;16: 2803-2816. 
 
18. Paulus U, Dreger P, Viehmann K et al.  Purging peripheral blood progenitor cell grafts 
from lymphoma cells: quantitative comparison of immunomagnetic CD34+ selection 
systems.  Stem Cells 1997;15:297-304. 
 
19. Williams CD, Goldstone AH, Pearce RM et al.  Purging of bone marrow in autologous 
bone marrow transplantation for non-Hodgkin’s lymphoma:  a case-matched comparison 
with unpurged cases by the European Blood and Marrow Transplant Lymphoma 
Registry. J Clin Oncol 1996;14:2454-2464. 
 
20. Bensinger WI.  Should we purge? Bone Marrow Transplant 1998;21:113-115. 
 
21. Maloney DG, Liles TM, Czerwinski DK et al.  Phase I clinical trial using escalating 
single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in 
patients with recurrent B cell lymphoma. Blood 1994;84:2457-2466. 
 
22. Reff ME, Carner K, Chambers KS et al.  Depletion of B cells in vivo by a chimeric 
mouse human monoclonal antibody to CD20.  Blood 1994;83:435-445. 
 
23. Shan D, Ledbetter JA, Press OW.  Apoptosis of malignant human B cells by ligation of 
CD20 with monoclonal antibodies. Blood 1998;91:1644-1652. 
 
24.  Coiffier B, Haioun C, Ketterer N, et al.  Rituximab (anti-CD20) monoclonal antibody) 
for the treatment of patients with relapsing or refractory aggressive lymphoma:  a multi-
center phase II study. Blood 1998;92:1927-1932. 
 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
A-3 
25. McLaughlin P, Grillo-Lopez AJ, Link BK et al.  Rituximab chimeric anti-CD20 
monoclonal antibody therapy for relapsed indolent lymphoma  half of patients respond to 
four-dose treatment program.  J Clin Oncol 1998;16:2825-2833. 
 
26. Colombat P, Salles G, Brousse N et al.  Rituximab as single first-line therapy for patients 
with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. 
Blood 2001;97:101-106. 
 
27. Buckstein R, Imrie K, Spaner D, et al.  Stem cell function and engraftment is not affected 
by ‘in vivo purging’ with rituximab for autologous stem cell treatment for patients with 
low-grade non-Hodgkin’s lymphoma. Semin Oncol 1999;5 (suppl 14):115-122. 
 
28. Salles G, Moullett I, Charlot C, et al. In vivo purging with rituximab before autologous 
peripheral blood progenitor cells transplantation in lymphoma patients. Blood 1999;94 
(suppl 1): 141a 
 
29. Haioun C, Delfau-Larue MH, Beaujean F et al.  Efficiency of in vivo purging with 
rituximab followed by high-dose therapy with autologous peripheral blood stem cell 
transplantation in B-cell non-Hodgkin’s lymphomas.  A single institution study. Blood 
2006;96 (Suppl 1):384a 
 
30. Goldberg SL, Pecora AL, Jennis AA et al.  Rituximab permits in vivo purging and 
collection of tumor-free stem cells prior to autologous transplantation for B-cello non-
Hodgkin’s lymphoma. Blood 1999;94 (suppl 1):141a 
 
31. Magni M, Di Nicola M, Devizzi L et al.  Successful in vivo purging of CD34 containing 
peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of 
both chemotherapy and rituximab infusion. Blood 2000;96:864-869. 
 
32. Voso MT, Pantel G, Weiss M, et al.  In vivo depletion of B cells using a combination of 
high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients 
with non-Hodgkin’s lymphoma. Br  J Haematol 2000;109:729-35 
 
33. Ladetto M, Zallio F, Ricca I, et al.  Concurrent administration of high-dose chemotherapy 
and rituximab is a feasible and effective chemo/immunotherapy for patients with high-
risk non-Hodgkin’s lymphoma.  Leukemia 2001;15:1941-1949 
 
34. Buckstein R, Imrie K, Spaner D et al.  Consolidative immunotherapy with rituxan in 
autologous stem cell transplantation in follicular lymphoma is associated with molecular 
remissions.  Proc Am Soc Clin Oncol 2000;19:26a 
 
35. Horwitz SM, Negrin RS, Blume KG,et al.  Rituximab as adjuvant to high-dose therapy 
and autologous hematopoietic cell transplantation for aggressive non-Hodgkin 
lymphoma.  Blood 2004; 103:777-783 
 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
A-4 
36. Verdonck LF, Dekker AW, Lokhort HM, et al.  Allogeneic versus autologous bone 
marrow transplantation for refractory and recurrent low-grade non-Hodgkin’s lymphoma.  
Blood 1997;90:4201-4205. 
 
37. van Besien K, Sobocinski KA, Rowlings PA, et al.  Allogeneic bone marrow 
transplantation for low grade lymphoma.  Blood 1998:92:1832-1836. 
 
38. van Besien KW, Khouri IF, Giralt SA.  Allogeneic bone marrow transplantation for 
refractory and recurrent low grade lymphomas: the case for aggressive treatment. J Clin 
Oncol 1995;13:1096-1102. 
 
39. Gale RP, Champlin RE.  How does bone marrow transplantation cure leukemia?  Lancet 
1984;2:28-30. 
 
40. Horowitz MM, Gale RP, Sondel PM, et al.  Graft-versus-leukemia reactions after bone 
marrow transplantation.  Blood 1990;75:555-562. 
 
41. Sullivan KM, Storb R, Buckner CD et al.  Graft-versus-host disease as adoptive 
immunotherapy in patients with advanced hematologic neoplasms.  N Engl J Med 
1989;320:828-834. 
 
42. Kolb JH, Schattenberg A, Goldman JM et al.  Graft-vs-leukemia effect of donor 
lymphocyte infusions in marrow grafted patients. Blood 1985;86:2041-2050. 
 
43. Collins R, Rogers Z, Bennett M, et al. Hematologic relapse of chronic myelogenous 
leukemia following allogeneic bone marrow transplantation:  apparent graft-vs-leukemia 
effect following abrupt discontinuation of immunosuppression.  Bone Marrow Transplant 
1992;10:391-395. 
 
44. Collins RH, Shpillberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients 
with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 
1997;15:433-444. 
 
45. Luznik L and Fuchs EJ.  Donor lymphocyte infusions to treat hematologic malignancies 
in relapse after allogeneic blood or marrow transplantation. 
Cancer Control 2002;9:123-37. 
 
46. Lokhorst HM, Schattenberg A, Cornelissen JJ et al. Donor lymphocyte infusions for 
relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors 
for response and long-term outcome. J Clin Oncol 2000;18:3031-3037 
 
47. van Besien KW, de Lima M, Moore DF et al.  Management of lymphoma recurrence 
after allogeneic transplantation: the relevance of graft-vs-lymphoma effect.  Bone 
Marrow Transplant 1997;19:977-982. 
 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
A-5 
48. Van Besien KW, Loberiza FR, Bajorunaite R, et al.  Comparison of autologous and 
allogeneic hematopoietic stem cell transplantation for follicular lymphoma.  Blood 2003; 
102:3521-3529 
 
49. Porter D, Connors J, Van Deerlin V, et al. Graft-versus-tumor induction with donor 
leukocyte infusions as primary therapy for patients with malignancies.  J Clin Oncol 
1999;17:1234-1243. 
 
50. Spitzer TR, McAfee S, Sackstein R, et al.  Intentional induction of mixed chimerism and 
achievement of anti-tumor responses after nonmyeloablative conditioning therapy and 
HLA-matched donor bone marrow transplantation for refractory hematologic 
malignancies. Biol Blood Marrow Transplant 2000;6:309-20. 
 
51. Sharabi Y, Abraham VS, Sykes M, et al.  Mixed allogeneic chimeras prepared by a non-
myeloablative regimen:  requirement for chimerism to maintain tolerance.  Bone Marrow 
Transplant 1992;9;191-197. 
 
52. Friedman TM, Varadi G, Hopely DD, et al.  Nonmyeloablative conditioning allows for  
more rapid T-cell repertoire reconstitution following allogeneic matched unrelated bone 
marrow transplantation compared to myeloablative approaches.  Biol Blood Marrow 
Transplant 2001;7:656-664. 
 
53. Chao NJ, Liu CX, Rooney B, et al. Nonmyeloablative regimen preserves "niches" 
allowing for peripheral expansion of donor T-cells. Biol Blood Marrow Transplant  
2002;8:249-56. 
 
54. Weissinger F, Sandmaier BM, Maloney DG, et al.  Decreased transfusion requirements 
for patients receiving nonmyeloablative compared with conventional peripheral blood 
stem cell transplant from HLA-identical siblings.  Blood 2001;98:3584-3588. 
 
55. Khouri I, Saliba RM, Giralt SA et al.  Nonablative allogeneic hematopoietic 
transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of 
toxicity, acute graft-vs-host disease, and treatment-related mortality. Blood 
2001;98:3595-3599. 
 
56. Robinson SP, Goldstone AH, Mackinnon S et al.  Chemoresistant or aggressive 
lymphoma predicts for poor outcome following reduced-intensity allogeneic progenitor 
cell transplantation: an analysis from the Lymphoma Working Party of the European 
Group for Blood and Bone Marrow Transplantation.  Blood 2002;100:4310-4316. 
 
57. Cheson BD, Horning SJ, Coiffier B, et al.  Report of an international workshop to 
standardize response criteria for non-Hodgkin’s lymphoma.  J Clin Oncol 1999;17:1244-
1253 
 
58. Zhang M, and Klein J.  Confidence bands for the difference of two survival curves under 
proportional hazards model.  Lifetime Data Analysis  72243-254, 2001. 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
A-6 
 
59. Cella D. Manual of the Functional Assessment of Chronic Illness Therapy (FACIT) 
Measurement Systems, Version 4.  Center on Outcomes, Research and Education (Core). 
Evanston: Northwestern Healthcare and Northwestern University, 1997. 
 
60. Ware JE, Snow K, Kosinski M, Gandek B.  SF-36 Health Survey, Manual and 
Interpretation Guide.  The Health Institute, 1993. 
 
61. Ware JE, Kosinski M, Keller SD.  SF-36 Physical and Mental Health summary Scales: A 
User’s Manual.  The Health Institute, 1994. 
 
62. Cella D, Eton D, Fairclough D, Bonomi P, Heyes A, Silberman C, Wolf M, Johnson D.  
What is a Clinically Meaningful Change on the Functional Assessment of Cancer 
Therapy - Lung (FACT-L) Questionnaire?  Results from Eastern Cooperative Oncology 
Group (ECOG) Study 5592. 
 
63. Billingham.  Simultaneous Analysis of Quality of Life and Survival.  Stat Med 11: 25-48, 
2002. 
 
64. Schluchter MD.  Methods for the analysis of informatively censored longitudinal data.  
Stat Med 11: 1861-70, 1992. 
 
65. Ibrahim JG, Chen MH, Sinha D.  Bayesian methods for joint modeling of longitudinal 
and survival data with application to cancer vaccine studies.  Applied Statistics, 2001. 
 
 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
 
APPENDIX B 
 
CONSENT FORMS 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
PATIENT CONSENT 
 
IRB # 
 
 
 
Page 1 of 24 
Patient Initials _________ 
 
Informed Consent to Participate in Research 
 
 
 
 
 
 
 
 
 
 
Please read this form carefully.  If there are words or part of this document that you do not 
understand, you should ask the research doctor or staff to explain any information that is not 
clear to you before making a decision whether to participate.  Your participation is entirely 
voluntary. You may choose not to participate and you may withdraw at any time.  
 
The Principal Investigator (the person in charge of this research) or a representative of the 
Principal Investigator will also describe this study to you and answer all or your questions. 
Please ask questions about anything that you do not understand.  
 
 
If you are a parent or guardian of a patient younger than 18 years old and have been asked to 
read and sign this form, the “you” in this document refers to the patient. 
 
This is a consent form for a research study.  This form is to help you decide if you want to 
participate in this study.   
 
The consent form describes a study for patients with follicular lymphoma who have entered 
remission from treatment with conventional chemotherapy but the lymphoma has now returned.  
Follicular lymphoma is not curable with standard chemotherapy.  Standard stem cell transplants 
have been used to get patients into remission and improve survival, but the disease still returns.   
 
This study will compare two types of transplants.  The purpose is to see if one type of transplant 
has better results than the other.  The study may also find that patients have similar results with 
either type of transplant.   
 
The results that are important to the study include:   
 Blood counts after transplant 
 Possible occurrence of infection 
 Graft-versus-host disease (GVHD) 
 Return of lymphoma 
 How long you live after transplant 
 Your quality of life  
 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
PATIENT CONSENT 
 
IRB # 
 
 
 
Page 2 of 24 
Patient Initials _________ 
This study will give more information to doctors about future treatment choices.  In addition: 
 You will not be paid to be in this study.   
 You or your insurance company will pay for all medical bills for your treatment. 
 You will not be charged for research tests. 
 You will also face the same risks and benefits as any other transplant patient. 
 
Before you decide to join the study, please read the information below.  Feel free to ask 
questions to understand your rights.  It is your choice to take part in this study.  You and your 
doctor will discuss other treatment options if you decide not to be in this study. 
 
 
1. 
Name of the Subject (“Study Subject”) 
 
 
2. 
Title of Research Study 
 
Autologous versus Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for 
Patients with Chemosensitive Follicular Non-Hodgkin’s Lymphoma Beyond First Complete 
Response or First Partial Response 
 
 
3a. 
Principal Investigator Contact Information 
 
Insert name, affiliation and contact information. 
 
 
3b. 
Contact Information for Emergencies After Hours or on Weekends or Holidays 
 
Call (xxx) xxx-xxxx, the in-patient Bone Marrow Transplant Unit.  Ask to speak to the Charge 
Nurse.  
 
 
4. 
Sponsor and Source of Funding or Other Material Support 
 
The research in this study is paid for by the National Institutes of Health (NIH).  The Blood and 
Marrow Transplant Clinical Trials Network (BMT CTN) will direct the research study. 
 
 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
PATIENT CONSENT 
 
IRB # 
 
 
 
Page 3 of 24 
Patient Initials _________ 
5. 
Study Purpose  
 
This study will compare the results from two types of blood stem cell transplant along with the drug 
rituximab for patients who have follicular lymphoma.  The two types of stem cell transplant 
(SCT) that are compared in this study are AUTOLOGOUS SCT and NON-MYELOABLATIVE 
ALLOGENEIC SCT.  Both autologous SCT and non-myeloablative allogeneic SCT have 
successfully treated this kind of lymphoma. 
 
 
6. 
Study Plan 
 
Patients who are able to use matched, donated stem cells from a brother or sister will have an 
allogeneic non-myeloablative SCT.  Patients without a matched brother or sister will have an 
autologous SCT. 
 
An autologous SCT uses your own stem cells for the transplant:   
 Before transplant, your stem cells are collected in a process called leukapheresis, then frozen 
(or cryopreserved).  
 You will have high doses of chemotherapy, with or without radiation, to kill the lymphoma 
cells in your body. 
 The high amounts of chemotherapy and radiation also damage your bone marrow and 
immune system. 
 Your blood stem cells will be given back to you to undo the effects of the chemotherapy. 
 
An allogeneic SCT uses blood stem cells from a brother or sister donor for the transplant.  The type 
of allogeneic transplant used in this study is called a non-myeloablative allogeneic stem cell 
transplant . 
 Non-myeloablative allogeneic SCTs use lower amounts of chemotherapy and radiation than 
what is used in standard allogeneic transplants.   
 After the chemotherapy, the stem cells from your donor will be given to you. 
 Your immune system will be replaced by the donor’s immune system. 
 A non-myeloablative allogeneic SCT depends on the donor’s immune system to destroy the 
lymphoma cells in your body. 
 
Rituximab Therapy 
Whether you receive the autologous or non-myeloablative allogeneic SCT, you also will receive 
several doses of a drug called rituximab.  Rituximab is a drug that is not considered 
chemotherapy but is called a monoclonal antibody.  This drug works by attacking only the B 
cells in your body.  B cells are a type of white blood cell in your blood, bone marrow and lymph 
nodes that normally help fight infection.  However, in patients with follicular lymphoma, it is the 
B cells that become malignant (cancerous) and become lymphoma cells.  Rituximab is already 
commonly used either alone or together with chemotherapy for patients with follicular 
lymphoma and other types of lymphoma. 
 
 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
PATIENT CONSENT 
 
IRB # 
 
 
 
Page 4 of 24 
Patient Initials _________ 
7. 
Procedures and Tests that are Being Done as Part of you Care 
 
If you agree to participate in this study, your transplant process will include many steps to: 
 Evaluate your health. 
 Determine if you have a matched brother or sister donor. 
 Prepare your body for a stem cell transplant. 
 Receive your stem cell transplant. 
 Help your body recover after transplant. 
 Measure your health and well-being over three years after your transplant. 
 
If you have a matched brother or sister donor, in order for them to participate they will also have 
a health evaluation and if able to donate their cells collected for transplant and sign a consent for 
the study. 
 
The treatment will start with cytoreduction.  Cytoreduction is a process to kill as many lymphoma 
cells as possible in your body before transplant.  All study participants will have cytoreduction 
before either type of stem cell transplant (autologous or allogeneic non-myeloablative).  This 
process uses chemotherapy and rituximab to lower the number of lymphoma cells and another 
drug, filgrastim (G-CSF) to rebuild your white blood cells: 
 
 Rituximab (also called Rituxan) – to lower the number of lymphoma cells, 
 Cyclophosphamide – also to lower the number of lymphoma cells, and 
 Filgrastim (G-CSF) – to increase production of healthy white blood cells.    
 
 
Table 1: Cytoreduction Schedule 
 
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8 
Rituximab 
 
 
 
 
 
 
 
 
Cyclophosphamide 
 
 
 
 
 
 
 
 
Filgrastim 
 
 
 
 
 
 
 
 
 
 
If you will be receiving the autologous SCT, you will undergo a procedure called leukapheresis 
about 12-13 days after receiving the cyclophosphamide.  This collects stem cells from your 
bloodstream as your blood counts recover from the treatment mentioned above.  The stem cells 
are then frozen and stored (cryopreserved).  The procedure is explained in more detail at the end 
of this form.  
 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
PATIENT CONSENT 
 
IRB # 
 
 
 
Page 5 of 24 
Patient Initials _________ 
A) 
Non-myeloablative stem cell transplant  
If you have a genetically (HLA) matched brother or sister, you will have a non-myeloablative 
allogeneic SCT.  Your brother or sister must be willing and able to donate blood stem cells for your 
transplant.   
 
Once your body recovers in about 4 to 6 weeks from the cytoreduction treatment, you will start 
the conditioning regimen also known as the preparative regimen.  This is done to prepare your 
body for transplant. 
 
Your doctor will use a combination of two drugs and rituximab given through your veins: 
 Rituximab – to lower the number of lymphoma cells, and 
 Cyclophosphamide – also to lower the number of lymphoma cells and lower the chance of 
donor stem cell rejection, and 
 Fludarabine – to lower the chance of donor stem cell rejection. 
 
The purpose of this treatment is to weaken your immune system and lower the chance that your 
body will reject the donated stem cells.   
 
You will receive two more drugs during this process to lower the chance of rejecting the donor cells 
and to lower the chance of developing serious graft-versus-host disease: 
 Tacrolimus 
 Methotrexate 
 
Tacrolimus can be taken as a pill or by injection into your vein.  Your doctor will decide how you 
will take it.  You will need to take the tacrolimus for at least 6 months.  You may need to take it 
longer if you develop graft-versus-host disease.  Methotrexate will be given through your vein for 3 
doses on the first, third and sixth day after your transplant.   
 
Graft-versus-host disease (GVHD) is a condition where the donated stem cells attack your skin, 
liver, intestines and other organs.  There is about a 50-60% chance that GVHD will happen after a 
non-myeloablative allogeneic SCT, but in most cases it is a mild form of GVHD.  GVHD can be 
both helpful and harmful.  Mild GVHD may protect against the return of your lymphoma, by 
attacking the cancer cells.  There is approximately a 10-15% chance that serious GVHD may cause 
organ damage or even death in some cases. 
 
 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
PATIENT CONSENT 
 
IRB # 
 
 
 
Page 6 of 24 
Patient Initials _________ 
Table 2:  Conditioning Schedule for Non-myeloablative SCT 
 
 
Days BEFORE Transplant 
 
  -13 
  -6 
  -5 
  -4 
  -3 
  -2 
   -1 
0 
Fludarabine  
 
 
 
 
 
 
 
 
Cyclophosphamide 
 
 
 
 
 
 
 
 
Rituximab  
 
 
 
 
 
 
 
 
Tacrolimus 
 
 
 
 
 
 
 
daily 
Transplant 
 
 
 
 
 
 
 
 
 
You will have your transplant on “Day Zero (0).” 
 
 
Days AFTER Transplant 
 
1 
2 
3 
4 
5 
6 
7 
8 
Rituximab  
 
 
 
 
 
 
 
 
Tacrolimus * 
 
 
 
 
 
 
 
 
Methotrexate 
 
 
 
 
 
 
 
 
* Tacrolimus will be given daily for at least 6 months or longer if GVHD occurs 
 
 
B) 
Autologous stem cell transplant  
If you have an autologous stem cell transplant, you will have your own cells collected before the 
transplant. 
 
Once your body recovers, about 4 to 6 weeks after the cytoreduction treatment, you will start the 
conditioning regimen which is also be called the preparative regimen.  The conditioning 
regimen will be chemotherapy based and may include total body irradiation.  Whether you 
receive irradiation in addition to chemotherapy will be determined by your physician and by 
what preparative regimen is routinely used at your particular hospital/institution.  This depends 
on the doctors at your transplant center.  Conditioning is done to prepare your body for 
transplant.  All of the drugs listed below will be given through your veins except the filgrastim, 
which will be given subcutaneously (injection just under the skin).  You will start daily 
subcutaneous injections of filgrastim starting 5 days after your transplant day to help your white 
blood cells recover faster.  
 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
PATIENT CONSENT 
 
IRB # 
 
 
 
Page 7 of 24 
Patient Initials _________ 
Your doctor will use: 
 Cyclophosphamide – to lower the number of lymphoma cells 
 Rituximab – also to lower the number of lymphoma cells 
 Carmustine or Fractionated Total Body Irradiation – to lower the number of lymphoma 
cells 
 VP-16 – to lower the number of lymphoma cells 
 Filgrastim (G-CSF) – to help your bone marrow make white blood cells after 
chemotherapy 
 
Only one of the tables below will apply to you.  It depends on if you receive total body irradiation 
plus chemotherapy, or chemotherapy alone.  You will have your transplant on “Day Zero (0).” 
 
 
Table 3:  Preparative Schedule Using Chemotherapy and Total Body Irradiation 
Day 
-8 
-7 
-6 
-5 
-4 
-3 
-2 
-1 
0 
 
Radiation 
Radiation 
Radiation 
Radiation 
VP-16 
 
Cyclopho-
sphamide 
 
Transplant 
 
 
Table 4:  Preparative Schedule Using Chemotherapy Only 
Day 
-6 
-5 
-4 
-3 
-2 
-1 
0 
 
Carmustine 
 
VP-16 
 
Cyclopho-
sphamide 
 
Transplant 
 
 
Your rituximab maintenance therapy will start about six weeks after your transplant.  You will 
receive 4 weekly doses of rituximab through your veins.  The rituximab therapy is to remove any 
lymphoma cells that may have survived the high dose chemotherapy. 
 
 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
PATIENT CONSENT 
 
IRB # 
 
 
 
Page 8 of 24 
Patient Initials _________ 
8. 
What are risks of this research study?  
 
Details of all potential side effects, including those that occur rarely, are discussed in the 
Appendix. 
 
You will face risks from the transplant itself, and from treatments given before and after the 
transplant.  Your doctor thinks these risks are less than the risk from your cancer.  Your heart, 
lungs, liver, bladder, kidneys, brain or other organs may be damaged by the chemotherapy or 
irradiation, or by other drugs given to you after the transplant.  Your risk of infection is also 
increased when undergoing a stem cell transplant. This is due to the chemotherapy that weakens 
your immune system. Potential infection can be caused by either a bacteria, virus or a fungal 
organism. Your doctors will monitor you closely for any sign of infection, especially fevers.  
 
During the cytoreductive phase, the most common complications are fever, chills and shortness 
of breath during infusion of rituximab, nausea from the cyclophosphamide, and bone pain from 
the filgrastim. Patients will be at risk for infections and may need transfusions during the 7-14 
days when the blood counts are low following this treatment.  Those patients who will have 
stem cells collected may experience temporary numbness or tingling of the fingertips or around 
the mouth during the blood stem cell collection procedure. 
 
Autologous transplant patients commonly experience some nausea when receiving the 
chemotherapy or irradiation.  Infusion of the stem cells may be accompanied by an unusual taste 
for a few hours, transient nausea, and occasionally shortness of breath.  Nausea, diarrhea and 
sore throat usually occur about a week after transplantation and lasts for several days.  The blood 
counts are very low for about 2 weeks after transplantation, and during this time, the patient is at 
high risk for infection and bleeding.  Most patients require transfusions of red blood cells and 
platelets during this time.  While the risk of early death following autologous transplant is low, 
death could occur.  The patient may also fail transplant treatment due to relapse of lymphoma. 
 
Allogeneic transplant patients may experience any of the side effects from chemotherapy, drug 
therapy or cell therapy as listed in the appendix.  The patient's blood counts are expected to be 
low for about 1 week after transplant and this increases the risk of serious and even life-
threatening infection.  Transfusions of blood and/or platelets and/or intravenous antibiotics may 
be necessary.  There is a possibility that the donor cells will not "take", in other words, not 
engraft.  The period of low blood counts could then be longer but the patient's own marrow 
function and cell count recovery would be expected to recover.  If engraftment occurs, there is 
about a 50% chance that graft versus host disease (GVHD) will occur.  GVHD occurs when the 
donor’s immune system attacks the patient's organs. The most common organs affected are: 1.) 
the skin which would result in rash, peeling, and/or deeper injury, 2.) the gut which would cause 
diarrhea, cramping and possible blood loss, and 3.) the liver which would cause inflammation 
and/or dysfunction or failure.  Medications, including tacrolimus and methotrexate will be given 
to reduce the risk of acute GVHD.  However, if GVHD occurs, additional therapy would be 
required to treat it.  The GVHD might be stopped or it could progress and result in life-
threatening medical problems, including late chronic GVHD or possibly death.  It is possible that 
the patient could experience injury to any organ or system as a result of required medications, 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
PATIENT CONSENT 
 
IRB # 
 
 
 
Page 9 of 24 
Patient Initials _________ 
transfusions, transplant, and/or other therapies.  While the risk of early death following non-
myeloablative transplant is low, death could occur.  The patient may also fail transplant 
treatment due to relapse of lymphoma. 
 
9. 
What other choices are there if I do not take part in this study? 
 
Participation in this study is entirely voluntary.  You are free to refuse to be in the study, and 
your refusal will not affect current or future health care you receive at this institution.  You and 
your doctor will discuss any other treatment options available to you including: 
 Treatment with other drugs or combination of drugs.  
 A standard autologous stem cell transplant. 
 A standard or non-myeloablative allogeneic stem cell transplant. 
 No therapy directed against your lymphoma at this time, with care to help you feel more 
comfortable. 
 
 
10. 
Are there benefits to taking part in this research study? 
 
You may receive no direct benefits from this study.  You may or may not benefit from the 
scheduled medical assessments required for this study, and extra support from personnel working 
for this study. 
 
You may be helping other patients get better treatment in the future. 
 
 
11. 
What will be done with my blood and tissue samples? 
 
Research Blood Samples 
Genetic material is any sample of tissue, blood, fluid, etc. obtained from you during the study.  
With your permission, 10 mL of your blood will be collected prior to the transplant and stored to be 
used solely for research purposes.  The samples will be stored for future studies that will look at 
responses to treatment based on factors not yet known.  These factors may relate to characteristics 
of your follicular NHL or to how your body tolerated the study treatments.  Usually these blood 
samples can be drawn from you at the time of routine blood collections.  Your confidentiality will 
be maintained because no identifying markers (name, etc.) will remain with the sample.   
 
All BMT CTN research samples will be paired with the respective donor or recipient sample and 
given unique bar code designations that cannot be linked back to the donor or the recipient.  All 
research samples will become property of the NHLBI after conclusion of the BMT CTN Protocol 
#0202 study.  An NHLBI Biologic Specimen Repository Utilization Committee will advise 
NHLBI on requests for samples to perform research with these anonymous samples.  If an 
Investigator’s request for these samples is approved by the committee, the NHLBI may provide a 
panel of the specimens requested using unique code numbers.  Laboratory test results, clinical 
information, etc., associated with the coded samples are provided to the Investigator only after 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
PATIENT CONSENT 
 
IRB # 
 
 
 
Page 10 of 24 
Patient Initials _________ 
completion of the main protocol.  Samples sent to researchers cannot be linked with any 
remaining sample at the repository.  
 
If you agree to allow your blood to be kept for research, you are free to change your mind at any 
time.  We ask that you contact {Principal Investigator} in writing and let him know you are 
withdrawing your permission for your blood to be used for research.  His mailing address is on the 
first page of this form.   
 
You are free not to take part in this additional future research.  There will be absolutely no 
change in your care as a result of your refusal to give these additional samples.  Please 
indicate your choice(s) below:  
 
 I agree to have 10 mL of blood collected for future research. 
 No, I do not agree to have10 mL of blood collected for future research. 
 
 
__________________________________ 
 
 
 
________________________ 
Signature 
 
 
 
 
 
 
 
Date 
 
12.  
What if not enough cells are collected to use for transplant? 
 
Your doctor will decide if it is safe to proceed to the planned transplant procedure, depending on 
how many stem cells are actually collected.  The risk of being transplanted with a low number of 
stem cells is that your blood counts may return to normal levels very slowly or they may stay low 
permanently.  If this occurs, you may need many blood and/or platelet transfusions and/or your risk 
of infection may increase.  If you do not proceed to transplant, your doctor can offer other 
alternatives such as chemotherapy and/or radiation if he/she feels this is appropriate.  
 
 
13. 
What are the costs? 
 
You and/or your insurance company will pay all medical expenses relating to, or arising from 
stem cell transplantation.  Research tests will not be charged to you.  
 
For questions about your costs, financial responsibilities, and/or medical insurance coverage for 
your transplant and this study, please contact /Center/ Financial Counselor at /Number/. 
 
 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
PATIENT CONSENT 
 
IRB # 
 
 
 
Page 11 of 24 
Patient Initials _________ 
14. 
Will I be paid to take part in this research study? 
 
No. 
 
 
15. 
What will happen if I am sick or hurt because of this study? 
 
If you are injured or become ill while taking part in this study, medical care will be provided at 
this center.  No funds have been set aside to pay you if you are injured.  You or your insurance 
company will be charged for ongoing medical care and/or hospitalization. 
 
Contact your doctor or one of the people listed at the start of this form if you are concerned about 
a research-related injury. 
 
 
16. 
Can I change my mind about taking part in this research study? 
 
You may decide to quit this study at any time, for any reason, without notice.  However, if you 
quit after you have had some or all of the treatment but before your transplant, then your blood 
counts may not return and you could die. 
 
If you decide to quit, we ask that you tell [the Principal Investigator] in writing (his/her address 
is on the front page of this form).  If you do take back your consent, there will be no penalty and 
you will not lose anything you are entitled to and will continue to receive medical care. 
 
If you have any questions about your rights as a study subject, you may phone the Institutional 
Review Board (IRB) office at /number/. 
 
 
17. 
Can my information still be collected and used if I leave the research study? 
If you quit the study, we ask that you let us continue using all information that was already 
collected.  We also ask that you let your doctor continue to tell us about your progress until 5 years 
after your transplant.  You may say no at any time. 
 
 
18. 
Can the Principal Investigator remove me from this research study? 
 
You can be taken off the study (with or without your consent) for any of these reasons: 
 Staying in the study would be harmful to you. 
 You need treatment not allowed in this study. 
 You do not follow directions. 
 The study is cancelled.  
 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
PATIENT CONSENT 
 
IRB # 
 
 
 
Page 12 of 24 
Patient Initials _________ 
 
19. 
How will my information be kept private? 
 
The centers and doctors in charge of this study will keep your personal information as private as 
possible.  They will do their best to see that it is shared only when required by state or federal law or 
the terms of this consent.  It is impossible to promise total privacy.   
 
In addition to following state and federal law, the organizations listed below may read or copy your 
records to make sure the study information is correct.  Your research and medical records will have 
your name on them.  They will include things such as your medical history, results of your blood 
tests and exams, as well as reports about your treatment and office visits.  We will do all we can to 
keep your medical records private.  Your name will not be used in any report of study results. 
 
In order to understand the results of the study, people from the /Center Name/ and the Blood 
Marrow Transplant Clinical Trials Network (BMT CTN) Data Coordinating Center (DCC) will 
need to see medical records with your name on them.  These people include: 
 Doctors in the study, 
 Transplant center committees, 
 People (who are not doctors) who check the safety and progress of studies, 
 Members of the Institutional Review Board (this committee safe-guards the rights of 
persons taking part in research), and 
 People from the government (the National Institutes of Health and the Food and Drug 
Administration) might also need to see medical records with your name on them. 
 
Your research and medical records may be shown to these organizations:  
 /Institution/ 
 The National Institutes of Health (NIH) 
 Office of Human Research Protection (OHRP) 
 The Food and Drug Administration (FDA)  
 Institutional Review Board (IRB) 
 Data and Safety Monitoring Board (DSMB), not part of /Institution/ 
 Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Data Coordinating 
Center (DCC) 
 Southwest Oncology Group (SWOG) 
 
Information related to or resulting from your stem cell transplant will be reported to the Center 
for International Blood and Marrow Transplant Research (CIBMTR).  The CIBMTR is a 
voluntary organization of basic and clinical scientists working together in an effort to gather 
information on results of stem cell and marrow transplants.  This information is used to guide 
clinical decisions and identify ways to improve transplant outcomes.  Scientific data or medical 
information (not identifiable with you) that could be useful to others may be presented at 
meetings and/or published in medical journals. 
 
For questions about access to your medical records, please contact /name / at/number/. 
 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
PATIENT CONSENT 
 
IRB # 
 
 
 
Page 13 of 24 
Patient Initials _________ 
20. 
How long do you keep my information? 
 
Study records will be kept indefinitely by the transplant center for re-analysis and follow-up. 
 
If you have questions about the keeping of your research records or access to your files, please 
call /name/at /number/. 
 
 
21. 
How will the researcher(s) benefit from your being in this study? 
 
The researchers have no money invested in this study.  But, in general, presenting research results 
helps the career of a scientist.  Therefore, the Principal Investigator may benefit if the results of this 
study are presented at scientific meetings or in the scientific press.  In addition, the Principal 
Investigator is being paid a small amount to cover the cost of performing the study at their Center. 
 
 
22. 
HIPAA1 authorization to use and disclose individual health information for 
research purposes 
 
a. Purpose:  As a research participant, I authorize the Principal Investigator and the researcher’s 
staff to use and disclose my individual health information for the purpose of conducting the 
research study entitled Autologous vs. Non-Myeloablative Allogeneic Hematopoietic Stem Cell 
Transplantation (HSCT) for Patients With Chemosensitive Follicular Non-Hodgkin’s Lymphoma 
Beyond First Complete Response or First Partial Response. 
 
b. Individual Health Information to be Used or Disclosed: My individual health information 
that may be used or disclosed to conduct this research includes: demographic information 
(e.g., age, date of birth, sex, weight), medical history (e.g., diagnosis, complications with 
prior treatment), physical examination findings, and laboratory test results obtained at the 
time of work up and after transplantation (e.g., CT scan, blood tests, biopsy results).  
 
c. Parties Who May Disclose My Individual Health Information:  The researcher and the 
researcher’s staff may obtain my individual health information from: 
(list hospitals, clinics or providers from which health care information can be requested) 
 
____________________________________________________________________________________ 
 
______________________________________________________________________ 
 
______________________________________________________________________ 
 
                                                   
1 HIPAA is the Health Insurance Portability and Accountability Act of 1996, a federal law related to privacy of health 
information 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
PATIENT CONSENT 
 
IRB # 
 
 
 
Page 14 of 24 
Patient Initials _________ 
 
d. Parties Who May Receive or Use My Individual Health Information: The individual 
health information disclosed by parties listed in item c and information disclosed by me 
during the course of the research may be received and used by the following parties: 
 Principal Investigator and the researcher’s staff 
 Dr. Ginna Laport and Dr. Robert Negrin, Study Chairpersons, and staff/laboratories at 
Stanford Hospitals and Clinics 
 Staff/laboratories identified in the protocol for the evaluation of other laboratory 
samples; e.g., TBD for quantitative PCR testing. 
 National Heart, Lung and Blood Institute (NHLBI) and the National Cancer Institute 
(NCI), both of the National Institutes of Health (NIH), study sponsors  
 Blood and Marrow Transplant Clinical Trials Network (BMT CTN), data 
coordinating center 
 Southwest Oncology Group (SWOG), clinical trials cooperative group 
 U.S. government agencies that are responsible for overseeing research such as the 
Food and Drug Administration (FDA) and the Office of Human Research Protections 
(OHRP) 
 U.S. government agencies that are responsible for overseeing public health concerns 
such as the Centers for Disease Control (CDC) and federal, state and local health 
departments. 
 
e. Right to Refuse to Sign this Authorization: I do not have to sign this Authorization.  If I 
decide not to sign the Authorization, I will not be allowed to participate in this study or 
receive any research-related treatment that is provided through the study.  However, my 
decision not to sign this authorization will not affect any other treatment, payment, or 
enrollment in health plans or eligibility for benefits.   
 
f. Right to Revoke:  I can change my mind and withdraw this authorization at any time by 
sending a written notice to the Principal Investigator to inform the researcher of my 
decision.  If I withdraw this authorization, the researcher may only use and disclose the 
protected health information already collected for this research study.  No further health 
information about me will be collected by or disclosed to the researcher for this study. 
 
g. Potential for Re-disclosure: My individual health information disclosed under this 
authorization may be subject to re-disclosure outside the research study and no longer 
protected.  Examples include potential disclosures for law enforcement purposes, 
mandated reporting or abuse or neglect, judicial proceedings, health oversight activities 
and public health measures. 
 
h. This authorization does not have an expiration date. 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
PATIENT CONSENT 
 
IRB # 
 
 
 
Page 15 of 24 
Patient Initials _________ 
23. 
Further Information 
 
If you have further questions concerning this study at any time, you are free to ask your physician 
whose contact information is available on the cover page of this consent form. 
 
If you have questions regarding your rights as a research participant, you may also contact a 
representative of the IRB at (XXX) XXX-XXXX. 
 
Dr./Ms./Mr. ___________________________ has explained the above matters to you and you 
understand that explanation.  She/he has offered to answer your questions concerning the 
procedures involved in this study.  You understand the purpose of this treatment as well as the 
potential benefits and risks that are involved.  You have decided to volunteer after reading and 
understanding all the information on this form.  You hereby give your informed and free consent 
to be a participant in this research investigation.  Upon signing this form you will receive a copy. 
 
 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
PATIENT CONSENT 
 
IRB # 
 
 
 
Page 16 of 24 
Patient Initials _________ 
24. 
Signatures 
 
As a representative of this study, I have explained to the participant the purpose, the procedures, 
the possible benefits, and the risks of this research study; the alternatives to being in the study; 
and how privacy will be protected: 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Signature of person obtaining consent  
 
 
 
Date 
 
Consenting Adults 
 
The purpose of this study, procedures to be followed, risks and benefits have been explained to me.  
I have been allowed to ask the questions I have, and my questions have been answered to my 
satisfaction.  I have been told whom to contact if I have additional questions.  I have read this 
consent form and agree to be in this study, with the understanding that I may withdraw at any time.  
I have been told that I will receive a signed copy of this consent form. 
 
Adult Consenting for Self.  By signing this form, you voluntarily agree to participate in this study.  
By signing this form, you are not waiving any of your legal rights. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Signature of Adult Consenting for Self 
 
 
 
Date 
Parent/Adult Legally Representing the Subject.  By signing this form, you voluntarily give your 
permission for the person named below to participate in this study.  You are not waiving any legal 
rights for yourself or the person you are legally representing.  After your signature, please print your 
name and your relationship to the subject. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Signature of Parent/Legal Representative 
 
 
 
Date 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Print Name of Legal Representative   
 
 
 
Relationship to 
 
 
 
 
 
 
 
 
 
 Participant 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
PATIENT CONSENT 
 
IRB # 
 
 
 
Page 17 of 24 
Patient Initials _________ 
 
Participants Who Cannot Consent But Can Read and/or Understand about the Study 
 
Although legally you cannot “consent” to be in this study, we need to know if you want to take 
part.  If you decide to take part in this study, and your parent or the person legally responsible for 
you gives permission, you both need to sign.  Signing below means that you agree to take part 
(assent).  The signature of your parent/legal representative above means that he or she gives 
permission (consent) for you to take part. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Assent Signature of Participant 
 
 
 
 
Date 
 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
PATIENT CONSENT 
 
IRB # 
 
 
 
Page 18 of 24 
Patient Initials _________ 
APPENDIX TO PARTICIPANT CONSENT 
 
RISKS AND TOXICITIES RELATED TO A STEM CELL TRANSPLANT  
 
 
There are certain risks related to a  blood stem cell  transplant.  There are risks from the 
medications and irradiation (if given) therapy you will receive as part of the conditioning for the 
transplant and risks related to the transplant itself.  Most of these risks and side effects are listed 
below, but they will vary from person to person.   
 
Risks Related to the Transplant Conditioning Regimen 
 
SECTION A 
 
FOR ALL PATIENTS  (AUTOLOGOUS AND ALLOGENEIC PATIENTS): 
 
Rituximab (Rituxan):  This medication is used to reduce cancer cells.  Common side effects 
associated with rituximab include a reaction such as fevers chills or shortness of breath during the 
actual infusion of the drug.  This typically can happen with your very first infusion of this drug.  
Your doctor or nurse may need to temporarily slow down or stop the drug infusion until your 
symptoms lessen.  A much less common side effect can be a severe allergic reaction called 
anaphylaxis, which could cause severe shortness of breath, low blood pressure or tightness in your 
throat.  Rituximab can also temporarily cause a low white blood cell count and/or weaken your 
immune system for up to several months after your last dose of rituximab, which may increase your 
risk of infection during that time period.  In people who have ever been infected with hepatitis B 
virus, there is a risk that the virus can flare up during treatment with drugs that affect your immune 
system, such as Rituxan.  This could lead to liver failure or even death.  The risk of hepatitis B virus 
flaring up may continue for several months after you stop taking Rituxan.  If you become jaundiced 
(yellowing of the skin and eyes) or develop viral hepatitis while taking Rituxan or after stopping 
treatment, you should tell your study doctor immediately.  Your study doctor will discuss this risk 
with you and explain what testing is recommended to check for hepatitis. 
 
Cyclophosphamide (Cytoxan): This is a common medication used to treat cancer.  This 
medication kills cancer cells by stopping them from growing.  Cyclophosphamide may cause you 
to have diarrhea (loose stools), nausea (feeling sick to your stomach), vomiting (throwing up), 
short-term hair loss, short-term bladder problems, and, at times, bleeding from the bladder (blood 
in your urine).  A few patients may have bladder damage and bleeding for a longer time.  You 
will be given large amounts of a sterile solution through your central line to protect your bladder. 
The central line is placed just prior to receiving the cyclophosphamide (within a few days of the 
first dose).   A bladder catheter (thin plastic tube) may be inserted into your bladder, if your 
physician thinks that it can help you.  Cyclophosphamide slows the making of new blood cells.  
This causes a risk of infection and/or severe bleeding until the transplanted donor cells begin to 
work in you.  You will get blood transfusions as needed.  Cyclophosphamide also lowers your 
immune (defense) system and as a result you may have more infections.  In a small number of 
patients, cyclophosphamide can damage the heart muscle causing the heart not to pump as well 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
PATIENT CONSENT 
 
IRB # 
 
 
 
Page 19 of 24 
Patient Initials _________ 
(heart failure).  If this occurs you may have shortness of breath and have fluids build-up in your 
body.  Cyclophosphamide can damage the male (testes) or female (ovaries) sex glands.  In men, 
the number of sperm may be reduced but you would still be able to have intercourse.  Women 
who are still menstruating may have irregular periods or may no longer have any periods.  
Whether you are a man or woman, this medication will likely greatly decrease your chances of 
being able to have a child.  
 
Filgrastim (also called G-CSF for Granulocyte Colony Stimulating Factor) : Less than ½ 
teaspoon (2 mL) filgrastim  will be injected under your skin each day and this could cause some 
minor pain at the injection site.  Most people experience varying levels of pain in their bones 
when treated with this drug which usually feels like muscle aches, bone pain and/or headaches.  
The pain is usually relieved with acetaminophen (Tylenol).  Aspirin or aspirin-containing 
drugs must not be taken during filgrastim administration and during leukapheresis without 
physician approval.  A less common side effect is a skin rash.  These symptoms go away within a 
few days after stopping the drug.  Other rare potential side effects include signs of allergy such 
as a rapid heart rate, dizziness, shortness of breath, itching or rash.  Temporary changes in 
laboratory values that monitor liver and bone changes can also occur as well as a temporary 
increase in your white blood cell count.  These return to normal after stopping the drug.   
 
Rarely, people receiving filgrastim have experienced swelling of their spleen and on occasion, 
internal bleeding from rupture of the spleen.  Rupture of the spleen can present as general fatigue 
and weakness, flank or abdominal pain or loss of consciousness from low blood pressure.  
Rupture of the spleen can be very serious and is potentially life threatening.  Management of this 
problem could require blood transfusions or surgery.  There is less than a 1% chance of this 
occurring.  If you have any unusual symptoms, you should report them immediately.   
 
 
Risks and Procedures Related to the Transplant Procedure 
 
The following risks are not specifically related to any one drug or the transplanted donor cells, but 
they are risks that are a part of the transplant procedure. The following applies to ALL patients. 
 
Venipuncture:  Although you may require a central venous catheter to donate cells, there may 
be an occasional need to have an intravenous catheter placed in your arm(s) or you may need to 
have blood withdrawn from the veins of your arm(s).  Drawing blood from the arm may be 
associated with bleeding into the skin and may very rarely result in an infection. 
 
Central Venous Catheter: A central venous catheter is a flexible sterile tube that can be placed 
into a large vein either under the collar bone or in your groin area so that blood can be 
withdrawn.  This tube is placed under local anesthesia and will be placed just prior to receiving 
the cyclophosphamide/rituximab that is given during the cytoreduction process.   Complications 
include blood clots and infection.  Clotting may necessitate removal of the catheter or treatment 
of the clot by injecting a medicine that dissolves blood clots.  If you develop an infection, you 
will require treatment with antibiotics.  If the catheter is placed under the collarbone, other 
uncommon side effects may include swelling of the face and arm and/or lung collapse.  If the 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
PATIENT CONSENT 
 
IRB # 
 
 
 
Page 20 of 24 
Patient Initials _________ 
lung collapses, it may be necessary to place a tube between the ribs to allow the lung to re-
expand. 
 
Bleeding: Platelets help your blood to clot.  Your platelets will be low until the new bone 
marrow grows and, as a result, bleeding may occur. This can be minor bleeding, such as 
nosebleeds or bruising, but more serious, life-threatening bleeding in the lungs, brain and other 
organs can occur if the platelet count remains low.  Usually, there is success in preventing major 
bleeding problems with transfusions of platelets.  However, some patients may not respond well 
to transfused platelets and may be at serious risk for bleeding.  
 
Veno-Occlusive Disease (VOD): This can occur as a result of high dose chemotherapy, 
radiation therapy, or both. Veno-occlusive causes severe damage to the liver.  Symptoms include 
jaundice (yellowing of the skin and eyes), weight gain, and extra fluid build-up in the abdominal 
cavity and other parts of the body.  It can often be managed successfully, and completely resolve 
but can potentially cause death.  
 
Mouth Sores and Diarrhea: The chemotherapy and radiation cause irritation in the lining of the 
mouth and intestines.  This can result in painful mouth sores and diarrhea and you may need 
medication to help control the pain.  If your mouth sores are severe you may not be able to eat 
normally until the sores are healed.  Mouth sores get better when the white blood count starts to 
rise. 
 
Capillary Leak Syndrome:  This may occur as a result of chemotherapy and radiation therapy. 
The blood vessels may become ‘leaky’ and fluid enters the abdominal cavity, lungs, and other 
tissues.  You may gain water weight and not go to the bathroom as often as you normally do. 
Capillary leak syndrome can be difficult to manage if extra fluid enters the lungs and causes 
difficulty breathing.  You may die if there is continued fluid collection in the lungs.  
 
Unexpected Organ Damage and Other Side Effects:  Although your major organs function 
well, it is possible you may experience unexpected, life-threatening heart, lung, kidney, or liver 
damage as a result of the transplant.  Occasionally, the high doses of chemotherapy and radiation 
cause severe lung damage that cannot always be treated. If this happens, you may need to use 
oxygen or even a respirator.  The lung damage can be life threatening.  Rarely, multi-organ 
failure (such as lung and kidney failure) may occur, which is often fatal.   
 
Late Effects:  You may experience side effects that occur several months to many years after 
your transplant.  You may experience poor function of the thyroid gland, requiring you to take 
thyroid medication.  As a result of radiation, cataracts may occur earlier in life compared to a 
person who had not had a transplant.  If you develop cataracts they may require treatment. It is 
rare, but your kidneys could be affected, causing anemia or high blood pressure.  There is also a 
risk you may develop a second cancer including leukemia as a result of the chemotherapy, 
radiation and/or your lymphoma.  If secondary cancers occur they generally do not occur until 10 
to 15 years after the transplant but can occur sometimes within five years after transplant.  The 
long-term effects upon heart, lung, and brain are unknown.  
 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
PATIENT CONSENT 
 
IRB # 
 
 
 
Page 21 of 24 
Patient Initials _________ 
Fluid Build-up: You will receive intravenous fluids during the transplant process and you may 
have difficulty eliminating this fluid.  Furosemide is a drug that is often given to help eliminate 
this excess fluid.  This drug may cause hearing loss and loss of body chemicals such as 
potassium and sodium. 
 
Risk to the Unborn 
The treatment that you are undertaking has not been proven to be safe at any stage of pregnancy.  
Therefore, if you are pregnant or nursing, you are not eligible for this study.  Women who have 
the potential of becoming pregnant must use some form of effective birth control.   
 
Sterility and Future Childbearing Potential for Men and Women 
Chemotherapy and/or irradiation may cause lasting effects on the reproductive potential of both 
men and women treated in this manner.  It should be emphasized that your cancer 
treatment/therapy may cause your menstrual periods to become irregular or cease altogether.  
However, this DOES NOT MEAN THAT YOU CANNOT BECOME PREGNANT, and you 
must use birth control.   
 
Risks Related to the Infusion of Bone Marrow or Peripheral Blood Stem Cells  
 
The stem cell infusion is given similar to a blood transfusion.  The infusion of stem cells usually 
has few side effects.  Rarely the infusion may cause a headache, chest pain or trouble breathing, 
a slight fever, or blood in the urine.  You will be given pre-medications just prior to the infusion 
to decrease the risk of a reaction.  For the autologous patients, some patients react to the 
preservative called DMSO, which is used in the freezing process of your stem cells.  Common, 
less serious reactions for patients of an autologous or allogeneic SCT include mild wheezing, 
mild shortness of breath, back or chest pain or lightheadedness.  In rare instances, a severe 
allergic reaction can occur called anaphylaxis, which could cause a drop in blood pressure or 
extreme difficulty in breathing.  You will be monitored very closely.  
 
 
SECTION B 
 
For AUTOLOGOUS STEM CELL TRANSPLANT PATIENTS: 
 
VP-16 (etoposide):  This is a common medication used to treat cancer.  This medication kills 
cancer cells by stopping them from growing.  VP-16 may cause you to have diarrhea (loose 
stools), nausea (feeling sick to your stomach), vomiting (throwing up), short-term hair loss  and 
skin peeling, especially in the areas of  your hands, feet and underarms. VP-16 slows the making 
of new blood cells.  This causes a risk of infection and/or severe bleeding until the transplanted 
donor cells begin to work in you.  You will get blood transfusions as needed.  VP-16 also lowers 
your immune (defense) system and as a result you may have more infections.  VP-16 can 
damage the male (testes) or female (ovaries) sex glands.  In men, the number of sperm may be 
reduced but you would still be able to have intercourse.  Women who are still menstruating may 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
PATIENT CONSENT 
 
IRB # 
 
 
 
Page 22 of 24 
Patient Initials _________ 
have irregular periods or may no longer have any periods.  Whether you are a man or woman, 
this medication will likely greatly decrease your chances of being able to have a child.  
 
Total Body Irradiation  (applicable to certain patients receiving the autologous SCT): Total 
body irradiation may cause you to have diarrhea (loose stools), nausea (feeling sick to your 
stomach), vomiting (throwing up), mouth sores, and painful swelling of the saliva glands for a 
few days.  You may also experience short-term hair loss.  Total body irradiation kills both sick 
and normal marrow, leading to a lack of red blood cells, white blood cells, and platelets.  The 
short-term loss of these blood cells could cause you to become anemic, develop an infection, 
and/or bleeding.  This will continue until the transplanted donor cells begin to work in you.  You 
will get blood transfusions as needed.  There is a risk that cataracts (cloudiness) may develop in 
your eyes.  This may mean partial loss of vision, and you may need contact lenses or surgery to 
remove the cataracts.  The total body irradiation dose used will probably result in sterility (not 
being able to have children) as noted in the cyclophosphamide paragraph on the previous page.  
It is not known whether the use of total body irradiation will cause more side effects or problems 
with your health in the future. 
 
Carmustine (also called BCNU) and Etoposide (also called VP-16) (applicable to certain 
patients receiving the autologous SCT): Side effects from these drugs include nausea (feeling 
sick to your stomach), vomiting (throwing up), low blood counts, skin rash, diarrhea (loose stools), 
mouth sores, fevers, and fatigue.  Rarely, liver and/or kidney damage can occur.  Because of your 
weakened immune system, a less common side effect is an infection that can be caused either by a 
bacteria, virus or fungus for which you will be immediately treated with antibiotics.  A delayed but 
less common side effect of the BCNU that can occur about 1-2 months after transplant is 
pneumonitis or inflammation of your lungs.  This can present as a persistent cough, shortness of 
breath, fevers, persistent fatigue, chest discomfort when taking a deep breath or a sudden decrease in 
stamina.  This would be treated with prednisone.  Lung injury from BCNU usually gets better with 
treatment but some patients have permanent lung damage and some patients die from this side 
effect. 
 
Leukapheresis: During this procedure, your central venous catheter will be connected to the 
leukapheresis machine.  This machine draws blood out of part of your catheter continuously and 
filters the stem cells out of your blood stream.  The rest of your blood is then returned to your 
body via another part of your line.  Your blood will be thinned with an anticoagulant during the 
collection procedure to keep your blood from clotting (clogging and thickening) in the tubing 
and in the machine.  This anticoagulant sometimes causes low calcium levels in your blood, 
which you would feel as temporary numbness or tingling of the fingertips or around the mouth.  
Should you experience any numbness, you must tell the nurse operating the machine so that oral 
or intravenous calcium can be given to you.  If not corrected, this complication could progress to 
severe muscle cramps.  Other possible unpleasant effects of the collection procedure include 
lightheadedness, nausea or more rarely, fainting due to temporary lowering of the blood pressure, 
as well as becoming chilled during the procedure.  This procedure takes about 3-4 hours per 
daily session.  Depending on the number of stem cells in your blood, it usually takes 1-3 daily 
sessions to collect enough stem cells. 
 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
PATIENT CONSENT 
 
IRB # 
 
 
 
Page 23 of 24 
Patient Initials _________ 
 
SECTION C 
 
For ALLOGENEIC STEM CELL TRANSPLANT PATIENTS: 
 
Fludarabine (applicable to patients receiving the allogeneic SCT): This medication is used in 
stem cell transplants to reduce the risk of rejecting the donor’s transplanted cells.  Likely side 
effects you may experience are low white blood cell count with increased risk of infection, low 
platelet count with increased risk of bleeding, and anemia (low red blood cell count) with 
tiredness or low energy.   
 
 
Risk Related Specifically to the ALLOGENEIC Transplant Procedure: 
 
Graft-versus-Host Disease (GVHD) 
After the graft begins to function, there is a further risk of a reaction of the graft against your 
tissues.  This reaction is called GVHD and may cause a skin rash, or abnormalities of the liver, 
or stomach.  GVHD may cause nausea (feeling sick to your stomach), vomiting (throwing up), 
lack of appetite, stomach cramps, diarrhea (loose stools), and bleeding of the gut.  Chronic 
GVHD may occur later after transplantation and may involve problems with the eyes, mouth, 
lips, throat and liver.  Early (acute) or late (chronic) GVHD may become severe enough to result 
in death.  GVHD is treated with drugs that weaken the immune system, and therefore make you 
more susceptible to infections. 
 
 
Risks Related to the Medications Used to Help Prevent Graft-versus-Host Disease (GVHD) 
 
NOTE: These drugs also decrease the risk of rejection of the donor cells. 
 
Tacrolimus: This medication is used to try to prevent GVHD.  The immediate side effects you 
may experience include nausea (feeling sick to your stomach) or vomiting (throwing up) when 
the medications are given orally.  Other side effects you may experience include high blood 
pressure (hypertension), shaking of the hands (tremor), increased hair growth and possibly an 
effect on mental function.  If you experience these effects they generally go away when the dose 
of the medication is decreased.  A few patients have had a seizure while taking these 
medications.  You may experience a change of liver or kidney function, in which case the 
medication dose will be reduced or possibly even withheld.  Occasionally, the kidney damage 
caused may require the use of an artificial kidney machine (hemodialysis). 
 
Some patients given tacrolimus develop diabetes and must take insulin while taking tacrolimus. 
 
Methotrexate: This is also a medication used to try to prevent GVHD.  Methotrexate causes 
damage to cells, and therefore can affect many different tissues of your body.  It may cause or 
can worsen the mouth sores or inflammation of the mouth which you may have already 
developed from the procedures and medications used to prepare you for the transplant.  It may 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
PATIENT CONSENT 
 
IRB # 
 
 
 
Page 24 of 24 
Patient Initials _________ 
also cause nausea (feeling sick to your stomach) and vomiting (throwing up).  Methotrexate may 
slow down the recovery of blood cells after transplantation.  Methotrexate can cause kidney 
damage.  If your kidney is already damaged for other reasons, it can worsen kidney function.  If 
kidney damage does occur, the methotrexate dose may be reduced or the mediation may not be 
given at all. 
 
Tacrolimus, Methotrexate, and Steroids: These medications interfere with the body’s defense 
system (the immune system).  This may cause you to have more infections (especially viral 
infections and pneumonia) for several months after transplant. 
 
 
 
 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
DONOR CONSENT 
 
IRB # 
 
 
 
Page 1 of 15 
Donor Initials _________ 
Informed Consent to Participate in Research 
 
 
 
 
 
 
 
 
 
 
 
Please read this form carefully.  If there are words or part of this document that you do not 
understand, you should ask the research doctor or staff to explain any information that is not 
clear to you before making a decision whether to participate. Your participation is entirely 
voluntary.  You may choose not to participate.  
 
The Principal Investigator (the person in charge of this research) or a representative of the 
Principal Investigator will also describe this study to you and answer all or your questions. 
Please ask questions about anything that you do not understand.  
 
 
This is a consent form for a research study.  This clinical trial is a research study to determine 
better treatment for patients with follicular lymphoma.   
 
We invite you to join this study because: 
 Your brother or sister has follicular lymphoma 
 Your blood stem cells are a match for your brother or sister 
 Your brother’s or sister’s disease may be treated by a blood stem cell transplant, and 
 Your brother or sister want to join the follicular lymphoma research study 
 
It is very important for you to know your choices before you decide to join a research study. 
 
Your brother or sister who has low grade follicular lymphoma may be helped by a blood stem 
cell transplant (SCT).  Stem cells are cells found in the bone marrow and blood stream that 
rebuild your blood, bone marrow and the immune system.   
 
This study uses two sources of blood stem cells for transplant:  autologous and allogeneic. 
 An autologous transplant uses blood stem cells collected from the patient. 
 An allogeneic transplant uses blood stem cells collected from a brother or sister who 
are a tissue match with the patient. 
 
Doctors currently use both sources of blood stem cells for transplants.  The doctors do not know 
which type of transplant, autologous or allogeneic, is the better treatment for patients with 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
DONOR CONSENT 
 
IRB # 
 
 
 
Page 2 of 15 
Donor Initials _________ 
follicular lymphoma.  Information from this study will help doctors understand the best treatment 
choices for follicular lymphoma.   
 
We determined that you are a tissue-match to your brother or sister by testing your blood.  We 
tested to see if your antigens matched your brother or sister’s antigens.  Since all of these 
antigens matched, your brother or sister is a tissue-match with you.  Therefore, your brother or 
sister has been assigned to receive an allogeneic stem cell transplant. 
 
This consent describes the collection of stem cells from your blood to transplant into your 
brother or sister.  The donation process for stem cells is not experimental.  The treatment for 
your brother or sister is part of a research clinical trial. 
 
This consent form outlines the process, potential risks and benefits of donating your stem cells 
for transplantation into your brother or sister. 
 
 
1. 
Name of the Donor 
 
 
 
2. 
Title of the Research Study 
 
Autologous vs. Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation 
(HSCT) For Patients With Chemosensitive Follicular Non-Hodgkin’s Lymphoma Beyond First 
Complete Response or First Partial Response 
 
 
3a. 
Principal Investigator Contact Information 
 
Insert name, affiliation, and contact information. 
 
 
3b. 
Contact Information for Emergencies After Hours or on Weekends or Holidays 
 
Call (xxx) xxx - xxxx, the in-patient Bone Marrow Transplant Unit.  Ask to speak to the Charge 
Nurse. 
 
 
4. 
Sponsor and Source of Funding and Other Material Support 
 
The research in this study is paid for by the National Institutes of Health (NIH).  The Blood and 
Marrow Transplant Clinical Trials Network (BMT CTN) will direct the research study. 
 
 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
DONOR CONSENT 
 
IRB # 
 
 
 
Page 3 of 15 
Donor Initials _________ 
5. 
Study Purpose 
 
You are being invited to participate in this research study because current therapy does not help 
everyone with follicular lymphoma.   
 
The goal of this clinical research study is to determine whether autologous or allogeneic stem 
cell transplantation is the better therapy for patients with low grade follicular lymphoma who 
require a transplant to treat their disease.  
 
You are being asked to donate blood stem cells to your brother or sister because you are a tissue 
match with them.  Donating blood stem cells is not experimental.  
 
 
6. 
What will be done if you take part in this research study? 
 
You will undergo a brief medical evaluation and a series of blood tests to prepare for the possible 
stem cell donation.  The following tests and procedures will be done: 
 Medical history, physical examination 
 Blood tests 
 Urine tests 
 If you are a woman able to have children, a blood test to check for pregnancy will be 
done.  If you are pregnant, you cannot take part in this study. 
 Other tests, such as a chest x-ray or electrocardiogram (ECG or EKG, a picture of the 
electrical action of the heart) will be done if your physician feels it is necessary. 
 
If your medical evaluation shows any problems or concerns, you will be told about them.  This 
will be kept private and not shared with your brother or sister unless you agree. 
 
Procedures: 
 
Only a small quantity of stem cells is normally present in the blood.  A drug called filgrastim, 
also called G-CSF (granulocyte-colony stimulating factor), can increase the number of these 
stem cells in the blood.  This drug allows enough stem cells to be collected from you for 
transplantation into your brother or sister. 
 
If the medical exam and blood tests confirm that you are a suitable donor, you will receive 
injections of filgrastim into the skin (like an insulin injection) once a day for 5 days to help the 
release of your stem cells into your blood.  You must come to the donor center or clinic each day 
for the filgrastim injections unless these can be arranged at home. 
 
On the fourth and fifth day of filgrastim injections (and possibly the sixth day) you will go to the 
donor center to have stem cells collected by a machine called a blood cell separator.  The 
procedure of collecting stem cells is called apheresis.  Each apheresis procedure takes about 4 to 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
DONOR CONSENT 
 
IRB # 
 
 
 
Page 4 of 15 
Donor Initials _________ 
6 hours.  The procedure of collecting stem cells involves removing blood from a vein in one arm, 
passing the blood through the machine where stem cells are collected, and the rest of your blood 
cells and plasma (the liquid portion of your blood) are returned to you through a vein in your 
other arm.  This procedure will involve placing a needle in each of your arms, collecting the cells 
over approximately four to six hours during which time you will be required to lie relatively still.  
If the veins in your arms are not large enough for the needles, you will need to have a temporary 
central venous catheter placed to collect your stem cells.  A central venous catheter is a sterile 
flexible tube that will be placed into a large vein under local anesthesia.  Your physician will 
explain this procedure to you in more detail and you will be required to sign a separate consent 
form for this procedure. 
 
Sometimes, not enough stem cells are obtained with two aphereses.  If this occurs, you will need 
to undergo a third apheresis procedure to try to collect enough stem cells. 
 
This process will not remove all of your blood and bone marrow of stem cells.  Healthy people 
have enough stem cells after the collection (aphereses) to make a normal amount of blood cells 
and the body will replace the lost stem cells with new ones. 
 
You will be weighed and have blood tests (1-2 teaspoons) including a complete blood count 
before each collection.  We repeat the complete blood count after each apheresis procedure.   
 
The following table summarizes the schedule and procedures you undergo when donating stem 
cells. 
 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
DONOR CONSENT 
 
IRB # 
 
 
 
Page 5 of 15 
Donor Initials _________ 
 
 
DONATION SCHEDULE 
 
Day 1 
Day 2 
Day 3 
Day 4 
Day 5 
Day 6 
 
 
Filgrastim  
(16 mcg/kg/SQ) 
injection 
 
 
 
 
 
 
 
 
 
 
 
You may need 
to do another 
day 
 
 
 
 
 
More blood 
tests done 
 
 
 
 
You may need 
to do another 
day 
 
 
 
 
 
(Apheresis) 
Blood stem 
cell collection 
 
 
 
 
You may need 
to do another 
day 
 
 
 
 
 
Blood cells 
counted 
 
 
 
 
You may need 
to do another 
day 
 
 
 
7. 
How long will I be in the study? 
 
You will be in the study for up to a few months from the time you sign the consent until 
approximately one month after stem cell collection.  The actual process of taking filgrastim and 
then collecting your stem cells though takes less than a week.  You will be contacted by phone 
approximately 30 days after initiation of G-CSF.  You will be asked to answer questions about 
your health since your stem cells were collected. 
 
Your doctor may decide to take your brother or sister off this study if their condition becomes 
worse, side effects of their treatment are severe or life threatening, or the treatment is no longer 
in their best interest.  If your brother or sister leaves the study there will be no need for you to 
donate stem cells. 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
DONOR CONSENT 
 
IRB # 
 
 
 
Page 6 of 15 
Donor Initials _________ 
 
Your doctor may also decide to take you off this study if the filgrastim or if the leukapheresis 
procedure causes severe, unmanageable or life threatening side effects to you. 
 
You may stop participating at any time.  However, if you decide to leave the study, we 
encourage you to talk to the study doctor first.  Leaving the study early may affect your brother 
or sister’s treatment. 
 
 
8. 
Will you provide blood samples for research? 
 
Research Blood Samples 
Genetic material is any sample of tissue, blood, fluid, etc. obtained from you during the study.  
With your permission, 3-5 teaspoons from your stem cell collection and 3-5 teaspoons of your 
blood (taken from your vein) will be collected prior to the recipient’s transplant and stored to be 
used solely for research purposes.  The samples will be stored for future studies that will look at 
responses to treatment based on factors not yet known.  Your confidentiality will be maintained 
because no identifying markers (name, etc.) will remain with the sample.    
 
All BMT CTN research samples will be paired with the respective donor or recipient sample and 
given unique bar code designations that cannot be linked back to the donor or the recipient.  All 
research samples will become property of the NHLBI after conclusion of the BMT CTN Protocol 
#0202 study.  An NHLBI Biologic Specimen Repository Utilization Committee will advise 
NHLBI on requests for samples to perform research with these anonymous samples.  If an 
Investigator’s request for these samples is approved by the committee, the NHLBI may provide a 
panel of the specimens requested using unique code numbers.  Laboratory test results, clinical 
information, etc., associated with the coded samples are provided to the Investigator only after 
completion of the main protocol.  Samples sent to researchers cannot be linked with any 
remaining sample at the repository. 
 
If you agree to allow your stem cells and blood to be kept for research, you are free to change your 
mind at any time.  We ask that you contact [Principal Investigator] in writing and let him know you 
are withdrawing your permission for your stem cells and blood to be used for research.  His mailing 
address is on the first page of this form.   
 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
DONOR CONSENT 
 
IRB # 
 
 
 
Page 7 of 15 
Donor Initials _________ 
You are free not to take part in this additional future research.  There will be absolutely no 
change in your care as a result of your refusal to give these additional samples.  Refusal to 
participate does not affect your brother or sister’s care.  Please indicate your choice(s) below:  
 
 I agree to have blood and stem cells collected prior to the recipient’s transplant for future 
research. 
 No, I do not agree to have blood and stem cells collected prior to the recipient’s transplant for 
future research. 
 
 
____________________________________  
 
_____________________________ 
Signature 
 
 
 
 
 
 
Date 
 
 
9. 
What will happen if not enough stem cells are collected from me? 
 
The doctor will decide if it is safe to proceed to the planned transplant procedure, depending on how 
many stem cells are actually collected.  The risk of being transplanted with a low number of stem 
cells is that your sibling’s blood counts will return to normal levels very slowly or they may stay 
low permanently.  If this occurs, he/she may need many blood and/or platelet transfusions and/or   
the risk of infection may increase.  If he/she does not proceed to transplant, the doctor can offer 
other alternatives such as chemotherapy and/or radiation if he/she feels this is necessary.  
 
 
10. 
What are the possible discomforts and risks? 
 
There may be side effects from taking filgrastim and donating stem cells.  The filgrastim and 
leukapheresis may cause some, all or none of the side effects listed below.  You should discuss 
these with your doctor. In addition, there is always the chance of new, unexpected or previously 
unknown side effects.  Other drugs will be given to make side effects less serious and less 
uncomfortable.  Many side effects go away shortly after the filgrastim and leukapheresis is 
stopped.   
 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
DONOR CONSENT 
 
IRB # 
 
 
 
Page 8 of 15 
Donor Initials _________ 
Risks and side effects include: 
Filgrastim (G-CSF): Less than ½ teaspoon (2 mL) filgrastim will be injected under your skin 
each day and this could cause some minor pain at the injection site.  Most people experience 
varying levels of pain in their bones when treated with this drug which usually feels like muscle 
aches, bone pain and/or headaches.  The pain is usually relieved with acetaminophen (Tylenol).  
Aspirin or aspirin-containing drugs must not be taken during figrastim administration and during 
leukapheresis without physician approval.  A less common side effect is a skin rash.  These 
symptoms go away within a few days after stopping the drug.  Other rare possible side effects 
include signs of allergy such as a rapid heart rate, dizziness, shortness of breath, itching or rash.  
Temporary changes in laboratory values that monitor liver and bone changes can also occur as 
well as a temporary increase in your white blood cell count.  These return to normal after 
stopping the drug.   
 
Rarely, normal donors receiving figrastim have experienced swelling of their spleen and on 
occasion, internal bleeding from rupture of the spleen.  Rupture of the spleen can present as 
general fatigue and weakness, flank or abdominal pain or loss of consciousness from low blood 
pressure.  Rupture of the spleen can be very serious and is potentially life threatening.  
Management of this problem could require blood transfusions or surgery.  There is less than a 
1% chance of this occurring.  Other, unpredictable side effects may, occur which have not been 
reported.  If you have any unusual symptoms, you should report them immediately.   
 
Possible interactions of figrastim with other drugs have not been fully evaluated; therefore, it is 
important that you report all drugs, both prescription and non-prescription to your physician.  
Long-term (beyond one year) safety data on filgrastim administered to normal, healthy people is 
limited but so far has not identified any late problems for donors. 
 
Leukapheresis; A needle will be placed in each arm.  Pain and bruising could occur in both 
arms, but severe bleeding in the arm is rare.  Your blood will be thinned with an anticoagulant 
during the collection procedure to keep your blood from clotting (clogging and thickening) in the 
tubing and in the machine.  This anticoagulant sometimes causes low calcium levels in your 
blood, which you would feel as temporary numbness or tingling of the fingertips or around the 
mouth.  Should you experience any numbness, you must tell the nurse operating the machine so 
that oral or intravenous calcium can be given to you.  If not corrected, this complication could 
lead to severe muscle cramps.  Other possible unpleasant effects of the collection procedure 
include lightheadedness, nausea or more rarely, fainting due to temporary lowering of the blood 
pressure, as well as becoming chilled during the procedure. 
 
You will lose some blood cells called platelets with the stem cells.  These cells help stop 
bleeding.  If your platelet count falls enough to place you in danger of bleeding, (less than  
30,000 mL) any further collections will be delayed until your platelet count increases. 
 
Central Venous Catheter; If your arm veins are inadequate (too small) to allow leukapheresis, 
you will need a central venous catheter to donate cells.  A central venous catheter is a flexible 
sterile tube that can be placed into a large vein either under the collar bone or in your groin area 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
DONOR CONSENT 
 
IRB # 
 
 
 
Page 9 of 15 
Donor Initials _________ 
so that blood can be withdrawn.  This tube is placed under local anesthesia.  Complications 
include blood clots and infection.  Clotting may require removal of the catheter or treatment of 
the clot by injecting a medicine that dissolves blood clots.  If you develop an infection, you will 
require treatment with antibiotics.  If the catheter is placed under the collarbone, other 
uncommon side effects may include swelling of the face and arm and/or lung collapse.  If the 
lung collapses, it may be necessary to place a tube between the ribs to allow the lung to re-
expand. 
 
Venipuncture; Although you may require a central venous catheter to donate cells, there may be 
an occasional need to have an intravenous catheter placed in your arm(s) or you may need to 
have blood withdrawn from the veins of your arm(s).  Drawing blood from the arm may be 
associated with bleeding into the skin and may very rarely result in an infection. 
 
Risks to the Unborn: Since the filgrastim used in this study can affect an unborn baby, you 
should not become pregnant or father a baby while on filgrastim.   
 
 
11a. 
What are the possible benefits to you for taking part in this study? 
 
If you agree to take part in this study, there is no direct medical benefit to you.  
 
 
11b. 
What are the possible benefits to others? 
 
The possible benefit to your brother or sister may be improvement in the control of their 
lymphoma and possibly prolonged survival.  We hope the information learned from this study will 
benefit other patients with lymphoma in the future. 
 
 
12. 
If you choose to take part in this study, will it cost you anything? 
 
There is no financial benefit to you by participating in this treatment protocol.  Usually, the 
insurance policy of the stem cell recipient will cover the cost of the donor evaluation and stem 
cell collection.  The transplant coordinator will help you identify insurance coverage before you 
incur charges for your evaluation and donation.  If you have concerns or questions regarding 
coverage or potential charges, you should contact (contact person’s name) at (xxx) xxx- xxxx to 
review the situation. 
 
 
13. 
Will you receive compensation for taking part in this research study? 
 
No. 
 
 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
DONOR CONSENT 
 
IRB # 
 
 
 
Page 10 of 15 
Donor Initials _________ 
14. 
What if you are injured because of the study? 
 
You agree to take the risks listed above.  If you experience an injury that is directly caused by this 
study, only the professional medical care you receive at the [participating clinical facility] will be 
provided without charge.  Hospital expenses will be paid by you or your insurance provider.  No 
other compensation is offered.  By signing this form, you have not waived any of your legal rights. 
 
 
15. 
What other options or treatments are available if you do not want to be in this study? 
 
Participation in this study is entirely voluntary.  You are free to refuse to be in the study and your 
refusal will not influence current or future health care you receive at this institution.   
 
Instead of being in this study, your brother or sister may have these options: 
 Treatment with other drugs or combination of drugs. 
 A standard autologous stem cell transplant. 
 A traditional allogeneic or non-myeloablative stem cell transplant. 
 No therapy at this time, with care to help them feel more comfortable. 
 
Your brother or sister may receive these treatments at this or other centers even if you or they 
choose not to take part in this study. 
 
 
16a. 
How can you withdraw from this research study? 
 
If you agree to be in this study, you are free to change your mind.  At any time you may withdraw 
your consent to be in this study.  If you do withdraw your consent, there will be no penalty and you 
will not lose any benefits to which you are otherwise entitled.  If you decide to withdraw, we ask 
that you notify [Principal Investigator] in writing; his/her mailing address is on the first page of this 
form.   
 
You must be aware, however, that a decision not to participate once treatment of your brother or 
sister begins, could have serious harmful consequences for the health of your brother/sister.  Not 
donating stem cells after your brother or sister has received their pre-transplant chemotherapy 
and/or irradiation may result in his or her death. 
 
If you have any questions regarding your rights as a donor, you may phone the Institutional Review 
Board (IRB) office at (xxx) xxx-xxxx. 
 
 
16b. 
If you withdraw, can information about you still be used and/or collected? 
 
If you withdraw from the study, we will ask your permission to continue using all information 
about you that has already been collected as part of the study prior to your withdrawal.   
 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
DONOR CONSENT 
 
IRB # 
 
 
 
Page 11 of 15 
Donor Initials _________ 
 
16c. 
Can the Principal Investigator withdraw you from this research study? 
 
Your participation can be withdrawn (with or without your consent) for any of the following 
reasons: 
 You do not qualify to be in the study because you do not meet the study requirements. 
 You need a medical treatment not allowed in this study. 
 The investigator decides that continuing in the study would be harmful to you. 
 The study treatments have a bad effect on you. 
 You become pregnant 
 Other protocol-specific reasons; for example, if the dose of treatment and/or drugs you have 
been given has been found to be unsafe. 
 The study is cancelled by the National Institutes of Health (NIH) for other administrative 
reasons. 
 
 
17. 
How will your privacy and the confidentiality of your research records be protected? 
 
Study records that identify you will be kept confidential as required by law.  You will not be 
identified by name in the study records.  Your records will be assigned a unique code number.  The 
key to the code will be kept in a locked file in the Data Coordinating Center.  Authorized persons 
from [Clinical Center Name], the hospital or clinic (if any) involved in this research, and the 
Institutional Review Board have the legal right to review your research records and will protect the 
confidentiality of them to the extent permitted by law.  This research study is sponsored and 
conducted under the authority of the National Institute of Health; therefore, the sponsor and the 
sponsor’s agent also have the legal right to review your research records.  Otherwise, your research 
records will not be released without your consent unless required by law or a court order. 
 
If the results of this research are published or presented at scientific meetings, your identity will not 
be disclosed. 
 
 
18. 
Expiration Date for Retention of Records 
 
The study results will be retained in your research record for at least six years or until after the study 
is completed, whichever is longer.  At that time either the research information not already in your 
medical record will be destroyed or your name and other identifying information will be removed 
from such study results.  Research information in your medical record will be kept indefinitely. 
 
 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
DONOR CONSENT 
 
IRB # 
 
 
 
Page 12 of 15 
Donor Initials _________ 
19. 
How will the researcher(s) benefit from your being in this study? 
 
In general, presenting research results helps the career of a scientist.  Therefore, the Principal 
Investigator may benefit if the results of this study are presented at scientific meetings or in 
scientific journals.  In addition, the sponsor is paying the Principal Investigator to conduct this 
study. 
 
 
20. 
HIPAA1 authorization to use and disclose individual health information for 
research purposes 
 
a. Purpose:  As a research participant, I authorize the Principal Investigator and the researcher’s 
staff to use and disclose my individual health information for the purpose of conducting the 
research study entitled Autologous vs. Non-Myeloablative Allogeneic Hematopoietic Stem Cell 
Transplantation (HSCT) for Patients With Chemosensitive Follicular Non-Hodgkin’s Lymphoma 
Beyond First Complete Response or First Partial Response. 
 
b. Individual Health Information to be Used or Disclosed: My individual health information 
that may be used or disclosed to conduct this research includes: demographic information 
(e.g., age, date of birth, sex, weight), medical history (e.g., diagnosis, complications with 
prior treatment), physical examination findings, and laboratory test results obtained at the 
time of work up and after transplantation (e.g., CT scan, blood tests, biopsy results).  
 
c. Parties Who May Disclose My Individual Health Information:  The researcher and the 
researcher’s staff may obtain my individual health information from: 
(list hospitals, clinics or providers from which health care information can be requested) 
 
____________________________________________________________________________________ 
 
______________________________________________________________________ 
 
______________________________________________________________________ 
 
 
d. Parties Who May Receive or Use My Individual Health Information: The individual 
health information disclosed by parties listed in item c and information disclosed by me 
during the course of the research may be received and used by the following parties: 
 Principal Investigator and the researcher’s staff 
 Dr. Ginna Laport and Dr. Robert Negrin, Study Chairpersons, and staff/laboratories at 
Stanford Hospitals and Clinics 
                                                   
1 HIPAA is the Health Insurance Portability and Accountability Act of 1996, a federal law related to privacy of health 
information 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
DONOR CONSENT 
 
IRB # 
 
 
 
Page 13 of 15 
Donor Initials _________ 
 Staff/laboratories identified in the protocol for the evaluation of other laboratory 
samples; e.g., TBD for quantitative PCR testing. 
 National Heart, Lung and Blood Institute (NHLBI) and the National Cancer Institute 
(NCI), both of the National Institutes of Health (NIH), study sponsors  
 Blood and Marrow Transplant Clinical Trials Network (BMT CTN), data 
coordinating center 
 Southwest Oncology Group (SWOG), clinical trials cooperative group 
 U.S. government agencies that are responsible for overseeing research such as the 
Food and Drug Administration (FDA) and the Office of Human Research Protections 
(OHRP) 
 U.S. government agencies that are responsible for overseeing public health concerns 
such as the Centers for Disease Control (CDC) and federal, state and local health 
departments. 
 
e. Right to Refuse to Sign this Authorization: I do not have to sign this Authorization.  If I 
decide not to sign the Authorization, I will not be allowed to participate in this study or 
receive any research-related treatment that is provided through the study.  However, my 
decision not to sign this authorization will not affect any other treatment, payment, or 
enrollment in health plans or eligibility for benefits.   
 
f. Right to Revoke:  I can change my mind and withdraw this Authorization at any time by 
sending a written notice to the Principal Investigator to inform the researcher of my 
decision.  If I withdraw this Authorization, the researcher may only use and disclose the 
protected health information already collected for this research study.  No further health 
information about me will be collected by or disclosed to the researcher for this study. 
 
g. Potential for Re-disclosure: My individual health information disclosed under this 
Authorization may be subject to re-disclosure outside the research study and no longer 
protected.  Examples include potential disclosures for law enforcement purposes, 
mandated reporting or abuse or neglect, judicial proceedings, health oversight activities 
and public health measures. 
 
h. This Authorization does not have an expiration date. 
 
21. 
Further Information 
 
If you have further questions concerning this project at any time, you are free to ask them of 
Dr._______________, who will be available to answer them.  His/her telephone number is located 
on the first page of this consent. 
 
If you have further questions about your disease you are also free to contact The Cancer Information 
Service of the National Cancer Institute (NCI) using their toll-free number 1-800-422-6237.


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
DONOR CONSENT 
 
IRB # 
 
 
 
Page 14 of 15 
Donor Initials _________ 
22. 
Signatures 
 
As a representative of this study, I have explained to the donor the purpose, the procedures, the 
possible benefits, and the risks of this research study; the alternatives to being in the study; and 
how privacy will be protected: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
______ 
Signature of person obtaining consent  
 
 
 
Date 
 
 
Consenting Adults 
 
The purpose of this study, procedures to be followed, risks and benefits have been explained to me.  
I have been allowed to ask the questions I have, and my questions have been answered to my 
satisfaction.  I have been told whom to contact if I have additional questions.  I have read this 
consent form and agree to be in this study, with the understanding that I may withdraw at any time.  
I have been told that I will receive a signed copy of this consent form. 
 
Adult Consenting for Self.  By signing this form, you voluntarily agree to participate in this study.  
By signing this form, you are not waiving any of your legal rights. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Signature of Adult Consenting for Self 
 
 
 
Date 
 
 
 
Parent/Adult Legally Representing the Subject.  By signing this form, you voluntarily give your 
permission for the person named below to participate in this study.  You are not waiving any legal 
rights for yourself or the person you are legally representing.  After your signature, please print your 
name and your relationship to the subject. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Signature of Parent/Legal Representative 
 
 
 
Date 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Print Name of Legal Representative   
 
 
 
Relationship to Participant 
 
 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
DONOR CONSENT 
 
IRB # 
 
 
 
Page 15 of 15 
Donor Initials _________ 
 
23. 
Participants Who Cannot Consent But Can Read and/or Understand about the 
Study 
 
Although legally you cannot “consent” to be in this study, we need to know if you want to take part.  
If you decide to take part in this study, and your parent or the person legally responsible for you 
gives permission, you both need to sign.  Your signing below means that you agree to take part 
(assent).  The signature of your parent/legal representative above means that he or she gives 
permission (consent) for you to take part. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Assent Signature of Donor 
 
 
 
 
 
Date 
 
 
 
 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
 
APPENDIX C 
 
LABORATORY PROCEDURES 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
C-1 
APPENDIX C 
 
LABORATORY PROCEDURES 
 
 
1. HLA TYPING 
 
HLA testing and evaluation must be completed within four weeks of study enrollment and prior 
to the initiation of the cytoreductive/mobilization therapy.  The cytoreductive/mobilization 
therapy must begin no later than four weeks from enrollment.   
 
HLA typing of heparinized peripheral blood can be done by either serologic or DNA methods for 
HLA-A, -B.  DNA methods must be utilized for DRB1.  
 
The specimens for HLA typing will be:  
a) Donor - 5 mL peripheral blood sample(s) from sibling member, and  
b) Patient - 5 mL peripheral blood sample from the recipient. 
 
 
2. CHIMERISM - Non-myeloablative Allogeneic HSCT Patients and Donor 
 
A heparinized peripheral blood sample from patient and donor is required for chimerism studies 
2 weeks pre-allogeneic HSCT to subsequently determine the host or donor origin of ANC 
recovery.  All pre-HSCT samples will be stored for future evaluation of post-HSCT chimerism. 
 
A 10 mL heparinized peripheral blood sample must also be obtained from the patient at weeks 4, 
8, and 12, then at 6 and 12 months post-allogeneic HSCT.  
 
 
3. PATHOLOGY/CYTOGENETICS STUDIES 
 
Unilateral bone marrow biopsies aspirates are required for pathology analysis and bone marrow 
aspirates are required for cytogenetic analysis prior to the cytoreductive/mobilization therapy.  
Other bone marrow assessments as summarized in the schedule of evaluations (Chapter 4) do not 
require the inclusion of bone marrow pathology/cytogenetics unless the original diagnostic 
marrow or the baseline marrow documented abnormal pathology/cytogenetics. 
 
Pathology and cytogenetic studies will be conducted per institutional guidelines. 
 
 
4. FLOW CYTOMETRY 
 
According to the BMT CTN Graft Evaluation MOP, the hematopoietic stem cell content of the 
product (graft) should be determined using CD45-FITC and CD34-PE staining to identify stem 
cells within the WBC component of the product. 
 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
C-2 
Allogeneic donor products will also be analyzed to determine the B, T and NK cell content using 
CD3, CD4, CD8, CD19 and CD56 expression as detected by flow cytometry.  Autologous grafts 
require CD34 enumeration at a minimum. 
 
Flow cytometry will be done in keeping with the BMT CTN MOP and local institutional 
practice, and will be performed prior to infusion of the graft. 
 
 
5. IMMUNOGLOBULIN MONITORING 
 
IgG levels will be monitored in non-myeloablative allogeneic and autologous HSCT patients.  
IgG levels should be determined at 12 weeks, 6 months and 1 year post-HSCT.  Testing will be 
done in keeping with the BMT CTN MOP and local institutional practice. 
 
 
6. POLYMERASE CHAIN REACTION (PCR) 
 
Peripheral blood (10 mL) will be collected for determination of the presence of t(14;18) by PCR.  
The initial evaluation (i.e., baseline sample) will be shipped directly to the BMT CTN Reference 
Laboratory, The Methodist Hospital (TMH), and results will be obtained real-time directly from 
TMH to the appropriate Transplant Center.   The baseline sample will be labeled with labels 
provided by the NHLBI Repository.  Baseline samples will be collected using two, 6.0 mL 
lavender top EDTA vacutainers (BD #367863) with 5 mL of peripheral blood in each vacutainer.  
Baseline samples will be shipped cool, using frozen gel packs, via Federal Express priority 
overnight Monday through Friday prior to the initiation of the cytoreductive/mobilization 
therapy.  The BMT CTN DCC will provide all shipping costs for these samples. 
 
It is the responsibility of the CRA, or designated individual, at the Transplant Center to inform 
TMH of an upcoming shipment via fax or email.  The communication should contain the date of 
shipment, the patient(s) transplant center-specific identifier and Federal Express tracking 
number.  The Protocol Coordinator at EMMES should be copied on e-mail communications 
and/or receive a copy of the faxed documents via fax at 301-251-1355. 
 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
C-3 
All other PCR t(14;18) assessments (i.e., all post-baseline samples) as summarized in the 
schedule of evaluation (Chapter 4) are not required to be obtained unless patient had a positive 
test at any time from initial diagnosis.  Other PCR samples will be collected using two 6.0 mL 
lavender top vacutainers (5.0 mL of peripheral blood in each vacutainer) with an ACD additive 
(BD #364816), processed by ficoll to obtain a white blood cell pellet and shipped quarterly to the 
NHLBI Repository, SeraCare BioServices, in compliance with the shipping procedures specified 
in the BMT CTN MOP. 
 
Misti Dowell 
NHLBI Repository 
SeraCare BioServices 
217 Perry Parkway 
Gaithersburg, MD  20877 
Phone: 
(301) 208-8100;  Fax: (301) 208-8829 
 
 
7. 
RESEARCH SPECIMENS 
 
BMT CTN research samples will be paired with the respective donor or recipient sample and 
given unique bar code designations that cannot be linked back to the donor or the recipient.  All 
research samples will become property of the NHLBI after conclusion of the BMT CTN Protocol 
#0202 study.  An NHLBI Biologic Specimen Repository Utilization Committee will advise 
NHLBI on requests for samples to perform research with these anonymous samples.  If an 
Investigator’s request for these samples is approved by the committee, the NHLBI may provide a 
panel of the specimens requested using unique code numbers.  Laboratory test results, clinical 
information, etc., associated with the coded samples are provided to the Investigator only after 
completion of the main protocol.  Samples sent to researchers cannot be linked with any 
remaining sample at the repository. 
 
For Donors:   
Five vials, each containing 2-5 x 106 nucleated cells (~1ml per cryovial) from the donor stem 
cells must be obtained prior to the allogeneic transplant.  Transplant Centers should follow 
controlled-rate freezing SOPs for cryopreserving research samples as for product storage.  
Samples will be shipped annually to the NHLBI Repository in compliance with the shipping 
procedures specified in the BMT CTN MOP.   
 
In addition, peripheral blood (10 mL nucleated cell sample) will be collected prior to 
mobilization and shipped quarterly to the Repository in compliance with the shipping procedures 
specified in the BMT CTN MOP. 
 
For Patients:   
Peripheral blood (10mL nucleated cell sample) will be collected for future testing prior to the 
non-myeloablative allogeneic or autologous transplant and shipped quarterly to the Repository in 
compliance with the shipping procedures specified in the BMT CTN MOP. 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
C-4 
SCHEDULE OF LABORATORY EVALUATION 
 
 
Type of Sample 
Type of Storage 
Dates Samples Obtained 
Shipping Specifications 
Test 
Location 
HLA Typing 
5 mL peripheral blood 
or according to 
institutional practice 
Store according 
to institutional 
practice 
Prior to cytoreductive/mobilization therapy. 
N/A 
Transplant 
Center 
Chimerism 
10 mL heparinized 
peripheral blood or 
according to 
institutional practice 
Store according 
to institutional 
practice 
2 weeks prior to the initiation of allogeneic 
HSCT conditioning therapy for patient and 
donor.  Weeks 4, 8 and 12, 6 months and one 
year post-allogeneic transplant for patient. 
N/A 
Transplant 
Center 
Pathology/ 
Cytogenetic 
Studies 
Volume of bone 
marrow biopsy and 
aspirate determined 
according to 
institutional practice 
Store according 
to institutional 
practice 
Prior to cytoreductive/mobilization therapy.  
Bone marrow biopsies and aspirates must be 
done prior to the transplant, prior to initiation 
of rituximab maintenance therapy (if 
applicable) and at 12 weeks, 6 months, and 
yearly until 3 years post-HSCT only if 
previously documented bone marrow 
involvement prior to cytoreductive/ 
mobilization therapy or at time of clinical 
suspicion for progression. 
N/A 
Transplant 
Center 
Flow Cytometry 
Volume of graft 
determined according 
to institutional practice 
Store according 
to institutional 
practice 
Prior to infusion of autologous or allogeneic 
stem cell product. 
N/A 
Transplant 
Center 
IgG Levels 
Volume of blood 
determined according 
to institutional practice 
Store according 
to institutional 
practice 
12 weeks, 6 months and 1 year post-HSCT. 
N/A 
Transplant 
Center 
Donor Research 
Specimen 
Nucleated Cells 
From Allograft  
5 vials each containing 
2 - 5 x 106 nucleated 
cells from allograft 
(~1 mL for each vial) 
Follow 
controlled-rate 
freezing SOPs for 
cryopreservation 
of samples as for 
product storage at 
-150° 
Prior to allogeneic transplant at time of 
donation. 
Liquid nitrogen shipment 
yearly to Repository in 
compliance with shipping 
procedures specified in 
the BMT CTN MOP 
TBD 


BMT CLINICAL TRIALS NETWORK 
  
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
C-5 
 
Type of Sample 
Type of Storage 
Dates Samples Obtained 
Shipping Specifications 
Test 
Location 
Donor Research 
Specimen 
Nucleated Cells 
from Peripheral 
Blood  
10 mL peripheral blood 
Obtain white 
blood cell pellet 
(by ficoll) and 
freeze in cryovial  
at -150° 
Prior to donor mobilization. 
Frozen shipment 
quarterly to Repository in 
compliance with shipping 
procedures specified in 
the BMT CTN MOP 
TBD 
Patient 
Research 
Specimen 
Nucleated Cells 
from Peripheral 
Blood  
10 mL peripheral blood 
Obtain white 
blood cell pellet 
(by ficoll) and 
freeze in cryovial  
at -150° 
≤ 2 weeks prior to initiation of HSCT 
conditioning non-myeloablative allogeneic or 
autologous transplant. 
Frozen shipment 
quarterly to Repository in 
compliance with shipping 
procedures specified in 
the BMT CTN MOP 
TBD 
PCR for 
Presence of  
t(14;18) 
10 mL peripheral blood 
(5 mL in each 
vacutainer) 
For baseline 
sample: 2 x 6 mL 
lavender top 
EDTA 
vacutainers.  
 
For all other 
samples: obtain 
white blood cell 
pellet (by ficoll) 
and freeze in 
cryovial at -150°. 
Any positive test from the time of diagnosis 
then required prior to transplant and post-
HSCT maintenance therapy (if applicable); 4 
and 12 weeks, 6 months, 12 months and 
annually until 3 years post-HSCT.  For 
autologous patients who were positive at 
study entry or prior: Each time leukapheresis 
product obtained. 
Baseline sample shipped 
real-time on frozen gel 
packs, via Federal 
Express priority 
overnight to Baylor 
College of Medicine, The 
Methodist Hospital.  All 
other samples frozen 
shipment quarterly to 
NHLBI Repository in 
compliance with shipping 
procedures specified in 
the BMT CTN MOP. 
Baseline 
sample: 
The 
Methodist 
Hospital;  
 
Post-
baseline 
samples: 
TBD 
 


BMT CLINICAL TRIALS NETWORK 
 
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
 
APPENDIX D 
 
HUMAN SUBJECTS


BMT CLINICAL TRIALS NETWORK 
 
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
D-1 
APPENDIX D 
 
HUMAN SUBJECTS 
 
 
1. 
Subject Consent 
 
A conference will be held with the patient, donor and family to discuss this study and alternative 
treatments available for the treatment of the underlying disease.  The Principal Investigator or 
another designated physician will conduct the conference.  All potential risks associated with the 
use of rituximab, cyclophosphamide, TBI, and immunosuppressive drugs should be discussed as 
objectively as possible.  It should be explained that patients offered this protocol have advanced 
FL with life expectancy of no more than several years with conventional treatments.  
Furthermore, it should be explained that the patient would be likely to benefit in terms of disease 
control and prolongation of survival from an autologous transplant alone, but would likely 
relapse from the disease.  In addition, the risk of conventional allogeneic transplant for FL 
should be described.  
 
The consent document should be reviewed with the patient and family prior to proceeding to 
either non-myeloablative or autologous HSCT and rituximab maintenance therapy (for 
autologous HSCT patients). 
 
The procedure for collecting hematopoietic stem cells and toxicities of G-CSF will be explained 
to the donor.  The donor should be counseled as to the risks of treatment with G-CSF and be 
informed that leukapheresis at several time points may be necessary.   
 
Informed consent from the donor and patient will be obtained using a form approved the 
Institutional Review Board of the institution enrolling the patient. 
 
2. 
Confidentiality 
 
Confidentiality will be maintained by individual names being masked and assigned a patient 
identifier code.  The code relaying the patient’s identity with the ID code will be kept separately 
at the center.  The ID code will be transmitted to the BMT CTN Data Coordinating Center upon 
enrollment. 
 
3. 
Participation of Women and Minorities and Other Populations 
 
Women and ethnic minorities and other populations will be included in this study.  Accrual of 
women and minorities at each center will be monitored to determine whether their rates of 
enrollment are reflective of the distribution of potentially eligible women and minorities 
expected from data reported to the CIBMTR and from published data on incidence of FL in these 
groups.  Centers will be notified if their rates differ significantly from those expected and asked 
to develop appropriate recruitment strategies. 


BMT CLINICAL TRIALS NETWORK 
 
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
 
APPENDIX E 
 
THE STATISTIC FOR TESTING THREE-YEAR 
PROGRESSION-FREE SURVIVAL 


BMT CLINICAL TRIALS NETWORK 
 
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
E-1 
APPENDIX E 
 
THE STATISTIC FOR TESTING THREE-YEAR  
PROGRESSION-FREE SURVIVAL 
 
 
The test statistic for this protocol is motivated by two requirements: 
 
1) The test statistic must consider only long-term differences in PFS.   
 
Differences in engraftment, graft-versus-host disease, and infectious complications may 
cause crossing hazards of mortality early in the study, and it is not desirable for these 
early survival differences to affect the final study outcome. 
 
2) The test statistic must be robust and maintain its size and power in the face of sparse 
strata.   
 
The study is not randomized, clinical center effects are problematic and a stratified test 
will be employed.  Many clinical centers, each potentially enrolling a small number of 
patients, will be required to meet the study’s accrual goals.   
 
The study focuses on a primary endpoint of three-year progression-free survival, as this endpoint 
will be unaffected by crossing hazards of mortality early in the study, and reflects the primary 
interest in long term cure.  Information past the three-year time-point is not considered in the 
primary analysis, as it complicates the interpretation and description of the endpoint, e.g. “three 
years and longer progression-free survival.” 
 
If the data were not subject to censoring, the ideal test statistic would be the stratified Cochran 
Mantel Haenszel test comparing the proportion of subjects who are alive without progression at 
three years post-transplant.  However, it is more realistic to assume that some individuals will be 
censored prior to the three-year time-point.  We propose to use a modified stratified CMH test, 
where the Kaplan-Meier actuarial estimates of survival replace the binomial proportions of 
survivors.   
 
This test statistic is based on the paper “A Partially Grouped Logrank Test” by Sposto, Stablein 
and Carter-Campbell, Statistics in Medicine, Vol. 16, 695-704 (1997).  The authors argue that in 
the setting where early differences in survival are irrelevant to the ultimate outcome, a grouped 
log-rank test which groups all information prior to a specified time point (tc) is preferable to a 
weighted log-rank test that de-emphasizes early differences in survival but does not ignore them.  
The authors derive the mean and variance of the contribution of the grouped data table to the 
Mantel-Haenszel version of the logrank statistic, using a hypergeometric argument.   
 


BMT CLINICAL TRIALS NETWORK 
 
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
E-2 
Grouped Data Table 
 
 
Failure 
Non-Failure 
At Risk 
Group 1 
x  
x
N 
1
 
1
N  
Group 0 
y  
y
N 
0
 
0
N  
Total 
y
x
z


 
z
N 
 
N  
 
 
Sposto et. al. estimate the quantities in the grouped table as follows:  
))
(
ˆ
1(
1
1
ct
S
N
x



,  and 
))
(
ˆ
1(
0
0
ct
S
N
y



, where 
1
N  and 
0
N  are the numbers initially at risk, and 
)
(
ˆ
1
ct
S
, 
)
(
ˆ
0
ct
S
are 
the product limit estimates of the survival functions at time ct . 
 
Under the assumption that 
)
(
)
(
)
(
0
1
t
S
t
S
t
S


for all 
ct
t 
, and using the asymptotic normal 
approximation to the distribution of the product limit estimate, Sposto et. al. show that the 
conditional distribution of xgiven 
y
x
z





 is normal with mean 
N
N
z
z
x
E
1
)
|
(




 and 
variance 
)]
(ˆ
[
)
|
(
0
1
ct
S
V
N
N
z
x
V



, where 
)
(ˆ
ct
S
is the product limit estimate in both samples 
combined, and 
)]
(ˆ
[
ct
S
V
 is its asymptotic variance, which in practice, is estimated using 
Greenwood’s formula. 
 
Sposto et. al. propose the following product limit based log rank test statistic: 


2
)
|
(ˆ
))
|
(
(













c
i
c
i
t
t
i
t
t
i
PL
V
z
x
V
S
z
x
E
x
LR
 
where 
iS  and 
iV  are the usual logrank numerator and denominator contributions for ordered 
failure times 
c
i
t
t 
. 
 
We re-express the test statistic in a simpler form as follows: 
 


2
0
1
0
0
)]
(ˆ
[ˆ
))
(
ˆ
)
(ˆ
(








c
i
c
i
t
t
i
c
t
t
i
c
c
PL
V
t
S
V
N
N
S
t
S
t
S
N
LR
 
 
In the primary analysis of the endpoint of three-year progression-free survival, we set 
ct = 3 
years, and do not collect information past this time point.  The square root of the LRPL test 
statistic is then summed over clinical strata to obtain a stratified test, and a continuity correction 
is introduced.  Using notation specific to our application, the test statistic is now written: 
 
 
 
 







strata
Pooled
Allo
Auto
strata
Auto
Pooled
Auto
PL
S
V
N
N
S
S
N
Z
))
3
(
ˆ
(ˆ
2
/
1
)3
(
ˆ
)
3
(
ˆ


BMT CLINICAL TRIALS NETWORK 
 
Follicular Lymphoma Protocol - 0202 
 
 
Version 4.0 dated January 17, 2006 
 
E-3 
 
 
It should be noted that in the absence of censoring, this test statistic reduces to the Mantel-
Haenszel test for comparing binomial proportions in stratified data. 
 
In the secondary analysis of the endpoint of three-year progression-free survival, we again set 
ct = 3 years, but use the original Sposto et. al. test statistic, LRPL , which includes the terms for 
the contributions of the log-rank test statistic after the three-year time-point.  It is not anticipated 
that LRPL will lead to qualitatively different results from ZPL, but the extra information may 
improve the power of the test substantively if accrual is much slower than anticipated.   
 
The Mantel-Haenszel formulation of the log rank test maintains its large sample properties in 
modest sample sizes, even though it is comprised of sparse strata corresponding to individual 
death times.  Similarly, the test statistic ZPL has been shown in simulation studies to control type 
I error at nominal target levels even in the presence of moderate censoring and sparse strata.   
 
When follow-up is complete (no censoring) the power of test statistic ZPL is that of a stratified 
CMH test of binomial proportions.  The power calculations given in Chapter 5, Statistical 
Considerations, are based on large sample results for the unstratified chi-squared test in the 
absence of center-to-center heterogeneity, but have been confirmed by simulations using 
stratified test statistic ZPL in the presence of center-to-center heterogeneity.